The role of inflammation in bladder cancer development and progression: a molecular and genetic epidemiological assessment by Czachorowski, Maciej Jan
  
UNIVERSIDAD AUTÓNOMA DE MADRID 
FACULTY OF MEDICINE 
Department of Preventive Medicine and Public Health 
 
 
 
 
 
 
 
 
 
 
THE ROLE OF INFLAMMATION IN BLADDER CANCER  
DEVELOPMENT AND PROGRESSION: A MOLECULAR AND 
GENETIC EPIDEMIOLOGICAL ASSESSMENT 
 
 
 
 
 
 
 
 
MACIEJ JAN CZACHOROWSKI 
 
 
APRIL 2013 
Madrid, Spain 
 
 
  
 
 
1 
 
ABSTRACT 
 
Growing epidemiologic and experimental evidence implicates chronic inflammation in risk and 
progression of urothelial carcinoma of the bladder (UCB). This thesis investigates the association 
between inflammation related factors (environmental, molecular and genetic) and UCB development and 
progression in the Spanish population. The ultimate aim is to further elucidate the role of chronic 
inflammation in this disease. Epidemiologic, medical, clinical and genetic data was collected as part of 
the Spanish Bladder Cancer/EPICURO Study, a hospital-based, case-control study of nearly 1300 
incident UCB cases, and age, gender and hospital matched controls from 18 hospitals in five regions of 
Spain.  
 In chapter 3, self-reported information on lifetime history of urinary tract infections (UTI) was 
used to investigate the association between bladder infection and risk of UCB. Nearly a 50% reduction in 
UCB risk was observed in patients who reported using UTI medication to treat episodes of infection as 
compared to uninfected individuals; while non-medicating patients exhibited a non-significant increase 
in UCB risk. Patients who used the urinary tract analgesic phenazopyridine also had a further reduction 
in UCB risk. In chapter 4, follow-up information spanning nearly ten years for almost 800 UCB 
patients with available tumor tissue was used to evaluate the prognostic utility of the inflammatory 
mediator COX2 in UCB. Tumor expression of COX2 did not confer independent prognostic utility over 
conventional clinicopathological factors for tumor recurrence and progression in patients with non-
muscle invasive bladder cancer, or for progression or survival of patients with muscle-invasive bladder 
cancer. A meta-analysis that included 11 evaluable studies corroborated these findings.  
 In chapter 5, 911 genetic variants in 214 genes linked to the inflammatory response and relevant 
to cancer were assessed for heterogeneity in susceptibility to UCB subtypes characterized by their level 
of COX2 expression. Variants rs187084 and rs352139 in the gene encoding the innate immune receptor 
TLR9 conferred heterogeneity in susceptibility to UCB subtypes. These associations remained robust 
after multiple testing correction and were not modified by patient history of bladder infections. The 
variant allele of TLR9-rs187084 also independently conferred a reduced rate of tumor progression in 
patients with COX2-negative tumors but only in those treated with BCG immunotherapy; suggesting that 
it may be used as a predictive marker of BCG response in these patients. 
The large patient size afforded by the Spanish Bladder Cancer / EPICURO Study enabled for a 
more precise evaluation of the prognostic potential of COX2 tumor expression than has been undertaken 
in the literature to date. Moreover, the association between UTI medication and UCB risk has never been 
evaluated in an observational study despite experimental evidence suggesting some common medications 
may confer urothelial tumor cytotoxicity. In this respect, the results presented herein are the first 
described using an observational approach to corroborate experimentally obtained data regarding the 
effect of UTI medication on UCB cytotoxicity. Despite the advantages afforded by a large sample size 
and extensive patient information, the observational nature of this study makes it susceptible to bias. Due 
to the self-reported nature of urinary tract infection history, there is potential for the misclassification of 
early UCB symptoms with those of infection. Moreover, although great effort was taken to minimize 
confounding by adjustment of all statistical models and by stratification, one cannot exclude that 
uncontrolled confounding influenced some of the results.  
 Collectively, these findings reiterate the complex interplay between inflammatory processes and 
UCB risk and progression and may have implications for antibiotic UCB prophylaxis and improvement 
of patient response to immunotherapy.  
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RESUMEN 
 
Un creciente cuerpo de evidencias epidemiológicas y experimentales implica a la inflamación crónica en el 
desarrollo y progresión del carcinoma urotelial de vejiga (CUV). Esta tesis investiga la asociación entre los 
factores relacionados con la inflamación (ambientales, moleculares y genéticos) y el desarrollo y progresión 
del CUV en población española con el objetivo último de elucidar el papel de la inflamación crónica en esta 
enfermedad. Los datos epidemiológicos, médicos, clínicos y genéticos fueron recogidos como parte del 
Estudio Español de Cáncer de Vejiga/EPICURO, un estudio de casos y controles hospitalarios con casi 1300 
casos incidentes de CUV y controles pareados por edad, género y hospital, procedentes de 18 hospitales de 
cinco regiones de España. 
En el capítulo 3, se utilizó la información autoreportada sobre la historia de infecciones del tracto 
urinario (ITU) para investigar la asociación entre esta exposición y el riesgo de CUV. Se observó una 
reducción de casi un 50% en el riesgo de CUV en los pacientes que reportaron el uso de medicamentos para 
tratar la ITU, en comparación con las personas que no habían reportado ninguna infección, mientras que los 
pacientes que no usaron medicamentos para tratar la ITU mostraron un aumento, aunque no significativo, del 
riesgo de CUV. Los pacientes que usaron fenazopiridina, el analgésico del tracto urinario, también tuvieron 
una reducción en el riesgo de CUV. 
En el capítulo 4, la información de seguimiento que abarca casi diez años para casi 800 pacientes con 
tejido tumoral disponible, se utilizó para evaluar la utilidad pronóstica del mediador inflamatorio COX2 en el 
CUV. La expresión tumoral de COX2 no mostró tener un valor pronóstica independiente de los factores 
clínico-patológicos convencionales para la recurrencia y progresión del tumor en pacientes con cáncer de 
vejiga no invasivo del músculo, ni para la progresión o la supervivencia de los pacientes con tumores de 
vejiga que invaden el músculo. Una meta-análisis que incluyó 11 estudios corroboró estos hallazgos. 
En el capítulo 5, se estudiaron 911 variantes genéticas en 214 genes ligados a la respuesta 
inflamatoria y relevantes en cáncer para valorar su heterogeneidad genética en relación con la susceptibilidad 
a padecer CUV caracterizado por una alta o baja expresión de COX2. Variantes (rs187084 y rs352139) en el 
gen que codifica el receptor de la inmunidad innata, TLR9, confirieron heterogeneidad en la susceptibilidad a 
CUV. Las asociaciones se mantuvieron después de la corrección por comparaciones múltiples y no fueron 
modificadas por la historia de UTIs en los pacientes y otros transtornos uropatológicos. La variante TLR9-
rs187084 también confirió, de forma independiente, un menor riesgo de progresión tumoral en pacientes con 
tumores negativos para COX2, pero sólo en los pacientes tratados con inmunoterapia de BCG; sugiriendo que 
esta variante podría ser utilizada como un marcador predictivo para la respuesta a BCG en estos pacientes. 
El gran tamaño muestral del estudio Español de Cancer de Vejiga / Estudio EPICURO ha posibilitado 
una evaluación más precisa del potencial pronóstico de la expresión de COX2 de lo que se ha realizado en la 
literatura hasta ahora. Además, nunca se ha evaluado antes en un estudio observacional la asociación entre la 
medicación utilizada para la infección del tracto urinario y el riesgo de CUV, a pesar de la evidencia 
experimental que sugiere que algunos medicamentos comunes pueden conferir citotoxicidad tumoral. En este 
sentido, los resultados presentados en esta tesis son los primeros descritos utilizando un diseño observacional 
que corroboran los datos obtenidos experimentalmente con respecto al efecto de la medicación para la 
infección del tracto urinario sobre la citotoxicidad en el CUV. A pesar de las ventajas que ofrece un tamaño 
muestral grande y una amplia información sobre los pacientes, la naturaleza observacional de este estudio lo 
hace susceptible a sesgos. Debido a la naturaleza auto-reportada de la historia de infecciones del tracto 
urinario, es posible que se haya producido una clasificación errónea de los primeros síntomas de CUV con los 
de la infección. Por otra parte, a pesar de un gran esfuerzo en minimizar la confusión mediante el ajuste de 
todos los modelos estadísticos y la estratificación de los analisis, no se puede excluir que la existencia de 
confusión residual haya podido influir en algunos de los resultados. 
Estos resultados muestran la relación compleja entre los procesos inflamatorios y el riesgo y 
progresión del CUV. Además, pueden tener implicaciones para la profilaxis antibiótica y la mejora de las 
tasas de respuesta a la inmunoterapia. 
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CHAPTER 1: INTRODUCTION 
 
1.1 BLADDER CANCER 
1.1.1 Burden of disease 
According to the International Agency for Research on Cancer (IARC) approximately 382,000 
new cases of bladder cancer were diagnosed globally in 2008 and more than 150,000 individuals died 
from the disease; ranking bladder cancer the 9
th
 most incident and 13
th
 deadliest cancer worldwide 
(Ferlay et al., 2010). Crude estimates place the global prevalence of the disease at nearly 2.7 million 
individuals, the majority of which present with superficial tumors with a favorable prognosis following 
treatment (Ploeg et al., 2009). However, due to a high rate of recurrence and risk of tumor progression, 
patients need to be closely followed-up over the course of their lives; contributing to making bladder 
cancer one of the most expensive cancers to treat on a per patient basis (Botteman et al., 2003). Age-
standardized bladder cancer incidence and mortality rates are highest in developed nations, while 
developing regions by comparison, observe reduced incidence and mortality rates by factors of three and 
two, respectively (Table 1.1). 
Table 1.1 Age-standardized bladder cancer incidence and mortality rates by gender and region* 
Region 
Men Women 
Incidence Mortality Incidence Mortality 
World 9.1 3.3 2.2 0.9 
More 
developed 
16.6 4.6 3.6 1.0 
Less developed 5.4 2.6 1.4 0.7 
Spain 27.7 8.3 3.2 1.1 
Adapted from Ferlay et al. 2010 
    
A histological dichotomy is also apparent in these regions, with nearly 90% of all bladder cancer patients 
diagnosed in developed nations presenting with urothelial carcinoma of the bladder (UCB), while more 
than 70% of cases in developing nations manifest squamous cell carcinoma (SCC) (Schottenfeld and 
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Fraumeni, 2006).Globally, men are three to four times more likely than women to be diagnosed with 
bladder cancer, and three times as likely to die of their disease (Table 1.1). However, in developed 
nations like the United States, women and black patients consistently present with more aggressive 
tumors upon diagnosis and observe decreased UCB survival rates compared to white males which cannot 
be entirely explained by demographic differences alone (Fajkovic et al., 2011; Mallin et al., 2011). 
In Spain, like in other developed nations, UCB is the predominant bladder cancer histology. 
Spanish men observe the highest UCB incidence rate in Europe (27.7 per 100,000 men) and the disease 
ranks as the fourth most incident tumor type following prostate, lung and colorectal cancers (Ferlay et al., 
2010). In 2008, more than 13,000 individuals (men and women) were diagnosed with UCB in this 
country and nearly 5,000 died as a result of the disease (GLOBOCAN). Between 1970 and 2005, while 
UCB mortality rates in several Western European nations steadily declined, age-standardized mortality in 
both men and women has remained relatively stable in Spain (Bosetti et al., 2011; Yako-Suketomo and 
Katanoda, 2010). By some estimates, UCB-specific male incidence and mortality are expected to 
decrease in Spain in the period between 2007 to 2022, while increasing slightly in Spanish women 
(Bernal-Perez et al., 2012). The proportion of men:women who develop bladder cancer in Spain is, at 
nearly 7:1, disproportionately higher than the global average of about 3:1 (Table 1.1). Due to its high 
incidence and public health impact in Spain, this thesis will focus on UCB in the Spanish population. 
1.1.2 Etiology of urothelial carcinoma of the bladder 
UCB is a complex disease with both genetic and non-genetic risk factors contributing to its 
etiology. Cigarette smoking, occupational exposure to azo-based dyes and arsenic, are among the best 
established environmental risk factors (Burger et al., 2013). At present, several genetic variants, mainly 
single nucleotide polymorphisms (SNPs), have also been independently associated with the risk of UCB 
through various candidate gene and genome-wide approaches (Rothman et al., 2010). The complexity of 
the disease is further underscored by the ability of some of these factors to interact and thereby alter 
UCB susceptibility as demonstrated for cigarette smokers harboring the slow-acetylator phenotype of N-
acetyl transferase 2 (NAT2); a phase-2 detoxification enzyme (Garcia-Closas et al., 2005).  
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Risk associations with environmental exposures and/or genetic aberrations in detoxifying 
enzymes have led to the proposal that UCB initiation may result from direct exposure of the urothelium 
to carcinogens excreted in the urine (Wu, 2005). UCBs are often multifocal with evidence to suggest that 
they may be monoclonal, arising from a single urothelial cell that spreads to other parts of the urothelium 
(Sidransky et al., 1992), or polyclonal, arising through a field effect through which carcinogens exposed 
to the urothelium initiate independent genetic alterations at several sites (Jones et al., 2005). 
1.1.2.1 Environmental risk factors of UCB 
Tobacco smoking is among the best established non-genetic risk factors of UCB having an 
estimated population attributable risk of about 50% men, and slightly less in Spanish women , with 
current smokers being 3 to 7 times more likely to develop UCB than never smokers (Freedman et al., 
2011; Samanic et al., 2006). Risk of UCB has been reported to increase linearly with intensity and 
duration of smoking and drop accordingly in former smokers with time since cessation of smoking, but 
do not reach the level found in never-smokers (Brennan et al., 2000; Samanic et al., 2006). Samanic et al 
only noted the inverse trend in UCB risk with time since cessation in former smokers of blond tobacco, 
but observed no apparent trend in former smokers of black tobacco in Spain (Samanic et al., 2006). 
Recent evidence from patients in the United Kingdom also suggests that smokers are  diagnosed with 
UCB at a younger age and present with more aggressive and larger malignant tumors than non-smokers 
(van Roekel et al., 2013). The particulate phase of cigarette smoke contains various compounds and 
carcinogens including polycyclic aromatic hydrocarbons (PAHs), N-nitrosamines, aromatic amines and 
metals (Pfeifer et al., 2002) which can contribute to bladder carcinogenesis by means that are not 
completely understood but may include aromatic amine induced urothelial cell DNA adduction, 
mutagenicity and oxidative damage (Besaratinia and Tommasi, 2013; Ohnishi et al., 2002). 
Occupations with a high risk of exposure to various carcinogens, such as textile, metal working, 
machining, equipment transport, and mining have been attributed to account for between 5 to 10% of 
UCB cases in men in Western Europe (Kogevinas et al., 2003). Specifically, aromatic amines such as 
benzidine and beta-naphthylamine commonly used in the dye, chemical, and rubber industries, as well as 
PAHs, have been cited as the compounds responsible for increasing occupational UCB risk (Golka et al., 
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2004). Bladder cancer specific mortality was reported to increase in dye stuff workers heavily exposed to 
aromatic amines with younger age at first exposure and increasing duration of exposure, with excess risk 
being apparent even 30 years after last exposure (Pira et al., 2010). Aromatic amines were also 
commonly used in hair dye products and two recent meta-analyses indicate that hairdressers observe at 
least a 30% increased risk of UCB (Harling et al., 2010; Takkouche et al., 2009); however no consistent 
associations have been reported between UCB risk and personal hair dye use (Koutros et al., 2011; Ros 
et al., 2012).  
Various other suspected environmental and lifestyle risk factors have been explored for their 
association with UCB risk. Increased risk has been associated with high exposure (dermal or oral) to 
water disinfection by-products such as trihalomethanes (THMs) (Castano-Vinyals et al., 2011; Michaud 
et al., 2007; Villanueva et al., 2007) as well as trace metals such as arsenic (Chiou et al., 2001; Smith et 
al., 1998) and a constantly low urinary pH (Alguacil et al., 2011). Reduced UCB risk has been found 
associated with increased nighttime urination frequency (Silverman et al., 2008), high fruit and vegetable 
intake (Garcia-Closas et al., 2007) and long-term use of non-aspirin non-steroidal anti-inflammatory 
drugs (Fortuny et al., 2006); no apparent associations (or only modest associations in certain strata) with 
UCB were reported for coffee consumption (Villanueva et al., 2009) or air pollution (e.g. low-level 
industrial PAH and diesel emissions near residential areas) (Castano-Vinyals et al., 2008). 
1.1.2.2 Genetic susceptibility factors 
UCB is not considered a hereditary cancer; however several recent case-control studies indicate 
that familial history of UCB may increase the risk of the disease in first-degree relatives by two- to 
fivefold (Aben et al., 2002; Lin et al., 2006; Murta-Nascimento et al., 2007). Somatic alterations in 
chromosome 9 and mutations in the RAS family of oncogenes (HRAS, KRAS and NRAS) are prevalent in 
both superficial and muscle-invasive UCB (Jebar et al., 2005; Sauter et al., 1995). However, the majority 
(>50%) of NMIBC are characterized by oncogenic mutations in FGFR3 (Cappellen et al., 1999; Jebar et 
al., 2005), while inactivating mutations in the tumor suppressor genes TP53 and RB characterize muscle 
invasive UCB (Cote et al., 1998; Sidransky et al., 1991). Genetic variants in several carcinogen 
detoxification genes have been associated with UCB susceptibility. N-acetyltransferases (namely NAT1 
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and NAT2) detoxify aromatic amines via the covalent addition of an acetyl group. Individuals who 
harbor two variant alleles of NAT2, known as a slow acetylator phenotype, are at an increased risk of 
UCB) (Garcia-Closas et al., 2005; Okkels et al., 1997). Similarly, glutathione-S-transferase M1 
(GSTM1) is an enzyme involved in the detoxification of electrophilic compounds like poly aromatic 
hydrocarbons (PAHs), and individuals that lack both copies of the gene encoding this enzyme (60% of 
the Spanish population) are nearly 1.7 times more likely to develop UCB compared to wildtype 
homozygotes/heterozygotes (Garcia-Closas et al., 2005). Lastly, numerous genome wide analysis studies 
(GWAS) have identified and corroborated at least a dozen UCB genetic susceptibility loci arising from 
SNPs that fall within or near the following genes: MYC, TP63, PSCA,CLPTM1L, TERT, TACC3, 
FGFR3, CBX6, APOBEC3A,CCNE1 UGT1A and NAT2 (summarized in (Garcia-Closas et al., 2011; Gu 
and Wu, 2011)).  
1.1.3 Chronic inflammation and UCB risk 
Inflammation is an adaptive immune response responsible for protecting the body against 
extrinsic and endogenous stress and mediating the clearance and repair process that follows its successful 
resolution . Broadly, inflammation can be divided into a highly regulated acute phase and a sustained 
chronic inflammatory phase that persists when the acute response is insufficient to mitigate the inducing 
threat. The presence of chronic inflammation has been implicated in all facets of tumor development 
including tumor cell initiation, promotion and progression in a wide array of tissues. In the urinary 
bladder, factors that predispose the urothelium to a state of sustained chronic inflammation also appear to 
increase bladder cancer risk (Kundu and Surh, 2008; Mantovani et al., 2008; Michaud, 2007). For 
example, calculi in the bladder, kidney or ureters, can agitate the urothelium and lead to localized chronic 
inflammation as well as obstructive urinary stasis conducive to bacterial infection of the bladder (Burin 
et al., 1995). These conditions have been associated with increased UCB risk and their contribution to 
UCB risk in the Spanish population is explored in more detail in chapter 3 of this thesis 
1.1.3.1 The inflammatory response 
In normal tissue, the acute inflammatory response is activated upon recognition of exogenous 
factors which may be microbial or non-microbial in nature, or by endogenous factors resulting from cell 
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or tissue damage (e.g. necrotic tissue) (Kumar et al., 2010). Macrophages, mast cells and endothelial 
cells in the vicinity of the infection or injury release pro-inflammatory cytokines (TNFa, IL-1B, IL-6, IL-
12) , chemokines (CXCL-1, -2, -8) (Cohen-Hillel et al., 2009) and vasodilators that signal for the 
recruitment of plasma proteins and phagocytic neutrophils to the afflicted region. Local vasodilation 
permits diffusion of plasma proteins and neutrophils from the capillary network into the tissue resulting 
in symptoms characteristic of the acute inflammatory response like redness, warmth, and swelling 
(Kumar et al., 2010). Direct contact with the irritant or with cytokines released by injured tissues, 
triggers neutrophilic release of enzymatic granules laden with reactive oxygen (ROS) and nitrogen 
species (RNS) and proteolytic enzymes capable of breaking down the pathogen or damaged tissue 
(Fialkow et al., 2007). Successful neutralization of the irritant initiates macrophage-mediated resolution 
of the acute inflammatory phase and enables tissue repair (Medzhitov, 2008). At this point, the balance 
of cytokine production shifts toward anti-inflammatory cytokines (IL-4, IL-10) that curtail the production 
of pro-inflammatory prostaglandins and limit neutrophil recruitment, thus allowing for the removal of 
dead cells and tissue remodelling by monocytes. 
Recalcitrant infection or persistent tissue irritation that does not clear up, however, triggers a 
heightened inflammatory response characterized by neutrophil replacement by macrophages and 
generation of cytolytic T-cells (CTLs) (Medzhitov, 2008). Notwithstanding, unmitigated prolongation of 
this heightened inflammatory state leads to localized chronic inflammation at the afflicted area. In a 
localized chronic inflammatory state, prolonged exposure of the surrounding cells to ROS and RNS 
produced by immune cells at the site of inflammation can result in DNA strand breaks contributing to 
replication errors and genomic instability, the induction of oncogenic mutations and inactivation of 
tumor suppressor genes, which collectively contribute to tumor initiation (Michaud, 2007). Furthermore, 
these reactive species can impart damage to the cell membrane through lipid peroxidation reactions and 
interfere with protein processing and cellular homeostatic functions thereby contributing to tumor 
promotion (Kundu and Surh, 2008). 
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1.1.3.2 Pathogen Associated Molecular Patterns and Toll-like receptors 
In the case of exogenous stimulation as observed in urinary tract infections (UTIs), pathogen 
associated microbial patterns (PAMPs) not found in the host organism are recognized by cognate pattern 
recognition receptors (PRRs) whose activation induces a proinflammatory signaling cascade (Tang et al., 
2012). In humans, the Toll-like receptors (TLRs) are a family of ten integral membrane PRRs found 
expressed both at the cell membrane and, in the case of TLRs 3, 7 and 9, in endocytic vesicles (Takeda 
and Akira, 2004). TLRs are predominantly expressed on immune cells including dendritic cells, 
macrophages and lymphocytes, but are also prevalent in a broad range of tissues including healthy and 
tumor urothelium (Ayari et al., 2011). TLRs recognize a broad variety of PAMPs such as microbial 
lipopeptides (TLRs 1, 2 and 6), lipopolysaccharide (LPS) (TLR4), flagellin (TLR5), and different 
microbial nucleotides including double-stranded RNA (TLR3), single-stranded RNA (TLRs 7 and 8), 
and hypomethylated CpG DNA (TLR9) (Takeda and Akira, 2004). The binding of PAMPs to their 
cognate TLRs induces receptor dimerization and MyD88-mediated intracellular signaling terminating in 
the activation of pro-inflammatory transcription factors like NF-kB and AP-1 and subsequent expression 
of inflammatory mediators, cytokines and chemokines which act in concert to mitigate the inducing 
stress (Janssens and Beyaert, 2003). 
1.1.4 Urinary tract infections and UCB risk 
Urinary tract infections (UTI) of the bladder are mostly due to Escherichia coli and are 
frequently characterized by increased voiding frequency, urgency and/or dysuria (Dhakal et al., 2008). 
They are more frequent in women than in men, with nearly 50% of women experiencing at least one 
episode in their life and 20% of these observing a recurrent event (Stamm and Hooton, 1993). Treatment 
generally entails a short-term (3 day) regimen of oral antibiotics such as nitrofurantoin, trimethoprim 
and/or sulfonamides, or broader spectrum fluoroquinolones like ciprofloxacin or levofloxacin, with 
extended treatment periods in the case of recurrent episodes (Hummers-Pradier and Kochen, 2002; 
Stamm and Hooton, 1993). In Spain, urinary tract analgesics are often taken concurrently with antibiotics 
during episodes of bladder infection to alleviate symptoms prior to clearance of the uropathogen. 
Phenazopyridine is a commonly prescribed azo-based, orally administered analgesic that achieves high 
15 
 
concentrations in the urinary tract and stains the urine with a bright orange color, easily recognized by 
patients (Zelenitsky and Zhanel, 1996). 
An increased risk of SCC exists in patients with Schistosoma haematobium infestation or 
protracted catheter use resulting from agitation of the urothelium, induction of chronic urothelial 
inflammation and/or concurrent infection(Michaud et al., 2007). However, the association between UTI 
and UCB is less well established. Acute bacterial infection of the urinary bladder induces an acute host 
inflammatory response which may become prolonged as a result of recurrent infections or 
uropathological conditions conducive to urinary stasis and extended bacterial dwell-time within the 
bladder. In experimental studies, rats with bladders physically or chemically agitated before exposure to 
attenuated or pathogenic strains of E. coli were more prone to develop neoplastic lesions and manifested 
a higher incidence of UCB than did uninfected rats (Davis et al., 1984; Higgy et al., 1987; Kawai et al., 
1994; Yamamoto et al., 1992). However, epidemiologic studies examining the association between UTI 
and UCB in humans exhibit a high degree of inconsistency with several studies reporting a positive 
association (Dunham et al., 1968; Kantor et al., 1984; La Vecchia et al., 1991; Wynder et al., 1963), 
while others reported no association (Gonzalez et al., 1991; Jhamb et al., 2007; Kjaer et al., 1989; Piper 
et al., 1986) or an inverse association in women only (Jiang et al., 2009). Moreover, the temporal 
relationship between infection and UCB diagnosis was not considered in many early studies and the use 
of bladder infection medication, an important confounding factor, has not been evaluated in any studies 
to date. In chapter 3 of this thesis, the association between UTIs and UCB is evaluated in more detail 
with specific focus on the effect of UTI medications on UCB risk in the Spanish population. 
1.1.5 Clinical manifestation, diagnosis and prognosis of UCB 
Early clinical symptoms of bladder cancer most commonly manifest as painless haematuria (i.e. 
presence of erythrocytes in the urine), that may be accompanied by urinary frequency, urgency and/or 
dysuria (Kaufman et al., 2009). Early symptoms may often be misdiagnosed due to their similarity with 
other urogenital conditions such as urinary bladder infection or symptoms secondary to benign prostatic 
hyperplasia (BPH). Upon presentation of symptoms, a urinalysis is often done to evaluate urine 
erythrocyte concentration followed by visual inspection of the bladder urothelium with the aid of a 
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cystoscope (Cheung et al., 2013). A cytological evaluation of the urine may also be undertaken to 
evaluate the presence and type of exfoliated tumor tissue present. Diagnosis is made by histological 
examination of resected bladder tumor tissue with which tumor histology, stage and grade can be 
accurately determined by a pathologist. Bladder tumors are graded based on their level of cellular 
differentiation on a three-point (1-3) scale, with strongly differentiated tissues graded as 1. In the work 
presented herein the three grade redefinition provided by the WHO was used (Eble et al., 2004; Mostofi 
et al., 1999). The standard histological staging of bladder tumors is based on the TNM classification 
which considers the depth of tumor tissue invasion (T), degree of lymph node invasion (N), and whether 
metastasis to the surrounding tissues has occurred (M) (Epstein et al., 1998). 
The majority of bladder tumors in developed nations present as UCB upon diagnosis (>90%), 
with less than 5% presenting as SCC and less than 2% presenting as adenocarcinomas (Kaufman et al., 
2009). UCB predominantly manifests (70-80% of patients) as a non-muscle invasive tumor (NMIBC: 
pTa-pT1) characterized by good overall prognosis following transurethral resection (TUR) in patients 
with low-risk tumors (pTaG1/2), and intravesical chemotherapy and/or Bacillus Calmette Guerin (BCG) 
instillation in patients with high-risk tumors (pTaG3 or pT1G2/3) (Wu, 2005). The proportion of patients 
with NMIBC surviving after 15 years is very good: 100% in patients with low-grade Ta; 74% in patients 
with high-grade Ta, and; 62% in patients with T1 tumors (Kaufman et al., 2009). However, 
approximately 50-70% of NMIBC patients suffer a recurrence following treatment and a further 10-20% 
progress, developing new tumors exhibiting muscle invasion (MIBC: pT2-pT4); the risk of progression 
being higher among patients with high-grade tumors (Kaufman et al., 2009; Wu, 2005). A lower 
proportion (20-30%) of UCB patients are diagnosed with muscle invasive tumors (MIBC; pT2-pT4) 
characterized by poor prognosis: 50% of these patients die from their cancer and the five year relative 
survival rate for metastatic disease is only 5% (Michaud, 2007; Wu, 2005). Genomic profiling and gene 
expression analyses indicate a strong correlation between these pathologic classifications and the 
underlying molecular architecture of UCB (Lindgren et al., 2010). 
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1.1.6 UCB treatment 
NMIBC treatment. While physical excision of papillary tumors by TUR is effective treatment for low-
grade NMIBCs, TUR of high-grade NMIBCs and carcinoma in situ (CIS) is generally followed by 
intravesical instillation of attenuated Mycobacterium bovis BCG to reduce the chance of tumor 
recurrence; an approach that is effective in 50-60% of treated patients. Although the exact therapeutic 
mechanism of BCG instillation remains unclear, a functional host innate immune system is necessary to 
induce a localized Th1-polarized inflammatory response that promotes tumor ablation (reviewed in (Luo 
et al., 2011)). Chemotherapeutic agents such as mitomycin are also commonly administered to these 
patients, with instillation directly following TUR showing particular efficacy in reducing tumor 
recurrence (Kaufman et al., 2009). The high propensity of NMIBCs to recur also necessitates close and 
continual surveillance of treated patients and entails regularly scheduled cystoscopic examinations and 
urine cytology analyses. 
MIBC treatment. Patients diagnosed with MIBCs are generally considered for radical cystectomy which 
entails surgical removal of the bladder, adjacent organs, and regional lymph nodes and the redirection of 
urine flow (Kaufman et al., 2009). UCB is highly sensitive to cisplatin chemotherapy and an assortment 
of chemotherapeutic regimens combining cisplatin and other chemotherapeutics have been developed in 
the treatment of metastatic disease with the most prevalent being a combination of methotrexate, 
vinblastine, doxorubicin and cisplatin (a.k.a. MVAC). Other cisplatin based chemotherapeutic regimens 
include gemcitabine and cisplatin (GC), and paclitaxel + GC (PGC) therapy which have shown 
therapeutic efficacy on the level of MVAC therapy (Kaufman et al., 2009). 
1.1.7 Prognostic factors of UCB 
Due to the aggressive nature of high grade UCB and the low survival rate associated with 
metastatic tumors, a means to accurately identify high-risk patients is imperative to tailor post-operative 
surveillance programs and diminish the burden of disease. The European Association of Urology (EAU) 
has established guidelines to predict recurrence and progression of NMIBC based on six of the most 
significant clinical and pathological prognostic factors determined from clinical studies evaluating 
patient response to intravesical therapy (Babjuk et al., 2008; Sylvester et al., 2006). These established 
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clinicopathological factors are directly associated with worse prognosis and include tumor multifocality, 
tumor size (</≥3cm), prior recurrence rate (≤/> 1 recurrence/year), T category, presence of concomitant 
CIS (worse prognosis in the presence of CIS) and tumor grade. Combinations of these factors are used to 
adjust the multivariate prognostic models of NMIBC recurrence or progression risk through 
nomograms/score approach.  
The most effective adjuvant currently administered after resection of high-risk NMIBC is BCG 
instillation. However, one-third of the high-risk NMIBC patients that receive BCG treatment do not 
respond to BCG and 15% observe tumor progression to MIBC with very poor prognosis; classifying 
failure to respond to BCG instillation as a parameter of poor patient prognosis. Clinicopathologic 
parameters such as older age, concomitant CIS, tumor multiplicity, and high-grade tumors are all 
independent predictive factors of poor outcome following BCG. However, evidence related to the 
predictive utility of immunologic, intracellular or genetic biomarkers in response to BCG therapy is 
extensive and heterogeneous, with only the presence in the urine of the Th-1 response-mediating 
cytokine interleukin-2 (IL-2) predicting favorable response to therapy (reviewed in (Zuiverloon et al., 
2012)).  
The best established clinicopathological factors of progression and disease-specific survival 
(DSS) in patients with MIBC include the pathological stage parameters of T category, presence of nodes 
(N) and distant metastases (M), all of which associate with unfavorable prognosis. The presence of 
lymphovascular tumor invasion and resistance to neoadjuvant chemotherapy are also established 
indicators of poor prognosis but were not included as covariables in the SBC study.  
1.1.8 Prognostic biomarkers of UCB 
While clinicopathological parameters of the tumor are currently the most informative and widely 
used clinical prognostic factors of UCB; they do not account for all disease heterogeneity(Netto, 2012). 
In this regard, numerous studies have evaluated the prognostic utility of molecular biomarkers 
representing distinct carcinogenic pathways involved in UCB as a means of more accurately representing 
the biology and clinical course of the disease (Matsushita et al., 2011). Emerging molecular prognostic 
biomarkers of UCB tend to mirror the key molecular genes and proteins altered in the divergent 
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molecular pathways that characterize NMIBC and MIBC (Netto, 2012). For example, FGFR3 activating 
mutations are characteristic of low-grade NMIBC, and evidence also suggests that they are associated 
with increased risk of recurrence in patients with TaG1 tumors (Hernandez et al., 2006). Conversely, 
TP53 and RB inactivating mutations are characteristic of MIBC, and several studies have reported that 
the altered expression of their protein products, p53 and pRb1 respectively, is associated with tumor 
recurrence, progression and patient mortality (Cote et al., 1998; Shariat et al., 2004; Shariat et al., 2010). 
Other molecular biomarkers of NMIBC include: HRAS alterations, proliferation indices characterized by 
Ki67 expression, multimarker immunoexpression analyses of proteins such as p53, p27, KI67, pRb1, 
p21, overexpression of angiogenic markers like VEGF, and promoter hypermethylation. On the other 
hand, molecular biomarkers reported to associate with prognosis of MIBC include: alterations in the 
expression of p16, 21, EGFR, ERBB2, VEGF and mTOR (reviewed in (Netto, 2012)) 
There are no established guidelines for undertaking biomarker studies, and even the most widely 
studied prognostic biomarkers of UCB (e.g. p53) exhibit a large degree of heterogeneity in effect among 
studies that differ in methodology and sample size (Malats et al., 2005). Due to its mediatory role in 
inflammation and overexpression in UCB, cyclooxygenase-2 (see the following section) has been given 
substantial attention as a prognostic biomarker with an array of studies evaluating its role in UCB 
recurrence, progression and patient survival (Aziz et al., 2010; Bamias et al., 2008; Diamantopoulou et 
al., 2005; Eltze et al., 2005; Friedrich et al., 2003; Gudjonsson et al., 2011; Hilmy et al., 2006; Kim et al., 
2002; Liedberg et al., 2008; Margulis et al., 2007; Mokos et al., 2006; Naruse et al., 2010; Shariat et al., 
2003a; Shariat et al., 2003b; Shirahama et al., 2001; Tiguert et al., 2002; Wild et al., 2005; Wulfing et al., 
2004; Yoshimura et al., 2001; Youssef et al., 2011). However, no clear consensus has been reached 
regarding the prognostic utility of COX2 in UCB as studies vary widely in antibodies and their 
concentrations, expression evaluation techniques, sample sizes, tumor subgroups analyzed, multivariable 
adjustment criteria and other factors that contribute to inter-study heterogeneity (see Table 4.4). In 
chapter 4 of this thesis, an attempt is made to homogenize and integrate the diversity of prognostic data 
available in the literature related to COX2 tumor expression in UCB through a systematic review of the 
literature and meta-analysis. Effectively, univariable and multivariable association analyses are modeled 
separately in NMIBC and MIBC to account for the higher COX2 expression levels in the latter group 
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(Czachorowski et al., 2012). Moreover, the largest sample of UCB patients to date is used to evaluate 
each of the pertinent prognostic endpoints and their association with tumor COX2 expression in the 
Spanish population. 
1.2 CYCLOOXYGENASE-2 
 
Cyclooxygenases (COX), also known as prostaglandin endoperoxide synthases (PTGS), are 
enzymes involved in the rate-limiting step of prostaglandin production from free arachidonic acid (Brock 
et al., 1999). Autocrine and/or paracrine secretion of prostaglandins and their activation of cognate 
membrane-bound or intracellular receptors mediates diverse homeostatic and immunoregulatory 
processes (Hata and Breyer, 2004). Deregulation of prostaglandin mediated signaling as a result of 
aberrant COX expression has been linked to various pathologies including autoimmune disease and 
cancer (reviewed in (Dubois et al., 1998)). Of the two primary COX isoforms (COX1/2) identified, 
COX1 exhibits constitutive expression in most human tissues and undertakes a variety of homeostatic 
functions labeling it a „housekeeping‟ enzyme (Crofford, 1997). In contrast, COX2  becomes induced by 
a variety of endogenous and external stimuli that may include growth factors, tumor promoters, viral or 
bacterial infections as well as an assortment of proinflammatory cytokines (Bakhle and Botting, 1996; 
Marnett, 2009). COX2 induction also plays a role in the resolution of the inflammatory response through 
the production of anti-inflammatory prostaglandins suggesting that it has a mediatory role in 
inflammation (Gilroy et al., 1999). Due to its association with the inflammatory response under most 
physiological conditions as well as the overexpression of COX2 in many tumors, including UCB, this 
isoform will be given the principle focus throughout this thesis. 
1.2.1 Cyclooxygenase gene structure 
COX1 and 2 proteins are found highly conserved in vertebrates and have also been identified in 
some invertebrates such as coral, but are absent from insects, plants and unicellular organisms suggesting 
they resulted from a gene duplication event early during vertebrate speciation (Simmons et al., 2004). 
The genes representing each isoform are found at distinct genetic loci and differ substantially in size; 
while COX1 maps to the long arm of chromosome 9 and measures 22kb, COX2 maps to the long arm of 
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chromosome 1 and at 8.3kb is nearly three times smaller than COX1. However, both isoforms share a 
similar number of coding nucleotides (approx. 1800 bp each) spread over 11 exons in COX1 and 10 
exons in COX2 that translate into similarly sized protein products consisting of 576 amino acids (68 
kDa) and 604 amino acids (70 kDa), respectively (Tanabe and Tohnai, 2002). The COX1 promoter 
contains multiple transcription start sites, is GC-rich, lacks a TATA-box promoter sequence, and 
contains a region delimited by two Sp1 binding sites whose integrity is important for maintaining 
constitutive expression of COX1; characteristics consistent with a constitutively active homeostatic gene 
(Mbonye and Song, 2009; Wang et al., 1993; Xu et al., 1997). Conversely, the COX2 promoter contains 
various cis regulatory elements including a TATA-box and CAAT enhancer region as well as binding 
sites for important transcriptional activators including a cAMP response element (CRE), NFkB, NF-IL6 
and AP-1, consistent with an immediate early gene  (Appleby et al., 1994; Hla et al., 1999; Mbonye and 
Song, 2009). COX2 mRNA is relatively unstable (half-life of approx. 30 min.) in comparison to COX1 
mRNA (half-life of approx. 4 hours) owing primarily to the presence of multiple copies of AU rich 
elements (ARE) found within the 3‟-UTR of COX2 mRNA which promote mRNA degradation (Mbonye 
and Song, 2009; Roy et al., 1996). However, COX2 mRNA becomes stabilized by ARE binding proteins 
in response to proinflammatory factors that activate the p38 MAPK signaling cascade (Lasa et al., 2000). 
Moreover, COX2 can be expressed as three alternatively polyadenylated transcripts that vary in size and 
mRNA stability and may also confer subcellular and tissue-specific targeting properties (Hall-Pogar et 
al., 2005; Ristimaki et al., 1996; Simmons et al., 2004). 
1.2.2 Cyclooxygenase protein structure 
The protein structures of both COX isoforms are nearly superimposable and share approximately 
60% amino acid similarity, with the most significant difference being a larger substrate binding site in 
COX2 resulting from the substitution of a Val residue in COX1 for an Ile at corresponding position 523 
within the cyclooxygenase active site of COX2 (Kurumbail et al., 1996; Picot et al., 1994). As a result of 
a larger substrate binding site, COX2 displays less substrate specificity than COX1 and is more apt to 
synthesize prostaglandins using bigger substrates (Simmons et al., 2004). Both COX isoforms are heme-
containing, integral membrane glycoproteins found inserted into the lumenal face of the endoplasmic 
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reticulum and within the perinuclear region. Morita et al observed that while both isozymes localize to 
the endoplasmic and nuclear membranes, COX1 displays activity predominantly at the ER membrane in 
contrast to COX2 which is active at both subcellular locations (Morita et al., 1995). Each isoform is a 
homodimer consisting of a short N-terminal domain, an amphipathic membrane binding domain, and a 
large catalytic domain that contains the active sites for cyclooxygenase and peroxidase activity on either 
side of a heme-moiety (Picot et al., 1994) 
1.2.3 Cyclooxygenase activity and products. 
 Both COX isoforms catalyze the same reaction and their luminal positioning within the lipid 
membrane facilitates access to mobilized arachidonic acid freed from the phospholipid bilayer by 
phospholipase A2. Arachidonic acid is oxygenated at the cyclooxygenase site to form the peroxide 
intermediate prostaglandin G2 (PGG2) which diffuses to the peroxidase active site where it is reduced to 
prostaglandin H2 (PGH2). PGH2 acts as a substrate for several prostaglandin synthases as well as 
thromboxane synthase, by which it becomes converted into various primary prostanoids including PGE2, 
PGD2, PGF2α, PGI2, and TXA2 (Simmons et al., 2004). These prostaglandins bind to cognate membrane 
bound G-protein-coupled receptors in an autocrine or paracrine fashion. In contrast, some prostaglandins 
including PGJ2, 15-deoxy-PGJ2 and PGA2 interact with intracellular peroxisomal proliferator activated 
receptors (PPAR) which induce transcriptional activity in the nucleus (Hla et al., 1999).  
Prostaglandins regulate the biological processes associated with COX isoform expression in a 
broad range of tissues under both physiological (largely attributed to constitutive COX1 activity) and 
pathological conditions (largely attributed to the induction of COX2 activity). For example, PGE2 and 
PGI2 confer cytoprotective effects in the gastrointestinal tract by reducing gastric acid and increasing the 
release of mucous, while in the kidneys these prostaglandins function as vasodilators that maintain renal 
homeostasis (Simmons et al., 2004). Other peripheral tissues which require constitutive prostaglandin 
secretion for the maintenance of proper function include the cardiovascular system, the lungs, 
reproductive system and the central nervous system. Alternatively, PGE2 and PGI2 also have 
proinflammatory, hyperalgesic and pyretic roles under pathological conditions (Simmons et al., 2004). 
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1.2.4 Cyclooxygenase expression and signaling. 
 COX1 is found constitutively expressed in most normal tissues of the body with similar 
expression levels maintained in tissues representing pathophysiological conditions such as osteoarthritis, 
atherosclerosis, and cancer (Koki et al., 2002; O'Neill and Ford-Hutchinson, 1993). Conversely, with 
exception of the brain, kidney, placenta and female reproductive tract, COX2 is not expressed 
constitutively under basal conditions and becomes induced upon exposure to pathophysiological stress 
such as inflammation, infection or vascular shear stress (Harris et al., 1994; Hirst et al., 1995; Koki et al., 
2002; O'Neill and Ford-Hutchinson, 1993). At the molecular level this stress may take the form of 
proinflammatory cytokines such as IL-1, TNF-α and IFN-γ, growth factors, tumor promoters, hormones 
or external factors such as endotoxins found on invading pathogens. Upon binding and activation of their 
respective cellular receptors these molecular factors induce receptor-mediated signaling cascades that 
terminate with transcriptional activation of COX2 via one of its promoter sites thereby facilitating 
prostaglandin mediated resolution of the stress-response. Receptor-mediated signaling cascades leading 
to COX2 transcriptional activation can be broadly classified as activating the NF-kB or mitogen 
activated protein kinase signaling (MAPK) pathways (Smith et al., 2000; Tanabe and Tohnai, 2002). 
Inflammatory factors such as TNF, IL-1 and other pro-inflammatory cytokines can activate both the NF-
kB and MAPK signaling pathways, acting through any one of the three major MAPKs of the latter 
pathway (e.g. ERK1/2, JNK or p38). Pathogen-induced COX2 expression may similarly act through NF-
kB and MAPK signaling pathways, but with signaling following the activation of pathogen specific toll-
like receptors (TLR) by pathogen associated molecular patterns (PAMPs) and the recruitment of the 
adaptor protein MyD88. For example, endotoxins such as LPS found on some bacterial membranes 
specifically activate TLR4, while hypomethylated viral or bacterial DNA binds to TLR9 within the 
endosome, thereby facilitating MyD88 recruitment and initiation of COX2 expression via NF-kB, C/EBP 
or AP1. Conversely, growth factors such as PDGF and FGF typically signal via MAPK signal-
transduction pathways (Smith et al., 2000). 
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1.2.5 COX inhibition.  
COX isozymes have a limited catalytic turnover and undergo self-inactivation within 1-2 minutes 
at AA concentrations inducing maximum reactivity (Simmons et al., 2004). Self-inactivation has been 
proposed to result from oxidative damage to the enzymes incurred from the generation of radical and 
high-state oxidative heme intermediates during the catalytic process (Tsai and Kulmacz, 2010; Wu et al., 
2007). Despite innate self-inactivation, a variety of medically available non-steroidal anti-inflammatory 
drugs (NSAIDs) targeting the cyclooxygenase active site of COX enzymes have been developed to 
provide immediate catalytic inhibition and relief of clinical symptoms that may include fever, pain and 
inflammation. The most widely used is acetylsalicylic acid or Aspirin, which is the only NSAID to 
covalently modify COX1/2 by acetylating a serine residue within the active site and thereby sterically 
block subsequent substrate binding and prostaglandin production (Loll et al., 1995). Aspirin completely 
inactivates COX1 activity, but due to conformational differences of several residues within the active 
sites of the two isozymes, COX2 is incompletely inactivated and capable of oxygenating arachidonic 
acid to produce lipoxins in lieu of prostaglandin H2 (Johnson et al., 1985; Rowlinson et al., 2000). 
However, the majority of medically relevant NSAIDs compete with arachidonic acid for key amino acid 
residues within the cyclooxygenase active site in a manner that is reversible. The main difference among 
non-covalently binding NSAIDs is the rate at which they inhibit COX activity . Ibuprofen and piroxicam 
are two commonly administered NSAIDs that bind and dissociate rapidly from the COX active site and 
confer immediate enzyme inhibitory effects. Conversely, NSAIDs such as diclofenac, flurbiprofen and 
indomethacin exhibit a time-dependent inhibitory response proposed by Selinsky et al to correlate with 
the speed and efficiency by which these drugs can reach and interact with Arg120 and Tyr355 within the 
catalytic pocket (Selinsky et al., 2001).  
1.2.6 Cyclooxygenase in the urinary bladder. 
 In the healthy urinary bladder, prostaglandin secretion maintains bladder tone and contributes to 
the normal functioning of the urinary process (reviewed in (Maggi, 1992)). The topical application of 
prostaglandins such as PGE2 and TXB2 to the urinary bladder of anesthetized rats was reported by 
Maggi et al to induce involuntary micturition (Maggi et al., 1988). Wheeler et al detected both COX1 
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and COX2 mRNA in the ureter, bladder muscle and urothelium of healthy individuals, but only the 
former isoform was detected in these tissues at the protein level (Wheeler et al., 2002). However, urinary 
PGE2 and COX2 protein expression in urine particulates was increased in patients with urogenital 
cancer, urinary tract infections and following processes that induced localized inflammation, such as 
BCG treatment, with no changes in COX1 expression reported. These results are consistent with those of 
Farkas et al who reported a significant increase in prostaglandin levels in patients with acute bacterial 
cystitis, compared to healthy controls, that correlated with the onset and duration of cystitis (Farkas et al., 
1980). Park et al observed that increased mechanical stretching of cultured rat bladder smooth muscle 
cells induced COX2 mRNA and protein expression in a time-dependent manner but had no effect on 
COX1 expression levels (Park et al., 1999). Collectively, these studies appear to suggest that 
prostaglandins serve a cytoprotective role in the healthy urinary bladder in which their levels are 
maintained by the constitutive expression of COX1, with COX2 induction resulting from exposure of the 
bladder to mechanical, inflammatory or pathogenic stress 
1.2.7 COX2 and (bladder) cancer. 
 In healthy tissues, transient COX2 expression generally occurs as part of an acute and highly 
regulated response to an assortment of predominantly pro-inflammatory stimuli (see above). However, 
aberrant overexpression of COX2, as in the case of recalcitrant infection or sustained exposure to pro-
inflammatory stimuli, primarily promotes the production of PGE2 which is sufficient to promote 
carcinogenesis by affecting the hallmarks of cancer in various tissues including the urothelium (reviewed 
in (Greenhough et al., 2009; Hanahan and Weinberg, 2011)). For example, using immortalized urothelial 
cells overexpressing COX2, Gee et al reported that PGE2 levels correlated significantly with cellular 
invasion through an artificial extracellular matrix (Gee et al., 2008). Furthermore, Adhim et al 
demonstrated that COX2 inhibition in T24 urothelial cancer cell lines by the COXIB etodolac could 
suppress the epithelial to mesenchymal transition (EMT); a process implicated in carcinoma invasion and 
migration (Adhim et al., 2011). Other in vitro studies relying on COXIBs to inhibit COX2 activity in 
UCB cell lines have reported dose-dependent decreases in cellular proliferation (Mohseni et al., 2004; 
Smakman et al., 2005) and promotion of apoptosis through the down regulation of the anti-apoptotic 
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protein Bcl-2 (Gee et al., 2006). Using NMIBC samples taken from 110 patients, Friedrich et al also 
observed a significant correlation between COX2 expression and blood vessel proliferation in the tumor 
zone suggesting a link between COX2 and angiogenesis in UCB (Friedrich et al., 2003). Moreover, 
PGE2 secreted by COX2 overexpressing tumors has immunoregulatory properties which promote tumor 
evasion by polarizing cytokine production towards a Th2 immune response and impair dendritic cell 
maturation and tumor infiltration (Ahmadi et al., 2008; Sharma et al., 2003). While PGE2 levels are kept 
in check by another COX2 prostaglandin product, 15-PGDH, which contributes to PGE2 degradation, 
15-PGDH activity has been found inhibited in bladder tumors (Gee et al., 2003).  
While the majority of the preceding studies relied on in vitro techniques to draw conclusions, 
they highlight the diverse roles of COX2/PGE2 expression in bladder carcinogenesis, and collectively 
suggest that increased COX2 expression could be conducive to bladder tumor development and 
progression in vivo. Strong evidence in support of this view came from the group of Klein et al, who 
developed a transgenic mouse that overexpressed COX2 under the control of the keratin-5 promoter. 
COX2 overexpression in the basal epithelial cells was sufficient to cause transitional cell hyperplasia in 
75% of homozygous transgenic mice and UCB in about 10% of mice; with significant increases in 
vascular endothelial growth factor (VEGF) expression above wild-type urinary bladders (Klein et al., 
2005). In another approach, tumor prone transgenic mice treated with a tumor promoter were 
significantly more likely to develop bladder tumors than mice concomitantly administered the COX2-
specific inhibitor rofecoxib (D'Arca et al., 2010). COX2 expression has been reported in various 
premalignant lesions and tumors including urinary bladder dysplasia and cancer (reviewed in 
(Subbaramaiah and Dannenberg, 2003)). Urothelial carcinomas in situ and squamous cell carcinomas 
express COX2 more highly relative to UCB, with expression generally accepted to increase with urinary 
tumor stage and grade (Shirahama and Sakakura, 2001). 
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1.3 SPANISH BLADDER CANCER/EPICURO STUDY 
 
1.3.1 Study design and population.  
The analyses carried out in the body of this thesis relied almost entirely on patient information 
collected as part of the Spanish Bladder Cancer (SBC)/EPICURO study. The SBC/EPICURO study is a 
hospital-based case-control study with 1219 incident UCB cases and 1271 hospital controls recruited 
from 18 Spanish hospitals in five regions of Spain (Asturias, Barcelona, Elche, Tenerife and Valles) 
between 1998-2001. Controls were inpatients with conditions unrelated to bladder cancer risk and were 
matched to cases on age (+/- 5 years), gender, hospital region and ethnicity (99% of all patients were of 
Caucasian ancestry). The majority of study participants were men (87%) and ranged in age from 21-80 
years old, with the median age of cases being slightly older than that of controls (66 years versus 65 
years, respectively). These general patient characteristics may vary slightly from the patient sub-groups 
used for the analyses in the body of this thesis depending on the completeness of the data for the 
variables considered but the show no significant demographic differences (see Chapters 3, 4 and 5). 
1.3.2 Information. 
Patient information concerning various bladder cancer risk factors was collected by trained 
monitors using a questionnaire administered via computer assisted personal interview (CAPI) at hospital 
admission to which 84% of cases and 88% controls approached responded. Information collected from 
patients regarded a broad range of environmental, occupational, lifestyle and medical risk factors. The 
CAPI data used in the analyses undertaken in this thesis (with pertinent references to the literature) 
includes factors relevant to: smoking (Samanic et al., 2006); drug use: non-aspirin NSAIDs (Fortuny et 
al., 2006); medical history regarding urinary tract infections; water intake; frequency of nocturia 
(Silverman et al., 2008); and constant urinary pH readings (Alguacil et al., 2011). 
Clinicopathological data regarding tumor characteristics was collected from cases after resection, 
with all tumors uniformly classified by a panel of pathologists according to the criteria of the TNM 
classification and the WHO-ISUP using the thre-grade redefinition provided by the ISUP-WHO as 
described above. All bladder tumor samples used in the study were collected prior to the administration 
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of any intravesical or systemic therapy. Other clinicopathological data collected that is used in this thesis 
includes tumor size and multiplicity and the type of treatment that patients were administered to treat 
their cancer. 
 Patients were also followed-up yearly by telephone interview and review of clinical charts 
following diagnosis to ascertain the state of their cancer, the number of tumors that may have had 
developed since diagnosis or the last follow-up, and the type of treatment they were receiving. Follow-up 
information ranged from 1 to 117 months, with a median follow-up time of 70.7 months. 
Several different types of biological samples were collected from patients, of which lymphocyte 
based blood samples, buccal swabs, and tumor tissue samples embedded in paraffin blocks were directly 
used for the analyses in this thesis. Specifically, lymphocytes and buccal swabs were collected for DNA 
extraction used for genotyping of the genes evaluated in chapter 5; while paraffin tissue blocks were used 
to construct tissue microarrays which were subsequently evaluated for tumor COX2 expression as 
detailed in chapters 4 and 5.  
Genotypes for genes of interest, as described in Chapter 3, were obtained using four different 
genotyping platforms at the Core Genotyping Facility of the U.S National Cancer Institute (NCI), or the 
Core Genotyping Centre of the Spanish National Cancer Research Centre (CNIO). These included the 
TaqMan, Illumina GoldenGate and Illumina Infinium HumanMap 1M platforms. 
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CHAPTER 2: HYPOTHESIS AND OBJECTIVES 
 
2.1 HYPOTHESIS 
 
Environmental or endogenous factors that induce or contribute to sustained urothelial inflammation can 
incite tumor cell initiation and promote tumor progression. Consequently, exposed individuals, or those 
harboring molecular or genetic aberrations that promote chronic inflammation in the bladder will have a 
higher risk of UCB and suffer from a worse prognosis. 
2.2 OBJECTIVES 
2.2.1 General objective 
 
To assess the involvement of local chronic inflammation in the development and clinical evolution of 
urothelial carcinoma of the bladder (UCB) by analyzing the association between inflammation-related 
factors (environmental, molecular and genetic) and UCB risk and prognosis in the Spanish population. 
2.2.1 Specific objectives 
 
1.) Evaluate the association between urinary tract conditions, specifically bladder infection, and 
UCB risk 
 
2.) Determine whether the use of urinary tract infection medications influences the association 
between bladder infection and UCB risk 
 
3.) Assess COX2 protein expression in UCB and its association with tumor clinicopathological 
factors  
 
4.) Evaluate the prognostic value of COX2 tumor expression in the recurrence and progression of 
NMIBC, and in the progression and survival of patients with MIBC 
 
5.) Determine whether SNPs in inflammatory genes confer heterogeneity in susceptibility to UCB 
characterized by low or high levels of COX2 tumor expression 
 
6.)  Determine whether COX2 tumor expression levels considered together with SNPs in 
inflammatory genes have prognostic value in UCB and/or predict responsiveness to BCG 
immunotherapy 
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3.1 SUMMARY 
Experimental models suggest that bacterial urinary tract infections (UTI) promote urothelial carcinoma 
of the bladder (UCB). However, epidemiologic studies provide conflicting results, suggesting a more 
complex relationship. In the following study the association between UTI and the UCB risk was 
examined with emphasis on the effect of UTI medication. Newly diagnosed UCB patients (n=1096) 
recruited between 1998-2001 from 18 Spanish hospitals and 1259 age, gender and hospital-matched 
controls were included in the study. Information regarding UTIs was collected in person by trained 
interviewers through personal interviews. Clinical data was retrieved from hospital charts. Unconditional 
logistic regression analysis was used to estimate odds ratios (OR) and 95% confidence intervals 
(95%CIs). A history of at least one UTI was reported in 182 (17.1%) cases and 255 (20.5%) controls 
yielding a 24% reduction in UCB risk (OR=0.76, 95%CI 0.60-0.95, P=0.014). The decreased risk was 
mainly observed in patients who reported >2 infections (OR=0.51, 95%CI 0.28-0.93, P=0.029)  and 
among those who reported using medication to treat their UTIs (OR=0.51, 95%CI 0.37-0.70, P=1.0e-04). 
Use of the azo-based urinary tract analgesic phenazopyridine, in particular, was associated with a 
reduction in UBC risk (OR=0.35, 95%CI 0.20-0.62, P=2.40e-4); however risk did not decrease with 
increased use of phenazopyridine. The main limitations were 1) the retrospective and self-reported nature 
of UTI history and use of UTI medication 2) limited statistical power in some stratified analyses. The 
cytotoxic properties of some commonly administered UTI medications may contribute to modifying the 
association between UTI and UCB risk. A protective effect was most pronounced among those 
individuals who received analgesic treatment with phenazopyridine. Given the uro-carcinogenic 
properties of azo-based compounds, uncontrolled confounding cannot be excluded and this association 
should be interpreted cautiously and investigated further experimentally and in future observational 
studies 
. 
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3.2 INTRODUCTION  
Urinary tract infections (UTI) of the bladder are mostly due to Escherichia coli and are frequently 
characterized by increased voiding frequency, urgency and/or dysuria (Dhakal et al., 2008). They are 
more frequent in women than in men, with nearly 50% of women experiencing at least one episode in 
their life and 20% of these observing a recurrent event (Stamm and Hooton, 1993). Treatment generally 
entails a short-term (3 day) regimen of oral antibiotics such as nitrofurantoin, trimethoprim and/or 
sulfonamides, or broader spectrum fluoroquinolones like ciprofloxacin or levofloxacin, with extended 
treatment periods in the case of recurrent episodes (Hummers-Pradier and Kochen, 2002; Stamm and 
Hooton, 1993). In Spain, urinary tract analgesics are often taken concurrently with antibiotics during 
episodes of bladder infection to alleviate symptoms prior to clearance of the uropathogen. 
Phenazopyridine is a commonly prescribed azo-based, orally administered analgesic that achieves high 
concentrations in the urinary tract and stains the urine with a bright orange color, easily recognized by 
patients (Zelenitsky and Zhanel, 1996). 
Strong associations between chronic UTI and squamous cell carcinoma have been established in 
cases of Schistosoma haematobium infestation and in spinal cord injury patients with protracted catheter 
use (Michaud et al., 2007). However, the association between UTI and urothelial carcinoma of the 
bladder (UCB), the predominant bladder cancer histology in developed nations, is less well established. 
In experimental studies, rats with bladders physically or chemically agitated before exposure to 
attenuated or pathogenic strains of E. coli were more prone to develop neoplastic lesions and manifested 
a higher incidence of UCB than did uninfected rats (Davis et al., 1984; Higgy et al., 1987; Kawai et al., 
1994; Yamamoto et al., 1992). However, epidemiologic studies examining the association between UTI 
and UCB in humans exhibit a high degree of inconsistency with several studies reporting a positive 
association (Dunham et al., 1968; Kantor et al., 1984; La Vecchia et al., 1991; Wynder et al., 1963), 
while others reported no association (Gonzalez et al., 1991; Jhamb et al., 2007; Kjaer et al., 1989; Piper 
et al., 1986) or an inverse association in women only (Jiang et al., 2009). Importantly, the temporal 
relationship between UTI and UCB diagnosis was not considered in many early studies and the use of 
UTI medication, has not been evaluated in any study to date. 
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The aim of this study was to investigate whether reported UTI and medication taken to treat and 
alleviate them are associated with UCB risk. 
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3.3. MATERIALS AND METHODS 
3.3.1 Population 
Patients were recruited from 18 hospitals in five regions of Spain as part of the Spanish Bladder Cancer 
(SBC)/EPICURO Study, a hospital-based case-control study described elsewhere (Garcia-Closas et al., 
2005). Eligible cases (N=1,096) were men and women newly diagnosed with UCB between 1998-2001 
and aged 22-81 years at the time of diagnosis. A pathologist review panel uniformly classified the level 
of invasiveness (T) and grade (G) of each tumor biopsy based on the TNM classification and the WHO-
ISUP 1999 (Eble et al., 2004; Mostofi et al., 1999). Individuals previously diagnosed with cancer of the 
urinary tract were not eligible for the study.  Eligible controls (N=1,259) were selected from in-patients 
at similar times as cases and from those individuals admitted to the hospital for conditions/diseases 
thought to be unrelated to the exposures under study. They were matched on age at diagnosis/interview, 
gender, hospital and ethnicity. 
The study was approved by the IRBs of participating centers and the U.S. National Cancer 
Institute. Prior to being interviewed, informed written consent was obtained from all study participants in 
accordance with the Ethics Committees of each participating hospital. 
3.3.2. Information 
Subjects were interviewed in each participating hospital using a computerized questionnaire (CAPI) with 
response rates for cases and controls of 84% and 88%, respectively. They were asked for past history of 
UTIs and their treatment, to characterize this exposure. Patients were specifically asked whether any of 
the medications they had taken turned their urine orange , indicating treatment with the urinary tract 
analgesic phenazopyridine. Additionally, data on kidney infection, bladder or kidney stones, and in men, 
prostatic symptoms secondary to BPH was also obtained. Information was collected regarding patient 
demographics and other factors previously found to be associated with UCB risk including smoking 
status, occupational exposures, fruit and vegetable consumption, daily water consumption, night-time 
urination frequency,urinary pH and non-steroidal anti-inflammatory drug (NSAID) use.  
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3.3.3 Statistical methods 
Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the relative risk of UCB and 
were computed for the exposure of interest using unconditional logistic regression models adjusting for 
age, gender, hospital region, and smoking status. UCB risk due to infection was also assessed distinctly 
in low-risk (pTaG1/G2) and high-risk (pTa/pT1G3) non-muscle invasive UCB (NMIBC) and muscle 
invasive UCB (MIBC). A history of prostatic symptoms secondary to BPH was included in final models 
for men.  
Interaction between two risk factors was tested by adding a cross-product term to the logistic 
model and conducting a likelihood ratio test. All statistical tests were done using R statistical software. 
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3.4 RESULTS 
Characteristics of the studied population (cases and controls) is shown in Table 3.1. 
3.4.1. Risk of UCB conferred by a history of UTI 
A history of UTI was reported by 17% of cases and 21% of controls, yielding a significant reduction in 
bladder cancer risk by 24% (OR=0.76, 95%CI 0.60-0.95) (Table 3.2). This effect was strengthened in 
women (OR=0.53, 95%CI 0.32-0.89) but not observed in men (OR=0.92, 95%CI 0.68-1.23). Histories of 
other urinary tract disorders were not significantly associated with UCB risk in men or women (Table 
3.2) and they were not confounding factors for the UTI association either (Table 3.3). However, men 
reporting prostatic symptoms secondary to BPH had a significant reduction in UCB risk (OR=0.68, 
95%CI 0.49-0.94; Table 3.2) and their exclusion from the analysis attenuated the inverse association for 
UTI among men (Table 3.3), suggesting it was a confounder. 
 To reduce the potential that UTI were misdiagnosed as, or resulted from, the early clinical 
manifestation of the tumor, UCB risk was evaluated considering the time between the last reported 
bladder infection and cancer diagnosis/interview (Table 3.4). While, compared to individuals with no 
reported UTI history, patients with an infection reported <1 year prior to diagnosis/interview did not 
have a reduction in UCB risk (OR=1.36, 95%CI 0.87-2.13), whereas those who reported bladder 
infections ≥1 year prior to cancer diagnosis/interview had a reduced risk (OR=0.58, 95%CI 0.43-0.79); 
which was apparent in both  women (OR=0.44, 95CI 0.23-0.86) and men (OR=0.66; 95%CI 0.47-0.94).  
 We next investigated whether the reduced UCB risk was associated with the number of episodes 
of reported UTI (Table 3.5). Patients reporting >2 episodes of UTI exhibited a more pronounced 
reduction in bladder cancer risk (OR=0.51, 95%CI 0.28-0.93) than those reporting ≤2 infections 
(OR=0.62, 95%CI 0.44-0.87). This pattern was observed for men but the reduced risks were no longer 
statistically significant.  
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Table 3.1. Distribution of selected characteristics of urothelial bladder cancer cases and controls 
 
 Cases   Controls  P-valuea 
 (n=1096) % (n=1259) %  
Gender     0.495 
Men 963 87.86 1094 86.89  
Women 133 12.14 165 13.11  
Region     0.835 
Barcelona 207 18.89 247 19.62  
Valles 185 16.88 190 15.09  
Elche 73 6.66 84 6.67  
Tenerife 192 17.52 223 17.71  
Asturias 439 40.05 515 40.91  
      
Age (yrs.), mean (±SD) 66.11 9.86 64.78 9.93 0.0012 
      
Smoking status     <0.0001 
Non-smokers 142 12.96 367 29.15  
Occasional 50 4.56 97 7.70  
Former 428 39.05 474 37.65  
Current 476 43.43 321 25.50  
Ever smoker     <0.0001 
Never 142 12.96 367 29.15  
Ever 954 87.04 892 70.85  
History of bladder infection    0.038 
No 885 82.85 990 79.52  
Yes 182 17.05 255 20.48  
missing 29  14   
Bladder infection medication    0.002 
No infection 885 86,34 990 82,98  
Yes 109 10,63 181 15.17  
No 31 30,23 22 1.84  
missing 71  66   
Urinary pH     0.010 
>6.0 379 54.14 410 61.10  
≤6.0 321 45.86 261 38.90  
missing 396  588   
Tumor subtype      
No tumor - 1259 100.00  
NMIBC low risk 603 55.02 -  
NMIBC high risk 235 21.44 -  
MIBC 258 23.54 -   
a From Fisher's exact test or t-test as appropriate; missing values excluded 
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Table 3.2: Urinary tract disorders and risk of urothelial bladder cancer by gender 
 
  All   Men   Women 
Variables
a
 Cases Controls OR
b
 95%CI P   Cases Controls OR 95%CI P   Cases Controls OR 95%CI P 
Bladder Infection
c
 
                No 885(82.9%) 990(79.5%) 1,00 REF 
 
610(85%) 728(84.1%) 1,00 REF 
 
86(66.7%) 88(54%) 1,00 
  Yes 182(17.1%) 255(20.5%) 0,76 (0,6-0,95) 0,014 
 
108(15%) 138(15.9%) 0,92 (0,68-1,23) 0,554 
 
43(33.3%) 75(46%) 0,53 (0,32-0,89) 0,015 
Kidney Infection  
                No 796(95.6%) 963(94.3%) 1,00 REF 
 
694(96%) 822(94.3%) 1,00 REF 
 
102(92.7%) 141(94.6%) 1,00 
  Yes 37(4.4%) 58(5.7%) 0,8 (0,51-1,24) 0,314 
 
29(4%) 50(5.7%) 0,73 (0,45-1,2) 0,220 
 
8(7.3%) 8(5.4%) 1,2 (0,41-3,5) 0,737 
Bladder Stones  
                No 814(97.6%) 996(97.7%) 1,00 REF 
 
704(97.4%) 851(97.7%) 1,00 REF 
 
110(99.1%) 145(98%) 1,00 
  Yes 20(2.4%) 23(2.3%) 1,04 (0,55-1,96) 0,908 
 
19(2.6%) 20(2.3%) 1,1 (0,56-2,16) 0,777 
 
1(0.9%) 3(2%) 0,56 (0,06-5,67) 0,626 
Kidney Stones  
                No 710(85%) 852(83.5%) 1,00 REF 
 
615(84.9%) 725(83%) 1,00 REF 
 
95(85.6%) 127(86.4%) 1,00 
  Yes 125(15%) 168(16.5%) 0,97 (0,74-1,27) 0,824 
 
109(15.1%) 148(17%) 0,95 (0,71-1,26) 0,713 
 
16(14.4%) 20(13.6%) 1,13 (0,54-2,34) 0,748 
Prostatic Symptoms 
                No 
      
643(89.4%) 742(85.6%) 1,00 REF 
      Yes 
      
76(10.6%) 125(14.4%) 0,68 (0,49-0,94) 0,021 
      a Data was missing for 2 cases on kidney infection; for 1 case and 2 controls on bladder stones; for 1 control on kidney stones; and 2 cases missing data on prostatic symptoms 
were also excluded for analyses in men 
b
 Unconditional logistic regression adjusted for age, gender, region, smoking status 
c
 Analysis in men additionally adjusted for history of 
prostatic symptoms; 1 case and 1 control missing bladder infection data but not prostatic symptoms data. 
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Table 3.3. Association between bladder infections and UCB considering effect of other  
Urinary tract disorders and diabetes medication 
      
  Cases Controls    
  N(%) N(%) ORa 95%CI P 
Bladder infection - All Cases      
No 890(83%) 994(79.5%) 1   
Yes 182(17%) 257(20.5%) 0,76 (0,6-0,95) 0,014 
Bladder infection - excluding bladder stones      
No 676(83.3%) 798(80.3%) 1   
Yes 136(16.7%) 196(19.7%) 0,77 (0,6-1) 0,049 
Bladder infection - excluding kidney stones      
No 591(83.6%) 691(81.2%) 1   
Yes 116(16.4%) 160(18.8%) 0,82 (0,62-1,08) 0,164 
Bladder infection - excluding kidney infections      
No 660(83.2%) 779(81%) 1   
Yes 133(16.8%) 183(19%) 0,84 (0,65-1,09) 0,199 
Bladder infection - excluding prostatic symptoms       
No 557(86.6%) 648(87.3%) 1   
Yes 86(13.4%) 94(12.7%) 1,03 (0,74-1,43) 0,852 
Bladder infection - excluding diabetes medications      
No 573(82%) 694(80.1%) 1   
Yes 126(18%) 172(19.9%) 0,8 (0,61-1,05) 0,110 
Bladder infection - excluding all urinary tract disorders and diabetes meds 
No 364(87.1%) 433(87.3%) 1   
Yes 54(12.9%) 63(12.7%) 0,98 (0,65-1,48) 0,931 
Bladder infection - excluding all urinary tract disorders and diabetes meds  
but including prostatic symptoms  
No 469(83.2%) 569(82%) 1   
Yes 95(16.8%) 125(18%) 0,86 (0,63-1,17) 0,343 
a Unconditional logistic regression adjusted for age, gender, region, smoking status with sequential  
  exclusion of patients with indicated conditions      
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Table 3.4 Bladder infection and risk of bladder cancer based on time since last infection 
 
  All   Men   Women 
Timea Cases Controls ORb 95%CI P   Cases Controls ORc 95%CI P   Cases Controls ORb 95%CI P 
                  No infection 885 990 1,00 
   
610 728 1,00 
   
86 88 1,00 
  < 1 year 49 39 1,36 (0,87-2,13) 0,174 
 
38 25 1,70 (0,99-2,93) 0,054 
 
11 14 0,89 (0,37-2,14) 0,788 
≥ 1 year 81 154 0,58 (0,43-0,79) 4,10E-04 
 
61 109 0,66 (0,47-0,94) 0,021 
 
20 44 0,44 (0,23-0,86) 0,017 
≥ 5 years 48 83 0,62 (0,42-0,92) 0,016 
 
34 69 0,57 (0,36-0,89) 0,013 
 
14 14 1,05 (0,43-2,55) 0,920 
≥ 10 years 39 61 0,70 (0,46-1,09) 0,115 
 
27 50 0,63 (0,38-1,05) 0,076 
 
12 11 1,07 (0,41-2,8) 0,895 
a Individuals diagnosed with bladder infection within 1, more than or equal to 1, 5 or 10 years of interview were compared in turn to individuals without a 
history of bladder infections; 52 cases and 62 controls did not provide data on time since last infection b Unconditional logistic regression adjusted for age, 
gender, region, smoking status c Additional adjustment for history of prostatic symptoms. 
 
 
Table 3.5 Bladder infection and risk of urothelial bladder cancer (excluding patients with last bladder infection within 1 year of diagnosis/treatment) 
 
  All   Men   Women 
Variablesa Cases Controls ORb 95%CI P   Cases Controls ORc 95%CI P   Cases Controls ORb 95%CI P 
Bladder infection frequency 
                no infection 885 990 1 REF 
  
610 728 1 REF 
  
86 88 1 REF 
 1 to 2 64 114 0,62 (0,44-0,87) 0,006 
 
51 88 0,7 (0,47-1,02) 0,064 
 
13 26 0,45 (0,2-1,01) 0,054 
> 2 17 37 0,51 (0,28-0,93) 0,029 
 
10 20 0,56 (0,25-1,24) 0,151 
 
7 17 0,46 (0,17-1,22) 0,120 
Medication for bladder infection 
               yes 64 136 0,51 (0,37-0,7) 5.25E-5 
 
48 94 0,59 (0,4-0,87) 0,007 
 
16 42 0,36 (0,18-0,74) 0,005 
no 15 16 1,3 (0,61-2,79) 0,497 
 
12 14 1,2 (0,52-2,8) 0,669 
 
3 2 2,21 (0,35-14,03) 0,400 
Specific infection medication taken 
               phenazopyridine 19 57 0,35 (0,2-0,62) 0,000 
 
11 35 0,34 (0,17-0,7) 0,003 
 
8 22 0,38 (0,15-0,97) 0,042 
other medication 37 54 0,76 (0,49-1,19) 0,232 
 
30 40 0,94 (0,56-1,58) 0,825 
 
7 14 0,47 (0,17-1,29) 0,143 
no medication 15 16 1,29 (0,6-2,77) 0,509 
 
12 14 1,2 (0,51-2,79) 0,675 
 
3 2 2,23 (0,35-14,14) 0,395 
a Data missing for 3 controls on bladder infection frequency; for 2 cases and 2 controls on medication for bladder infection; for 10 cases and 27 controls on 
specific medication taken. b Unconditional logistic regression adjusted for age, gender, region, smoking status. c Additional adjustment for history of prostatic 
symptoms. 
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3.4.2 The effect of UTI treatment 
A significant reduction in UCB risk was observed only in patients who reported taking medication to 
treat their infection (OR=0.51, 95%CI 0.37-0.70) (Table 3.5). In contrast, those patients that did not use 
any medication showed a non-significant increased UCB risk (OR=1.30, 95%CI 0.61-2.79). More 
specifically, the protective effect conferred by medication use was confined to patients who used the 
urinary tract analgesic phenazopyridine (OR=0.35, 95%CI 0.20-0.62); while patients who took other 
medications did not observe a significant reduction in UCB risk (OR=0.76, 95%CI 0.49-1.19). The 
observed reduced risk associated with phenazopyridine use was apparent in both sexes.  
 Individuals who medicated with phenazopyridine for each one of multiple reported episodes of 
UTI did not appear to benefit from a greater reduction in UCB risk compared to those who used the drug 
only once (Phet=0.873) (Table 3.6). The reduction in UCB risk was restricted to individuals who had 
medicated with phenazopyridine between one to five years prior to UCB diagnosis/interview (OR=0.11, 
95%CI 0.02-0.45). Comparable effects were observed in analyses stratified by gender, although small 
sample sizes affected the significance values in several strata.  
3.4.3 The effect of cigarette smoking and other UCB risk factors 
Cigarette smoking, the best established risk factor for UCB, did not significantly modify the reduction in 
UCB risk attributed to UTI medication (Pinteraction= 0.218) (Table 3.7). Phenazopyridine reduced UCB risk 
in all individuals irrespective of smoking status but the reduction was slightly larger in ever smokers 
(OR=0.35; 95% CI, 0.17-0.69) than in never smokers (OR=0.42, 95%CI 0.17-1.03). In contrast, only 
never smokers who reported using other medications had a reduction in UCB risk (OR=0.30, 95%CI 
0.10-0.92), while no association between other medication use and UCB risk was observed in ever 
smokers (OR=0.95, 95%CI 0.58-1.57). Never smokers who did not report any treatment for their UTI 
showed a non-significant increased risk (OR=1,93, 95%CI 0,55-6,75, P=0,300). No significant interaction 
was observed between smoking*UTI treatment on UCB risk. Similar effects were observed in males and 
females.
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Table 3.6 Phenazopyridine (DPP) medication in urinary bladder infection and risk of bladder cancer (excluding patients with last bladder infection within 1 year of 
diagnosis/treatment) 
  All   Men   Women 
Variablesa Cases Controls ORb 95%CI P   Cases Controls ORc 95%CI P   Cases Controls ORb 95%CI P 
                  Frequency of DPP treatment for bladder infection 
              no infection 885 990 1 REF 
  
610 728 1,00 REF 
  
86 88 1,00 REF 
 1 10 30 0,33 (0,15-0,7) 0,004 
 
7 20 0,35 (0,14-0,84) 0,019 
 
3 10 0,31 (0,07-1,32) 0,113 
> 1 6 15 0,53 (0,2-1,43) 0,213 
 
3 7 0,60 (0,14-2,54) 0,490 
 
3 8 0,44 (0,11-1,77) 0,247 
no treated/with DPP 52 70 0,87 (0,59-1,28) 0,481 
 
42 54 1 (0,64-1,57) 0,990 
 
10 16 0,65 (0,27-1,58) 0,344 
Pheterogeneity
d 
    
0,873 
            Age at first DPP treatment for bladder infection 
              < 43 yrs. 9 24 0,47 (0,21-1,07) 0,073 
 
5 14 0,42 (0,15-1,22) 0,112 
 
4 9 0,54 (0,14-2,06) 0,366 
≥ 43 yrs. 9 25 0,34 (0,15-0,75) 0,008 
 
6 16 0,40 (0,15-1,07) 0,068 
 
3 10 0,26 (0,06-1,11) 0,070 
no treated/with DPP 52 70 0,87 (0,59-1,28) 0,481 
 
42 54 1,01 (0,64-1,57) 0,982 
 
10 16 0,66 (0,27-1,6) 0,357 
Pheterogeneity 
    
0,996 
            Age at last DPP treatment for bladder infection 
              < 50 yrs. 8 23 0,49 (0,21-1,15) 0,103 
 
4 14 0,37 (0,12-1,18) 0,093 
 
4 9 0,68 (0,18-2,51) 0,563 
≥ 50 yrs. 8 24 0,32 (0,14-0,74) 0,008 
 
6 15 0,45 (0,17-1,22) 0,118 
 
2 9 0,17 (0,03-0,93) 0,041 
no treated/with DPP 52 70 0,87 (0,59-1,28) 0,483 
 
42 54 1,01 (0,64-1,57) 0,977 
 
10 16 0,67 (0,27-1,62) 0,371 
Pheterogeneity 
    
0,827 
            Time since last DPP treatment 
                ≥ 1 to < 5 yrs. 2 19 0,1 (0,02-0,45) 0,003 
 
2 9 0,30 (0,06-1,46) 0,135 
 
0 10 0,00 NA 0,987 
≥ 5 to < 20 yrs. 6 8 0,82 (0,28-2,45) 0,725 
 
3 7 0,39 (0,1-1,54) 0,180 
 
3 1 6,30 (0,57-69,8) 0,134 
≥ 20 yrs. 8 20 0,52 (0,22-1,22) 0,130 
 
5 13 0,52 (0,17-1,53) 0,231 
 
3 7 0,63 (0,15-2,67) 0,533 
no treated/with DPP 52 70 0,87 (0,59-1,28) 0,478 
 
42 54 1,00 (0,64-1,57) 0,983 
 
10 16 0,69 (0,28-1,71) 0,425 
a Data missing for 3 cases and 12 controls on frequency of DPP treatment; for 1 case and 8 controls on age at first DPP treatment; for 3 cases and 10 controls on 
age at last DPP treatment; for 3 cases and 10 controls for time since last DPP treatment b Unconditional logistic regression adjusted for age, gender, region, 
smoking status. c Additional adjustment for history of prostatic symptoms. d P-values for tests of heterogeneity were calculated by excluding individuals without a 
history of bladder infection and those not treated/with DPP  
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Table 3.7 Urinary tract infection and risk of bladder cancer (excluding patients with last  
bladder infection within 1 year of diagnosis/treatment) 
    
  All   
  Cases Controls ORa 95%CI P P-int. 
Smoking status       
never smokers      0.218 
no infection 109(87.2%) 274(83%) 1,00 REF   
phenazopyridine 7(5.6%) 27(8.2%) 0,42 (0,17-1,03) 0,057  
other medication 4(3.2%) 22(6.7%) 0,30 (0,10-0,92) 0,035  
no medication 5(4%) 7(2.1%) 1,93 (0,55-6,75) 0,300  
ever smokers       
no infection 776(93.4%) 716(91%) 1,00 REF   
phenazopyridine 12(1.4%) 30(3.8%) 0,35 (0,17-0,69) 0,002  
other medication 33(4%) 32(4.1%) 0,95 (0,58-1,57) 0,847  
no medication 10(1.2%) 9(1.1%) 1,05 (0,42-2,61) 0,922  
Urinary pHc      0.217 
>= 6.0       
no infection 308(90.9%) 325(87.4%) 1 REF   
phenazopyridine 13(3.8%) 18(4.8%) 0,62 (0,28-1,34) 0,224  
other medication 12(3.5%) 23(6.2%) 0,5 (0,23-1,06) 0,069  
no medication 6(1.8%) 6(1.6%) 1,45 (0,41-5,16) 0,564  
< 6.0       
no infection 260(91.9%) 202(85.6%) 1 REF   
phenazopyridine 3(1.1%) 14(5.9%) 0,14 (0,04-0,51) 0,003  
other medication 15(5.3%) 16(6.8%) 0,59 (0,27-1,30) 0,188  
no medication 5(1.8%) 4(1.7%) 1,12 (0,26-4,90) 0,877  
Tumor stage/grade      NA 
NMIBC Low Risk       
no infection 491(91.8%) 990(88.6%) 1,00 REF   
phenazopyridine 14(2.6%) 57(5.1%) 0,47 (0,25-0,87) 0,016  
other medication 21(3.9%) 54(4.8%) 0,78 (0,46-1,33) 0,362  
no medication 9(1.7%) 16(1.4%) 1,27 (0,53-3,04) 0,585  
NMIBC High Risk       
no infection 190(94.1%) 990(88.6%) 1,00 REF   
phenazopyridine 3(1.5%) 57(5.1%) 0,25 (0,07-0,82) 0,023  
other medication 5(2.5%) 54(4.8%) 0,45 (0,17-1,16) 0,098  
no medication 4(2%) 16(1.4%) 1,63 (0,50-5,25) 0,417  
MIBC       
no infection 204(93.2%) 990(88.6%) 1,00 REF   
phenazopyridine 2(0.9%) 57(5.1%) 0,16 (0,04-0,69) 0,014  
other medication 11(5%) 54(4.8%) 1,08 (0,54-2,17) 0,822  
no medication 2(0.9%) 16(1.4%) 0,68 (0,15-3,16) 0,620  
MIBC and NMIBC High Risk       
no infection 394(93.6%) 990(88.6%) 1,00 REF   
phenazopyridine 5(1.2%) 57(5.1%) 0,20 (0,08-0,53) 0,001  
other medication 16(3.8%) 54(4.8%) 0,75 (0,41-1,35) 0,335  
no medication 6(1.4%) 16(1.4%) 1,20 (0,43-3,31) 0,726  
Pheterogeneity
b     0,271  
a Unconditional logistic regression adjusted for age, gender, region, smoking status    
b Multinomial logistic regression constraining the type of medication used in each  
  tumor subtype examined c Constant urinary pH data was available for 700 cases   
  (63.9%) and 671 (53.3%) of original study population    
51 
 
 The inverse association between UTI medication/phenazopyridine and UCB risk was maintained in 
nearly all strata examined of fruit and vegetable consumption, daily water consumption, night-time voiding 
frequency, history of NSAID, use and constant urinary pH reading (Table 3.8). Reported users of 
phenazopyridine exhibited a significant reduction in UCB risk when their urinary pH was <6.0 (OR=0.14, 
95%CI 0.04-0.51); those who had a constant urinary pH≥6.0 observed a less pronounced non significant 
reduction in UCB risk (OR=0.62, 95%CI 0.28-1.34) (Table 3.7). However, urinary pH did not significantly 
modify the association between UTI medication use and UCB risk (P=0.217). 
3.4.4 The risk according to UCB subphenotypes  
We also examined whether the observed reduction in cancer risk was maintained in all pathological subtypes 
of UCB (Table 3.7). The magnitude of the association between UTI medication and UCB risk was similar in 
all tumor subtypes evaluated (Phet=0.271). Compared to individuals with no reported history of UTI, patients 
who used phenazopyridine to treat their infection observed a significant reduction in UCB risk that 
strengthened with increasing tumor severity. Conversely, no significant associations with UCB risk were 
observed in any of the tumor subtypes examined in individuals who used medications other than 
phenazopyridine or no medication at all (Table 3.7). Similar associations were observed in males and 
females. 
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Table 3.8: UCB risk depending on urinary tract infection medication taken by strata of other  
UCB risk factors 
       
  Cases Controls         
Factor N(%) N(%) ORa 95%CI P P-interaction 
All Cases       
no infection 885(92.6%) 990(88.6%) 1    
phenazopyridine 19(2%) 57(5.1%) 0,4 (0,2-0,62) 0,000  
other medication 37(3.9%) 54(4.8%) 0,8 (0,49-1,19) 0,232  
no medication 15(1.6%) 16(1.4%) 1,3 (0,6-2,77) 0,509  
urinary pH      0,217 
pH >= 6.0       
no infection 308(90.9%) 325(87.4%) 1    
phenazopyridine 13(3.8%) 18(4.8%) 0,6 (0,28-1,34) 0,224  
other medication 12(3.5%) 23(6.2%) 0,5 (0,23-1,06) 0,069  
no medication 6(1.8%) 6(1.6%) 1,5 (0,41-5,16) 0,564  
       
pH < 6.0       
no infection 260(91.9%) 202(85.6%) 1    
phenazopyridine 3(1.1%) 14(5.9%) 0,1 (0,04-0,51) 0,003  
other medication 15(5.3%) 16(6.8%) 0,6 (0,27-1,3) 0,188  
no medication 5(1.8%) 4(1.7%) 1,1 (0,26-4,9) 0,877  
NSAIDs      NA 
never users       
no infection 621(90.7%) 709(87.1%) 1    
phenazopyridine 18(2.6%) 44(5.4%) 0,4 (0,23-0,74) 0,003  
other medication 31(4.5%) 46(5.7%) 0,7 (0,44-1,15) 0,164  
no medication 15(2.2%) 15(1.8%) 1,3 (0,6-2,82) 0,498  
       
ever users       
no infection 29(90.6%) 49(76.6%) 1    
phenazopyridine 1(3.1%) 8(12.5%) 0,4 (0,04-4,16) 0,450  
other medication 2(6.2%) 6(9.4%) 1,2 (0,19-7,98) 0,839  
no medication 0(0%) 1(1.6%) 0 (0-Inf) 0,995  
vegetable and fruit consumption      0,262 
1st quartile       
no infection 200(94.3%) 169(86.2%) 1    
phenazopyridine 1(0.5%) 9(4.6%) 0,1 (0,01-0,78) 0,029  
other medication 8(3.8%) 16(8.2%) 0,3 (0,13-0,84) 0,021  
no medication 3(1.4%) 2(1%) 1,1 (0,15-7,71) 0,931  
       
2nd quartile       
no infection 160(87.9%) 174(88.8%) 1    
phenazopyridine 7(3.8%) 9(4.6%) 0,7 (0,25-2,21) 0,585  
other medication 13(7.1%) 11(5.6%) 1,4 (0,58-3,43) 0,443  
no medication 2(1.1%) 2(1%) 1,6 (0,19-13,95) 0,652  
       
3rd quartile       
no infection 167(91.8%) 176(90.7%) 1    
phenazopyridine 8(4.4%) 10(5.2%) 0,7 (0,25-1,93) 0,486  
other medication 2(1.1%) 3(1.5%) 0,7 (0,1-4,28) 0,663  
no medication 5(2.7%) 5(2.6%) 1,4 (0,35-5,69) 0,626  
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(Table 3.8 cont’d) 
  Cases Controls         
Factor N(%) N(%) ORa 95%CI P P-interaction 
4th quartile       
no infection 143(92.9%) 161(84.3%) 1    
phenazopyridine 2(1.3%) 12(6.3%) 0,2 (0,05-1,04) 0,056  
other medication 6(3.9%) 14(7.3%) 0,5 (0,17-1,34) 0,160  
no medication 3(1.9%) 4(2.1%) 0,8 (0,13-4,15) 0,739  
water consumption      0,370 
<400mL/day       
no infection 58(89.2%) 79(87.8%) 1    
phenazopyridine 4(6.2%) 4(4.4%) 1,4 (0,3-6,52) 0,679  
other medication 2(3.1%) 6(6.7%) 0,4 (0,06-2,28) 0,292  
no medication 1(1.5%) 1(1.1%) 1,6 (0,08-33,83) 0,761  
       
400-1399mL/day       
no infection 170(88.5%) 273(87.5%) 1    
phenazopyridine 5(2.6%) 9(2.9%) 0,7 (0,22-2,42) 0,601  
other medication 14(7.3%) 23(7.4%) 0,9 (0,45-1,93) 0,839  
no medication 3(1.6%) 7(2.2%) 0,7 (0,17-3,04) 0,662  
       
>=1400mL/day       
no infection 83(93.3%) 197(88.3%) 1    
phenazopyridine 1(1.1%) 15(6.7%) 0,1 (0,02-1,09) 0,060  
other medication 3(3.4%) 9(4%) 0,5 (0,11-2,11) 0,339  
no medication 2(2.2%) 2(0.9%) 3,3 (0,41-26,15) 0,263  
Nocturnal urination frequency      0,942 
0       
no infection 443(90.4%) 451(85.6%) 1    
phenazopyridine 11(2.2%) 29(5.5%) 0,4 (0,17-0,76) 0,008  
other medication 25(5.1%) 37(7%) 0,7 (0,38-1,15) 0,141  
no medication 11(2.2%) 10(1.9%) 1,1 (0,43-2,73) 0,875  
       
1       
no infection 146(90.7%) 183(85.9%) 1    
phenazopyridine 6(3.7%) 15(7%) 0,4 (0,13-1,12) 0,081  
other medication 7(4.3%) 12(5.6%) 0,6 (0,23-1,64) 0,326  
no medication 2(1.2%) 3(1.4%) 1,5 (0,21-10,22) 0,699  
       
2+       
no infection 88(92.6%) 170(89.9%) 1    
phenazopyridine 1(1.1%) 11(5.8%) 0,2 (0,02-1,46) 0,109  
other medication 4(4.2%) 5(2.6%) 1,7 (0,4-7,49) 0,468  
no medication 2(2.1%) 3(1.6%) 2,2 (0,3-16,21) 0,436   
a Unconditional logistic regression adjusted for age, gender, region, smoking status and stratifying for each 
factor indicated in turn 
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3.5 DISCUSSION 
In this study, a reduced UCB risk was observed in patients reporting a UTI one or more years before 
cancer diagnosis. This inverse association was restricted to individuals who used UTI medication, 
particularly those with a history of phenazopyridine use. Moreover, the reduction in UCB risk was not 
materially affected by a history of other urinary tract disorders in the studied population. However, given 
the low incidence of UTI in men compared to women, and the increased risk of UTI reported for men 
with BPH, the reduced UCB risk observed in men with prostatic symptoms secondary to prostate 
enlargement in this study was mediated by UTI. 
Early studies reported an increased risk of UCB in patients with a history of UTI (Dunham et al., 1968; 
Kantor et al., 1984; Wynder et al., 1963), while more recent investigations excluding patients with recent 
infections reported no association (Gonzalez et al., 1991; Jhamb et al., 2007; Kjaer et al., 1989; Piper et 
al., 1986). These discrepancies may be due to a misclassification of early clinical symptoms of cancer 
with those of UTI. Similarly, we observed an increased albeit non-significant risk of UCB in patients 
reporting infections within a year of cancer diagnosis while an inverse association was observed when 
this group was excluded from the analysis. Jiang et al. reported an inverse association between UCB risk 
and UTI confined to women who had their last infection >5 years prior to cancer diagnosis (Jiang et al., 
2009). These authors hypothesized that the UCB protection could be attributed to the anti-tumorigenic 
effects of antibiotics taken to treat UTI. Consistent with this hypothesis we observed an inverse 
association between UCB risk and UTI in individuals who reported using medication (i.e. antibiotics 
and/or analgesics) for UTI. Interestingly, a non-significant increased risk was seen among those 
individuals that reported not having received treatment for UTI. 
Antibiotics used to treat UTI may have at least a two-fold effect that could account for the protective 
properties conferred against UCB in this study. Firstly, by clearing uropathogens in the bladder, 
antibiotics could indirectly decrease UCB risk though reducing pathogen induced promotion of initiated 
tumors as observed in animal models of urinary bladder infection and UCB (Davis et al., 1984; Higgy et 
al., 1987; Kawai et al., 1994; Yamamoto et al., 1992). On the other hand, antibiotics may confer 
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cytotoxic effects directly against initiated urothelial tumor cells.  Combination treatments of 
sulfamethoxazole and trimethoprim for UTI have significantly inhibited cell proliferation and induced 
cytotoxicity of human UCB cell lines in a dose-dependent manner (Casini et al., 2002; Kamat and 
Lamm, 2004; Seay et al., 1996). As for phenazopyridine, this drug has been available in Spain for more 
than 50 years as a dual combination for UTI therapy together with the short duration sulfonamide 
sulfamethizole.  A high localized concentration of active sulfamethizole in the bladders of patients who 
used the phenazopyridine combination therapy may efficiently induce cytotoxicity of initiated bladder 
tumors and contribute to the observed reduction in UCB risk in this group. The increased absorption of 
sulfamethizole through urothelial tumor tissue in patients having constantly low urinary pH would 
presumably further contribute to tumor cell cytotoxicity (Mishina et al., 1986).  
 It may also be phenazopyridine that is the active component of the combination therapy 
conferring tumor reduction through a mechanism that is distinct from, or complemented by, the 
sulfonamide. Experimental evidence indicates that the physiological reduction of phenazopyridine 
generates reactive oxygen species (ROS) like superoxide as well as hydrogen peroxide; the latter of 
which can accumulate to high levels in the peroxidase-free urinary environment (Munday and Fowke, 
1994). Localized accumulation of ROS in the bladder could tip initiated bladder tumors beyond a 
sustainable oxidative threshold, while not adversely affecting benign urothelial cells subsisting at an 
inherently lower oxidative level (Trachootham et al., 2009).  
An oxidative-stress induced tumor cytotoxic response may also offer a clue as to why a more pronounced 
reduction in tumor risk was observed by phenazopyridine users who were ever smokers, as compared to 
never smokers. Cigarette smoke increases free radical levels in urothelial cell lines (Ohnishi et al., 2002; 
Onol et al., 2007) while reducing the total radical trapping antioxidant potential (TRAP) of smokers 
(Chelchowska et al., 2011; Sharpe et al., 1996); presumably, conditions favorable for the further 
accumulation of free radicals and oxidative stress induced tumor cytotoxicity. The reduction in UCB risk 
was further strengthened in patients with constantly low urinary pH. Oxidative-stress induced tumor 
cytotoxicity may be most efficient at a low urinary pH in which nitrogen containing nucleophilic 
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functional groups (e.g. TAP) would not be influenced by the underlying chemical properties of 
glucuronide. 
Whether the inverse association observed can be attributed to sulfamethizole, phenazopyridine or the 
concerted and complementary action of both drugs remains to be determined. Our observations suggest 
that the combination therapy may target pre-existing bladder tumors rather than preventing tumor 
formation. Sujects that benefitted of the greatest reduction in UCB risk were those who used the 
medication later in life. Consistent with this hypothesis, is the observation that treatment conferred the 
greatest protection against high-risk NMIBC and MIBC. 
The current study is the largest to evaluate the relationship between UTI on UCB risk and the first to 
investigate the effect of UTI medication on this association. Information regarding the temporal 
relationship between the last infection and recruitment in the study was collected so as to minimize 
misclassification between UTI and UCB symptoms. Other urinary tract disorders, as well as use of 
diabetes medication were also investigated to rule out potential confounding. Moreover, the sample 
population accurately represents UCB in the general population as they were included from a good mix 
of referral centers and county hospitals. Despite these considerations, information collected about history 
of UTIs and medications was entirely self-reported. Recall bias is unlikely to influence the results 
substantially as UTI and bladder cancer were inversely associated. However, individuals with frequent 
UTIs may be more likely to receive cytoscopic examination for early signs of UCB resulting in selection 
bias that could contribute to the observed reduction in UCB risk. Lastly, although our study population 
was large, upon sub-stratification in patients who reported taking phenazopyridine several of the 
subgroups were small and the risk estimates should be interpreted with caution. 
This is the first epidemiologic study to identify a protective effect against UCB resulting from 
medication taken to treat UTI. The greatest reduction in cancer risk was observed in patients who 
reported taking the urinary tract analgesic phenazopyridine through a mechanism that we propose may be 
dependent on the cytotoxic properties of its free radical generating metabolites. These results should be 
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examined in more detail in experimental studies and may have implications for the potential use of UTI 
medication as a prophylactic therapy against UCB. 
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4.1 SUMMARY 
Aberrant overexpression of cyclooxygenase-2 (COX2) is observed in urothelial carcinoma of the bladder 
(UCB). Studies evaluating COX2 as a prognostic marker in UCB report contradictory results. We 
determined the prognostic potential of COX2 expression in UCB and quantitatively summarize the 
results with those of the literature through a meta-analysis. Newly diagnosed UCB patients recruited 
between 1998-2001 in 18 Spanish hospitals were prospectively included in the study and followed-up 
(median, 70.7 months). Diagnostic slides were reviewed and uniformly classified by expert pathologists. 
Clinical data was retrieved from hospital charts. Tissue microarrays containing non-muscle invasive 
(n=557) and muscle invasive (n=216) tumours were analyzed by immunohistochemistry using 
quantitative image analysis. Expression was evaluated in Cox regression models to assess the risk of 
recurrence, progression and disease-specific mortality. Meta-hazard ratios were estimated using our 
results and those from 11 additional evaluable studies. COX2 expression was observed in 38% (211/557) 
of non-muscle invasive and 63% (137/216) of muscle invasive tumors. Expression was associated with 
advanced pathological stage and grade (p<0.0001). In the univariable analyses, COX2 expression - as a 
categorical variable - was not associated with any of the outcomes analyzed. As a continuous variable, a 
weak association with recurrence in non-muscle invasive tumors was observed (p-value=0.048). In the 
multivariable analyses, COX2 expression did not independently predict any of the considered outcomes. 
The meta-analysis confirmed these results. We did not find evidence that COX2 expression is an 
independent prognostic marker of recurrence, progression or survival in patients with UCB. 
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4.2 INTRODUCTION  
Urothelial carcinoma of the bladder (UCB) is the most common bladder cancer type in 
developed nations (Jemal et al., 2011). UCB predominantly manifests (70-80% of patients) as a 
non-muscle invasive tumor (NMIBC: pTa-pT1) characterized by an overall good prognosis 
following transurethral resection in patients with low-grade tumors (pTaG1/2), and intravesical 
chemotherapy and/or Bacillus Calmette Guerin (BCG) instillation in patients with high-grade 
tumors (pTaG3 or pT1G2/3) (Wu, 2005). Approximately 70% of NMIBC patients suffer a 
recurrence following treatment and a further 15% progress, developing new tumors exhibiting 
muscle invasion (MIBC: pT2-pT4); the risk of progression being higher among patients with 
high-grade tumors (Wu, 2005). Due to a high rate of recurrence and the need for close follow-up 
over a patient‟s lifetime, UCB remains one of the most expensive tumors to treat on a per patient 
basis (Botteman et al., 2003). A lower proportion (20-30%) of UCB patients are diagnosed with 
muscle invasive tumors (MIBC; pT2-pT4) characterized by poor prognosis: 50% of these 
patients die from their cancer (Wu, 2005). Genomic profiling and gene expression analyses 
indicate a strong correlation between these pathologic classifications and the underlying 
molecular architecture of UCB (Lindgren et al., 2010). 
Growing evidence indicates that chronic inflammation may increase the risk of UCB 
(Michaud, 2007). Studies investigating the prolonged use of cyclooxygenase-2 (COX2) 
inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) have reported a decrease in UCB 
risk (Daugherty et al., 2011; Fortuny et al., 2006). COX2 is a prostaglandin endoperoxide 
synthetase that catalyzes the production of prostanoids upon induction by proinflammatory 
cytokines, growth factors, tumor promoters and other external stimuli (Harris, 2007). COX2 
activation mediates cellular processes also implicated in carcinogenesis such as angiogenesis, 
cell survival/proliferation and apoptosis (Greenhough et al., 2009). Moreover, studies have 
shown that bladder tissue from patients with cystitis or UCB exhibits elevated COX2 levels in 
contrast to benign bladder tissue (Shirahama, 2000; Wheeler et al., 2002).   
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 While numerous groups have investigated the prognostic potential of COX2 expression 
in UCB (Aziz et al., 2010; Bamias et al., 2008; Diamantopoulou et al., 2005; Eltze et al., 2005; 
Friedrich et al., 2003; Gudjonsson et al., 2011; Hilmy et al., 2006; Kim et al., 2002; Liedberg et 
al., 2008; Margulis et al., 2007; Mokos et al., 2006; Naruse et al., 2010; Shariat et al., 2003a; 
Shariat et al., 2003b; Shirahama et al., 2001; Tiguert et al., 2002; Wild et al., 2005; Wulfing et 
al., 2004; Yoshimura et al., 2001; Youssef et al., 2011), there is no clear consensus on its utility. 
The objective of this study was to assess whether COX2 protein expression in UCB cells is 
associated with prognosis using a large and standardized cohort of newly diagnosed bladder 
cancer patients. A meta-analysis was also done to summarize these results together with those 
from other studies published on the topic.  
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4.3 MATERIALS AND METHODS 
4.3.1 Study population 
A total of 773 newly diagnosed UCB cases aged 22-80 years (mean ± SD = 66 ± 10 yrs) with a 
median follow-up of 70.7 months (range 0.7 - 117.7 months) and available tumor tissue were 
used in the current analysis. All cases were recruited between 1998 and 2001 from 18 hospitals 
in five regions of Spain as part of the Spanish Bladder Cancer (SBC) / EPIdemiology of Cancer 
of the UROthelium (EPICURO) study, a hospital-based case-control study described previously 
(Garcia-Closas et al., 2005). A pathologist review panel uniformly classified the T stage and 
grade (G) of each tumor biopsy according to the criteria of the TNM classification and the 
WHO-ISUP (Epstein et al., 1998), using the three grade redefinition provided by the WHO (Eble 
et al., 2004; Mostofi et al., 1999). All bladder tumor samples used in the study were collected 
prior to the administration of any intravesical or systemic therapy. Clinical information related to 
diagnostic procedures, tumor characteristics and treatment was collected from medical records, 
and a computerized questionnaire was used for the collection of sociodemographic data. 
NMIBCs were removed by transurethral resection and patients received intravesical chemo- or 
immunotherapy (i.e. BCG) as appropriate. The majority of patients presenting with MIBCs were 
treated by radical cystectomy; in cases where surgery was not possible, radiotherapy or systemic 
chemotherapy were administered. Follow-up information was collected annually from hospital 
records and through direct telephone interviews by trained monitors using structured 
questionnaires. Among NMIBCs, recurrence was defined as the appearance of a new NMIBC 
following a previous negative follow-up cystoscopy, and progression, as the development of a 
MIBC. In patients initially presenting with MIBCs, any tumor reappearance after treatment was 
considered progression, regardless of whether the tumor relapse was local or distal. Tumour-
specific survival was assessed only for patients with MIBCs. Informed written consent was 
obtained from study participants in accordance with the Ethics Committees of each participating 
hospital. 
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4.3.2 Immunohistochemistry 
Tissue blocks of formalin-fixed, paraffin-embedded primary bladder tumors were used to 
construct tissue microarrays (TMA) containing tumor cores of 0.6-mm in diameter represented 
in duplicate and selected from the most representative regions of the tumor on which T and G 
were based. After deparaffinisation and heat-induced antigen retrieval, all slides were stained 
simultaneously at the Histology and Immunohistochemistry Core Unit of the CNIO using the PT 
LINK system as per manufacturer‟s instructions (Dako Inc., Glostrup, Denmark). Briefly, tissue 
sections were incubated with anti-COX2 rabbit monoclonal antibody (ThermoFisher Scientific, 
Fremont, CA, USA; #RM-9121-R7; pre-diluted, ready-to-use) at room temperature, followed by 
visualization using the EnVision Flex Visualization system (Dako Inc., Glostrup, Denmark) and 
exposure to diaminobenzedine. Tissues were then counterstained with haematoxylin, dehydrated 
and mounted. A section of colon tissue was used as a positive control.   
4.3.3 Evaluation of COX2 immunostaining 
COX2 expression was quantified using the Ariol SL-50 (version 3.1.2, Applied Imaging Corp., 
San Jose, CA, USA) high-throughput slide imaging scanner.  All cores were imaged and 
processed using a light microscope and the accompanying TMA Multistain Imaging software. 
The program was trained by a pathologist (SM) to maximize the inclusion of positively stained 
tumor epithelium while minimizing stromal material, as described previously (Wahlin et al., 
2010). COX2 expression score was calculated as the product of the mean intensity of staining 
(by defining the background and saturation limits of the antibody and imaging sensor, 
respectively) and the proportion of cellular antibody-positive area divided by total cellular area. 
Values from replicate cores were averaged to provide a final expression score for each patient. 
Furthermore, one randomly selected TMA (representing 10% of all cores) was analyzed by 
direct visual microscopic inspection by an independent pathologist (MMM) to enable 
comparison with the automated scoring approach. The pathologist-derived score was calculated 
as the product of COX2 staining intensity (1=weak, 2=intermediate, 3=strong) and a quartile of 
the percentage of epithelial tumor cells stained (0-4; with 0 representing 0% staining), providing 
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a final categorical score in the range of 0-12. There was a high and significant correlation 
between the machine and pathologist derived scores (Spearman rho=0.85; 95%CI=0.79-0.90; p-
value<0.00001). COX2 expression was analyzed as both a continuous variable and categorical 
variables partitioned at the median and extreme tertiles. Additionally, expression was examined 
as a categorical variable dichotomized at a threshold (0.340 arbitrary units [au]) above which 
COX2 expression was considered to be positive. This expression threshold was derived by 
comparing the pathologist‟s (MMM) binary assignment of positive expression (i.e. score of 0 vs. 
score ≥1, as described above) to the machine-derived continuous score using receiver operating 
characteristic (ROC) curve analysis (area under the curve = 0.95; 86% sensitivity and 92% 
specificity) (Metz, 1978).  
4.3.4 Meta-analysis 
The meta-analysis included COX2 expression results from our own series (using the ROC-derived 
categorical expression variable) and relevant studies published before 1 January 2012 identified by 
searching PubMed and ISI Web of Knowledge. The search string used was: (cox2 OR cox-2 OR 
cyclooxygenase-2 OR "cyclooxygenase 2" OR ptgs2) AND (prognos* OR survival OR mortality OR 
recurrence OR relapse OR progression) AND ("bladder cancer"). Studies were considered eligible if: (i) 
they reported the effect measure (as HRs, survival curves or log-rank p-values) of COX2 protein 
expression on recurrence, progression or disease-specific survival; (ii) COX2 was assessed in primary 
tumors exhibiting homogeneity in tumor histology (≥75% UCB), and subphenotype (≥75% NMIBC or 
MIBC); (iii) they were written in English or Spanish (Table 4.4). Reviews, abstracts, non-clinical studies, 
and duplicate publications were excluded. HRs and 95%CIs were directly extracted from the publications 
whenever available. For those reporting only the log-rank p-value or the Kaplan–Meier survival curves, 
the HRs and 95%CIs were independently calculated by two of the co-authors (MJC, AFSA) using the 
spreadsheet prepared by Sydes and Tierney with any discrepancies resolved by discussion (Tierney et al., 
2007). In a few indicated cases, authors were directly contacted for clarification or provision of data not 
shown in the published manuscripts (Table 4.4). The level of heterogeneity among studies was calculated 
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by means of the I
2
 statistic (Higgins and Thompson, 2002), and publication bias was assessed by 
analyzing funnel plots and Egger‟s asymmetry test (Egger et al., 1997).   
4.3.5 Statistical analysis 
Associations between demographic and clinico-pathological parameters and COX2 expression 
were assessed using Fisher‟s exact test. In NMIBCs, expression was also assessed distinctly in 
low-grade/risk (pTaG1/G2) and high-grade/risk (pTa/pT2G3) tumors, based on our previous 
evidence suggesting differential prognostic, genetic and molecular profiles between these 
subgroups (Hernandez et al., 2006; Lopez-Knowles et al., 2006). Recurrence-free, progression-
free, and overall disease-specific survival curves were generated using the Kaplan-Meier 
method, with statistical significance assessed using the log-rank test. Time to each endpoint was 
calculated from date of primary treatment to the date of event, date of last follow-up, or date of 
patient‟s death. Individuals who did not present any event until the end of the study, those lost to 
follow-up, or those who died from other causes were censored either at the time of last medical 
visit or at death. Time to recurrence and progression were defined by applying the “mid-time” 
between the date of the previous disease-free visit and that when a new event was diagnosed. 
Survival time was measured as the time from initial treatment to death resulting from cancer. 
Univariable and multivariable Cox-proportional hazards analysis was used to calculate hazard 
ratios (HR) and 95% confidence intervals (CI). Schoenfeld residual analysis did not suggest any 
departure from the proportional hazards assumption in multivariable models.   
All statistical analyses were done using STATA (version 10.1 SE, StataCorp, College Station, 
TX, USA). Statistical tests were two-sided and p-values less than 0.05 were considered significant. The 
REMARK (McShane et al., 2005) guidelines for prognostic studies as well as the PRISMA (Moher et al., 
2009) guidelines for systematic reviews and meta-analyses were adhered to in the preparation of the 
manuscript.  
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4.4 RESULTS 
4.4.1 Patients and COX2 expression in bladder cancer TMAs 
COX2 expression was assessed in 557 patients with NMIBCs and 216 individuals with MIBCs. 
Median COX2 expression was 0.121 au (range 0-42.590; interquartile range 1.382) in NMIBCs, 
and 0.760 au (0-30.806; 3.600) in MIBCs (p-value=4x10
-12
). Representative COX2 
immunostaining patterns in UCBs are shown in Figure 4.1. Of patients with NMIBCs, 41% 
(230/557) were treated only by transurethral resection, with the remainder (56%) receiving 
endovesical BCG immunotherapy and/or chemotherapy following transurethral resection, or 
other treatment (3%; Table 4.1). Nearly half (46%) of patients with MIBCs were treated by 
cystectomy, with the remainder receiving systemic chemotherapy, radiotherapy, superficial or 
other treatment, or some combination thereof (Table 4.2).   
4.4.2 COX2 expression and clinicopathological features 
Two-hundred eleven (38%) NMIBCs and 137 (58%) MIBCs expressed COX2 (Tables 4.1 and 
4.2, respectively), with positive expression defined as a score equal to or greater than the ROC-
derived threshold of 0.340 au. Patient and tumor characteristics in the analyzed sample did not 
differ significantly from the initial SBC/EPICURO study population with the exception of 
geographic region and tumor size in NMIBC patients (data not shown). The distribution of 
COX2 positivity was assessed according to established bladder cancer prognosticators including 
tumor invasion and grade, tumor multiplicity, tumor size and treatment, among others. 
Demographic factors like age, gender and region were not associated with COX2 expression, nor 
was the type of primary treatment received by patients (Tables 4.1 and 4.2).  In NMIBCs, COX2 
expression was significantly associated only with T and G; being more prominent in low-
grade/risk pTaG1/2 tumors than in high-grade/risk pTa/pT1G3 tumors (p-value<0.0001; Table 
4.1). Further assessment of COX2 distribution in relevant molecular subtypes of UCB (Lindgren 
et al., 2010), revealed a greater proportion of pTaG2 than pTaG1 tumors positively expressing 
COX2 in low-grade NMIBCs (p<0.0001, subtype 1; Figure 4.2). COX2 expression did not differ 
among high-grade/risk NMIBCs (p=0.075), but a
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Figure 4.1. Immunohistochemical staining of COX2 in primary UCBs on TMAs. Expression 
was scored as a product of the percentage of epithelial area stained and the staining intensity 
using automated imaging analysis. A score of < 0.340 au was considered negative for COX2 
expression, while a score of ≥ 0.340 was considered positive. Representative sections of a 
pTaG1 UCB lacking COX2 expression (A and D) and a pT2G3 UCB expressing COX2 (B and 
E) are shown. Normal colon tissue was used as a positive control (C and F). Upper panels show 
sections under 100x magnification (A-C); lower panels show sections under 200x magnification 
(D-F).   
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Table 4.1. Distribution of characteristics of patients with NMIBCs by COX2 expression. 
   
COX2 expression* 
Patient characteristics Total, N negative, n positive, n P value† 
 
557 346 211 
 Area 
   
0,506 
Barcelona 98 68 30 
 Valles 105 66 39 
 Elche 51 32 19 
 Tenerife 122 71 51 
 Asturias 181 109 72 
 Age (yrs.) 
   
0,385 
≤60 140 81 59 
 >60 and ≤70 210 130 80 
 >70 207 135 72 
 Gender 
   
0,891 
Men 494 306 188 
 Women 63 40 23 
 Tumor Invasion 
   
<0,0001 
Ta 477 277 200 
 T1 80 69 11 
 Grade 
   
<0,0001 
GI 200 131 69 
 GII 219 95 124 
 GIII 138 120 18 
 Low/High Grade 
   
<0,0001 
Low (TaG1/TaG2) 408 221 187 
 High (TaG3/T1G2/T1G3) 149 125 24 
 Number of tumors 
   
0,106 
1 348 209 139 
 >1 178 120 58 
 missing 31 17 14 
 Tumour Size 
   
0,564 
≤3 cm 294 188 106 
 >3 cm 111 67 44 
 missing 152 91 61 
 Number of Recurrences 
   
0,409 
none 366 232 134 
 at least 1 191 114 77 
 Treatment‡ 
   
0,393 
TUR 230 133 97 
 TUR+BCG 158 105 53 
 TUR+Chem. 132 83 49 
 TUR+BCG+Chem. 19 14 5 
 Other 18 11 7 
 * COX2 expression score dichotomised at the threshold of positivitiy (0,340 au) 
†
 Fisher's exact test comparing distribution of COX-2 negative versus positive patients; missing values 
excluded from analysis where applicable 
‡
 TUR: transurethral resection; BCG: Bacillus Calmette-Guerin instillation; Chem.: chemotherapy via 
endovesical instillation 
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Table 4.2. Distribution of characteristics of patients with MIBCs by COX2 expression. 
   
COX2 expression* 
Patient Characteristics Total, N negative, N positive, N P value† 
 
216 79 137 
 Area 
      
0,207 
Barcelona 39 16 23 
 Valles 36 9 27 
 Elche 15 9 6 
 Tenerife 39 14 25 
 Asturias 87 31 56 
 Gender 
   
0,816 
Men 194 72 122 
 Women 22 7 15 
 Age (yrs.) 
   
0,426 
≤60 45 14 31 
 >60 and ≤70 84 35 49 
 >70 87 30 57 
 Tumor invasion 
   
0,896 
T2 114 42 72 
 T3 55 21 34 
 T4 47 16 31 
 Grade 
   
0,326 
GII 19 9 10 
 GIII 197 70 127 
 Metastases 
   
0,296 
M0 168 57 111 
 M1 29 13 16 
 Mx 19 9 10 
 Lymphatic invasion 
   
0,862 
N0 141 50 91 
 N1, N3 49 16 33 
 Nx 26 13 13 
 Number of tumors 
   
0,008 
1 146 63 83 
 >1 54 12 42 
 missing 16 4 12 
 Tumour size 
   
0,572 
≤3 cm 53 19 34 
 >3 cm 66 28 38 
 missing 97 32 65 
 Treatment‡ 
   
0,417 
Cystectomy 67 19 48 
 Cystectomy+Chem. 32 15 17 
 Chem. only 23 9 14 
 RT +/- Chem. 19 7 12 
 Superficial Treatment 13 3 10 
 Others 61 25 36 
 missing 1 1 0 
 * COX2 expression score dichotomised at the threshold of positivity (0,340 au) 
†
 Fisher's exact test comparing distribution of patients with negative or positive COX-2 expression; 
missing, Nx and Mx values excluded from analysis where applicable 
‡
 Chem.: Systemic chemotherapy; RT: Radiation therapy 
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Figure 4.2. Distribution of positive COX2 expression in urothelial carcionomas of the bladder classified 
by their molecular and pathological stage-grade subtypes. Positive COX2 expression assessed as 
described in Figure 4.1. Statistical significance assessed using Fisher‟s exact test with a 0.05 significance 
level. pT1G2 tumors excluded due to low sample size in the current study (n=11), and a reported 
tendency to overlap both molecular subtypes. 
 
 
0
20
40
60
80
pTaG1 (n=200) pTaG2 (n=208) pTaG3 (n=69) pT1G3 (n=69) >=pT2 (n=216)
low-grade NMIBCs high-grade NMIBCs MIBCs
molecular subtype 1 molecular subtype 2
C
O
X
2
 p
o
si
ti
ve
 t
u
m
o
rs
 (
%
)
p<0.0001
p=0.075
p<0.0001
 73 
 
 
greater proportion of MIBCs positively expressed COX2 than did all high-grade/risk NMIBCs 
combined (p<0.0001, subtype 2; Figure 4.2). Only tumor multiplicity was associated with 
positive COX2 expression in MIBC patients (p-value=0.008; Table 4.2).   
4.4.3 COX2 expression and prognosis in bladder cancer patients  
We analyzed the association of COX2 expression with tumor recurrence and progression in 
patients with NMIBCs and with progression and disease-specific survival in patients with 
MIBCs (Table 4.3; Figure 4.3). When considered as a continuous variable in the univariable 
analysis, COX2 expression was marginally associated with an increased risk of recurrence in 
NMIBCs (HR=1.02, 95%CI=1.00-1.04, p-value=0.048; Table 4.3). However, this association 
disappeared upon multivariable analysis when adjusting for region, gender, tumor stage and 
grade, multiplicity, tumor size, and treatment. Moreover, COX2 expression was not significantly 
associated with recurrence in NMIBCs when considered as a categorical variable, neither in the 
univariable nor multivariable analyses (Figure 4.3A; Figure 4.4AC; Table 4.3). Lastly, no 
significant association between COX2 expression and progression or survival was observed in 
patients with NMIBCs or MIBCs, regardless of whether expression was considered as a 
continuous or categorical variable in non-adjusted or adjusted analyses (Figure 4.3B-D; Figure 
4.4B, 4.4D-H; Table 4.3). 
4.4.4 Meta-analysis of COX2 expression and bladder cancer prognosis 
Twenty publications on COX2 expression and bladder cancer prognosis were identified through 
the literature review (Table 4.4) (Aziz et al., 2010; Bamias et al., 2008; Diamantopoulou et al., 
2005; Eltze et al., 2005; Friedrich et al., 2003; Gudjonsson et al., 2011; Hilmy et al., 2006; Kim 
et al., 2002; Liedberg et al., 2008; Margulis et al., 2007; Mokos et al., 2006; Naruse et al., 2010; 
Shariat et al., 2003a; Shariat et al., 2003b; Shirahama et al., 2001; Tiguert et al., 2002; Wild et 
al., 2005; Wulfing et al., 2004; Yoshimura et al., 2001; Youssef et al., 2011).  Three of them 
lacked prognostic data, two overlapped with other larger studies and four included patient 
cohorts that did not meet the eligibility criteria outlined earlier, leaving 11 
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Table 4.3. Analysis of COX2 expression in NMIBCs and MIBCs; univariable and multivariable analyses 
 
Univariate COX-regression 
 
Multivariate COX-regression† 
Score Categorization* Patients, n Events, n HR (95% CI) P value‡ 
 
Patients, n Events, n HR (95% CI) P value‡ 
Non-muscle invasive tumors 
               Recurrence § 
               Continuous 556 191 1,02 1,00 - 1,04 0,048 
 
401 141 1,02 1,00 - 1,04 0,140 
Negative vs. Positive 556 191 1,08 0,81 - 1,44 0,612 
 
401 141 1,11 0,78 - 1,59 0,555 
Median 556 191 1,08 0,82 - 1,44 0,583 
 
401 141 1,17 0,82 - 1,67 0,390 
Extreme tertiles 370 127 1,06 0,89 - 1,27 0,483 
 
268 94 1,08 0,86 - 1,37 0,510 
Progression 
               Continuous 557 48 0,92 0,84 - 1,01 0,094 
 
526 43 0,96 0,87 - 1,05 0,350 
Negative vs. Positive 557 48 0,72 0,39 - 1,33 0,302 
 
526 43 1,38 0,61 - 3,11 0,434 
Median 557 48 0,67 0,38 - 1,20 0,181 
 
526 43 1,11 0,53 - 2,33 0,780 
Extreme tertiles 371 33 0,71 0,49 - 1,01 0,059 
 
351 29 0,92 0,54 - 1,56 0,750 
Muscle invasive tumors 
               Progression 
               Continuous 216 131 0,99 0,96 - 1,03 0,617 
 
189 110 0,99 0,96 - 1,03 0,750 
Negative vs. Positive 216 131 0,94 0,66 - 1,34 0,734 
 
189 110 0,85 0,56 - 1,29 0,448 
Median 216 131 0,97 0,69 - 1,37 0,869 
 
189 110 0,89 0,60 - 1,32 0,560 
Extreme tertiles 144 85 0,92 0,75 - 1,14 0,464 
 
128 75 0,90 0,70 - 1,15 0,410 
Disease specific survival 
               Continuous 216 110 1,00 0,97 - 1,04 0,908 
 
187 89 1,01 0,97 - 1,05 0,730 
Negative vs. Positive 216 110 0,91 0,61 - 1,34 0,627 
 
187 89 0,77 0,48 - 1,23 0,267 
Median 216 110 0,94 0,64 - 1,36 0,726 
 
187 89 0,78 0,50 - 1,23 0,290 
Extreme tertiles 144 68 0,90 0,71 - 1,15 0,407 
 
126 57 0,78 0,58 - 1,04 0,090 
*
 Expression cut-points used for categorical variables: "Neg. vs. Pos." - NMIBC/MIBC: 0.340; "Median" - NMIBC: 0.121, MIBC: 0.760; "Extreme tertiles" - NMIBC: (<0.0239, 
>0.586), MIBC: (<0.270, >2.149) 
†
 Multivariate models adjusted for established bladder cancer prognostic factors as follows: NMIBC Recurrence adjusted by region, gender, tumour stage and grade, # 
tumours, size of tumours, and treatment; NMIBC Progression adjusted by region, # recurrences, age, tumour stage and grade, # tumours, and treatment; MIBC Progression 
adjusted by region, tumour stage, treatment, and presence of nodes; MIBC Survival adjusted by region, tumour stage, treatment, presence of nodes, and metastases 
‡
 Cox proportional hazards analysis 
§
 One patient excluded due to incomplete follow-up record 
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Figure 4.3. Kaplan-Meier survival curves corresponding to failures in superficial (A, B) and invasive (C, 
D) tumors for specified prognostic endpoints. Dashed curves: patients with tumors positive for COX2 
protein staining; solid curves: patients with tumors negative for COX2 protein staining. Significance 
values from two-sided logrank test. 
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Figure 4.4. Kaplan-Meier survival curves corresponding to failures in superficial (A, B, C, D) and 
invasive (E, F, G, H) tumors for specified prognostic endpoints and quantiles of COX2 expression. 
Dashed curves: patients with tumors expressing COX2 at lower specified quantiles; solid curves: patients 
with tumors expressing COX2 at upper specified quantiles. Significance values from two-sided logrank 
test.
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Table 4.4. Main characteristics of eligible studies used in meta-analysis 
                              
First Authour Year Country 
Patients 
w/ 
follow-
up 
Median 
follow-
up 
(months) Histology Stage Tissue 
Antibody for IHC, 
dilution 
Definition of COX2 
positivity HR Estimation Evaluable Notes/reason excluded Ref. 
Aziz 2010 Canada 266 NS TCC (>75%), SCC T2-T4 whole section Cayman, 200 > 5% HRs/95% CIs Yes   12 
Bamias 2008 Greece 42 72 TCC pT3, pT4 whole section SantaCruz, 50 > 10% HRs/95% CIs; from author Yes only bladder tumours analyzed 13 
Diamantopoulou 2005 Greece 55 48 TCC pTa, pT1; pT2-T4 whole section SantaCruz, 130 >= 10% HRs/95% CIs; from author Yes 
 
14 
Eltze 2005 Germany 132 88 TCC pT1; pT2-pT4 whole section Cayman, 200 > 0, categorical Surv. curves No overlap with Wulfing et al 2004 15 
Friedrich 2003 Germany 91 26 TCC pTa, pT1 NS Oxford, 200 > 10% No data No insufficient prognostic data 16 
Gudjonsson 2011 Sweden 52 37,2 TCC Ta TMA Dako, 5 1, categorical HRs/95% CIs No 38% primary tumours in cohort 17 
Hilmy 2006 UK 103 60 TCC Tis, pTa, pT1; pT2-pT4 whole section Cayman, NS tertiles examined HRs/95% CIs No pooled cohort of N/MITs 18 
Kim 2002 South Korea 37 27 TCC T1G3 whole section SantaCruz, 200 > 5% Surv. curves Yes 
 
19 
Liedberg 2008 Sweden 128 16 TCC Tis, pT0, pT1; pT2-pT4 TMA Dako, 5 > 0, categorical No data No no prognostic data 20 
Margulis 2007 USA 157 66 TCC Ta, Tis; T1-T4 (>75%) TMA SantaCruz, NS > 10% Surv. curves; HRs/95% CIs Yes 
 
21 
Mokos 2006 Croatia 70 24 TCC Tis, Ta, T1 whole section Oxford, 50 > 0%, categorical Surv. curves Yes negative vs. positive staining 22 
Naruse 2010 Japan 46 NS TCC pT2-pT4 whole section SantaCruz, 20 > 10% Surv. curves Yes 
 
23 
Shariat 2003a USA 37 120 TCC Tis, pT1 whole section NS, 100 > 10% rec.; > 20% prog. Surv. curves Yes 
 
24 
Shariat 2003b USA 80 101 TCC Tis, pTa, pT1; pT2-pT4 (>75%) whole section SantaCruz, 100 >10% of cells Surv. curves Yes 
 
25 
Shirahama 2001 Japan 108 75 TCC pT1; pT2-T4 whole section NS, 200 >= 5% HRs/95% CIs No pooled cohort of N/MITs 26 
Tiguert 2002 Canada 172 NS TCC MIT NS NS, 100 >= 5% of cells Surv. curves No overlap with Aziz et al 2010 27 
Wild 2005 Germany 617 39 TCC pTa, pT1; pT2-4 TMA Cayman, 5ug/ml > 0, categorical HRs/95% CIs; from author Yes 
 
28 
Wulfing 2004 Germany 157 88 TCC (>75%), SCC Tis, pT1; pT2-pT4 (>75%) whole section Cayman, 200 > 0, categorical Surv. curves; HRs/95% CIs Yes negative vs. positive staining 29 
Yoshimura 2001 Japan 118 NS TCC, SCC pTis, pT0, pT1; pT2-pT4 whole section "in house", 100 > 0, categorical No data No no prognostic data 30 
Youssef 2010 Egypt 315 63,2 TCC (<75%), SCC, AD pT1; pT2-pT4 TMA ThermoFisher, 200 > 20% Surv. curves; HRs/95% CIs No TCC (<75%) 31 
Abbreviations: AD, adenocarcinoma; HRs/95% CIs, hazard ratios/95% confidence intervals; MIT, muscle invasive tumour; NMIT, non-muscle invasive tumour; NS, not specified; Ref., publication reference; Surv. Curves, survival curves; SCC, squamous 
cell carcinoma; TCC, transitional cell carcinoma; TMA, tissue microarray. 
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evaluable publications (Aziz et al., 2010; Bamias et al., 2008; Diamantopoulou et al., 2005; Kim 
et al., 2002; Margulis et al., 2007; Mokos et al., 2006; Naruse et al., 2010; Shariat et al., 2003a; 
Shariat et al., 2003b; Wild et al., 2005; Wulfing et al., 2004) plus the current study for the meta-
analysis (Figure 4.5). Studies were classified by the tumor subtype(s) they reported on (i.e. 
NMIBC or MIBC), and whether adjustment for covariates was considered for each prognostic 
endpoint examined (i.e. univariable or multivariable; Figures 4.6 and 4.7). Of the four meta-
analyses conducted with univariable data, only the metaHR of the association between COX2 
expression and recurrence in NMIBCs showed marginal significance (metaHR=1.35, 
95%CI=1.00-1.83; Figure 4.6). This result was not affected by study heterogeneity (I
2
 p-
value=0.13) but exhibited significant publication bias, as evidenced by Egger‟s test (p-
value=0.019). The remaining meta-analyses considering univariable data suggested increased, 
albeit non-significant, risks of tumor progression in patients with NMIBCs (metaHR=2.07, 
95%CI=0.76-5.64) and MIBCs (metaHR=1.45, 95%CI=0.77-2.74), and death in patients with 
MIBCs (metaHR=1.13, 95%CI=0.8-1.59; Figure 4.6). Notably, the summary effect for 
progression in NMIBCs and that observed for survival in MIBCs were both significantly 
affected by study heterogeneity (I
2
 p-values: 0.006 and 0.004, respectively), with the former also 
significantly influenced by publication bias (Egger‟s test p-value=0.001).  
 Due to a paucity of published prognostic studies performing multivariable analysis on 
patients with NMIBCs, we could only address the multivariable meta-association with 
progression and survival in patients with MIBCs (Figure 4.7). A small, non-significant increased 
summary risk of progression (metaHR=1.12, 95%CI=0.53-2.35; Figure 4.7) was observed in 
COX2 expressing MIBCs that was unaffected by study heterogeneity (I
2 
p-value=0.139). 
Similarly, a null summary effect was observed for survival (metaHR=0.97, 95%CI=0.69-1.36; 
Figure 4.7). This effect was influenced neither by study heterogeneity (I
2 
p-value=0.114) nor by 
publication bias (Egger‟s test p-value=0.108).
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Figure 4.5. Flow diagram of study selection and inclusion in meta-analysis 
 
 
 
 
 
 
*reasons for exclusion of full-text articles included: no reported prognostic data (n = 3), patient overlap with a larger study (n = 2), 
pooled analysis on superficial and invasive bladder tumors (n = 2), inclusion of tumors other than UCB in analysis (n = 1), inclusion 
of non-primary tumors in analysis (n = 1) 
 
Template adapted from:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
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Figure 4.6. Forest plots from selected univariable studies indicating the risk of reaching the indicated 
prognostic endpoints in non-muscle invasive (NMIBC; two upper panels), and muscle invasive (MIBC; two 
lower panels) UCBs in the presence of urothelial COX2 expression. 
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Figure 4.7. Forest plots from selected multivariable studies indicating the risk of reaching the indicated 
prognostic endpoints in non-muscle invasive (NMIBC; two upper panels), and muscle invasive (MIBC; two 
lower panels) UCBs in the presence of urothelial COX2 expression. 
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4.5 DISCUSSION 
Despite many published studies, contradictory findings prevail on COX2 expression as an 
independent prognostic marker in patients with UCB. The current study suggests that COX2 
expression is not an independent marker associated with recurrence, progression or survival in 
patients with UCB.  
Using the largest cohort of patients with NMIBCs evaluated for COX2 expression to 
date, we observed that 38% of these tumors expressed the protein. Other groups have reported 
frequencies ranging from 53-88%; however, these studies used different COX2 antibodies and 
expression evaluation techniques and had smaller sample sizes (Friedrich et al., 2003; 
Mohammed et al., 1999; Ristimaki et al., 2001; Wild et al., 2005; Wulfing et al., 2004). In 
accordance with reported results (Hilmy et al., 2006; Ristimaki et al., 2001; Shirahama, 2000) 
we observed significantly higher COX2 expression in MIBCs (58%) than in NMIBCs. This 
frequency is similar to that observed in other large, histologically homogeneous studies 
(Margulis et al., 2007; Wild et al., 2005), while groups using heterogeneous cohorts of squamous 
and transitional cell carcinomas report frequencies different from our own (Aziz et al., 2010; 
Wulfing et al., 2004).  Collectively, these findings reiterate the importance of homogeneity, or 
stratification, in tumor marker studies. 
The association between COX2 and clinico-pathological characteristics remains a 
contentious issue in the literature. The majority of studies report an association between COX2 
overexpression and advanced tumor invasion and grade, but use heterogeneous populations of 
NMIBCs and MIBCs in their assessments (Komhoff et al., 2000; Margulis et al., 2007; Shariat et 
al., 2003b; Shirahama et al., 2001; Wild et al., 2005). Given the known disparity in COX2 
expression between NMIBCs and MIBCs, an association of this type would be expected in a 
mixed tumor population. After pooling NMIBCs and MIBCs in our study we also observe a 
strong significant association between COX2 overexpression and advanced tumor invasion 
(p>0.0001) and grade (p>0.0001). Notably, several groups report no association between COX2 
expression and T and G (Diamantopoulou et al., 2005; Ristimaki et al., 2001; Wulfing et al., 
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2004); especially those working strictly with homogeneous cohorts of MIBCs (Aziz et al., 2010; 
Naruse et al., 2010). Similarly, in our study, COX2 expression did not differ significantly among 
pT2, pT3 and pT4 tumors (p=0.896). Interestingly, we observed lower COX2 positivity in pT1 
and high-grade/risk NMIBCs, than in pTa and low-grade/risk NMIBCs tumors. This result may 
seem counterintuitive if grade progression is considered a linear trait and COX2 expression is 
deemed to increase linearly with T and G.  However, there is strong evidence indicating that 
UCB exists as two molecularly distinct subtypes, with high-grade/risk NMIBCs having a 
molecular signature more similar to MIBCs than to low-grade/risk NMIBCs (Lindgren et al., 
2010; Lopez-Knowles et al., 2006). In this respect, we observed that COX2 positivity increased 
significantly with increasing T and G within each molecular tumor subtype (Figure 4.2). 
Shirahama et al. (Shirahama et al., 2001) reported a COX2 distribution similar to ours, observing 
8% positivity in pT1 tumors and 50% in MIBCs when using whole section staining and a 5% 
expression threshold. Collectively, these results reiterate the disparity in COX2 expression 
between NMIBCs and MIBCs first reported by Komhoff et al. (Komhoff et al., 2000), and 
highlight the importance of considering expression within the proper molecular context. 
 To minimize the effects resulting from selecting an arbitrary expression threshold, we 
investigated COX2 protein expression as a continuous variable and three categorical variables. 
Only when considered as a continuous variable in the univariable analysis was COX2 expression 
found to be associated with a slight increase in the risk of recurrence. The meta-analysis, 
consisting of five other univariable studies, reiterated this association and showed a 35% 
increased risk of recurrence in patients with COX2 expressing NMIBCs. However, both effect 
estimates exhibit only marginal significance, suggesting that the observed associations may be 
due to chance. Moreover, the association observed in the univariable analysis did not hold after 
adjustment for conventional prognostic factors of recurrence in the multivariable analysis. 
Lastly, the summary effect observed in the meta-analysis may have been skewed by two small 
studies which selected only high risk NMIBCs (T1G3 (Kim et al., 2002) and Cis (Shariat et al., 
2003a)). When a sensitivity analysis was performed removing these two studies from the meta-
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analysis, the association between recurrence and COX2 expression was no longer maintained 
(metaHR=1.14, 95%CI=0.94-1.38). The observed disparity between effect estimates of 
progression in the present study and the meta-analysis could also be attributed to the inclusion of 
these two studies. Upon their exclusion, the summary HR showed no association with 
progression (metaHR=0.98, 95%CI=0.47-2.03). These results do not support a role for COX2 
expression in NMIBCs as an independent prognostic marker of recurrence or progression.  
 Several groups have investigated the ability of COX2 expression to predict outcome in 
patients with MIBCs. Despite wide inter-study variation in methodology, antibodies used, 
sample size, and adjustment parameters in the case of multivariable analyses, the majority of 
these studies did not identify any significant association between COX2 expression and 
progression or survival, consistent with our findings (Bamias et al., 2008; Diamantopoulou et al., 
2005; Naruse et al., 2010; Wild et al., 2005; Wulfing et al., 2004). Shariat and Margulis and their 
colleagues observed a negative association between high COX2 expression and tumor 
progression and mortality (Margulis et al., 2007; Shariat et al., 2003b).  However, both studies 
relied on heterogeneous sample populations which included a small proportion of patients with 
NMIBCs; potentially accounting for the observed associations given the disparity in COX2 
expression between superficial and advanced bladder tumors (Ristimaki et al., 2001). In another 
study, Wulfing et al. reported that high COX2 expression was an independent predictor of poor 
overall survival in a subgroup of 62 patients with MIBC treated with cisplatin-based 
chemotherapy (Wulfing et al., 2004). We did not identify any meaningful interaction between 
COX2 expression and treatment (data not shown), and were unable to replicate their findings in 
a smaller subset of 39 patients treated with cisplatin (HR=1.47, 95%CI=0.48-4.51, p-
value=0.497). Aziz et al. reported a 36% survival advantage associated with increased COX2 
levels in a cohort of 266 patients with MIBCs (221 with UCB) that was independent of lymph 
node status and neo/adjuvant chemotherapy (Aziz et al., 2010). While we also observed 
improved survival among patients with COX2 overexpressing MIBCs, this association did not 
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reach significance, consistent with other univariable (Naruse et al., 2010; Wild et al., 2005) and 
multivariable (Shirahama et al., 2001) analyses. 
Our study had a large sample size, included only incident cases and relied on extensive 
and accurately acquired follow-up information spanning ten years. Additionally, we used 
automated scoring of immunostained TMAs, a strategy providing a reproducible assessment of 
expression that correlated highly with the independent evaluation of a subset of samples by an 
independent pathologist. COX2 staining was done in one laboratory to avoid heterogeneity in 
immunohistochemical staining and scoring, and evaluated as a continuous variable in the 
prognostic analyses to avoid potential bias related to selection of an expression threshold. 
Moreover, the sample population provides an accurate representation of bladder cancer in the 
general population as no inclusion criteria were applied in the recruitment process which 
included a good mix of referral centers and county hospitals. Lastly, the recommendations of the 
REMARK and PRISMA studies were followed in all of the reported analyses. 
Despite these considerations and attempts to accurately quantify COX2 expression only 
in epithelial cells, the pathologist-trained automated imaging system may have incorporated 
some immunostained stromal material found on the tissue core, thereby increasing type I error. 
To reduce potential error we averaged the expression scores from duplicate cores and also 
explored a method investigated by Henriksen et al. (Henriksen et al., 2007) in which the higher 
score was used (data not shown). Both methods produced similar material associations between 
COX2 expression and clinico-pathological parameters or HRs. Moreover, adjusted analyses for 
progression in NMIBCs should be interpreted cautiously given the low number of events in 
relation to covariates.  Also, different patient management practices across recruitment hospitals 
could increase sample heterogeneity, necessitating the inclusion of both recruitment area and 
treatment regimen in our multivariable analyses.   
The results presented herein focus on COX2 expression levels measured in tumor 
epithelial cells – only one aspect of the complex interplay between the tumor and the host 
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immune/inflammatory response (Mantovani et al., 2008). The prognostic potential of COX2 (if 
any) may only be revealed when considered together with other tumoral markers. When 
investigating several potential prognostic parameters in UCB, Hilmy et al. concluded that 
systemic factors of the inflammatory response such as levels of C-reactive protein were superior 
to tumor-based factors such as grade, COX2 expression or T-lymphocytic infiltration (Hilmy et 
al., 2006). Moreover, in models of cervical cancer, Ferrandina et al. observed that while COX2 
expression was mutually exclusive in the tumor and stromal inflammatory cells, high expression 
in both cell types could be used as an independent marker of poor survival (Ferrandina et al., 
2002).  Future studies investigating the prognostic value of COX2 expression in UCB should 
take into consideration the multi-factorial and multi-dimensional context of the inflammatory 
response during carcinogenesis.  
The current study is the largest to investigate COX2 expression as an independent 
marker of outcome in a prospective cohort of UCB patients. These findings, supported by a 
meta-analysis that included our own data and that from other relevant studies, do not support 
COX2 tumor cell expression being an independent prognosticator of UCB. 
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5.1 SUMMARY 
Cyclooxygenase-2 (COX2) mediates the acute inflammatory response and exhibits elevated 
expression in urothelial carcinoma of the bladder (UCB) in contrast to benign bladder tissue. We 
aimed to determine whether genetic variants (SNPs) in inflammatory pathway genes are 
differentially associated with UCB risk according to COX2 protein expression levels in tumor 
tissue. SNPs identified as conferring heterogeneity in genetic susceptibility to UCB subtypes 
defined by COX2 expression were also evaluated for their prognostic and/or predictive utility in 
these tumors, with emphasis on patient response to BCG immunotherapy. COX2 expression was 
determined in 604 bladder cancer cases from the Spanish Bladder Cancer/EPICURO study using 
immunohistochemical analysis of tissue microarrays (TMA). In total, 331 COX2-negative and 
273 COX2-positive cases and 988 matched controls were included in the analysis. Nine-hundred 
eleven SNPs in 214 inflammatory genes were genotyped in the same population. Polytomous 
logistic and Cox regression models were applied to estimate the odds ratios (OR) and hazard 
ratios (HR) for cancer risk and progression, respectively. Two common SNPs in TLR9 
(rs187084; rs352139) showed evidence of risk heterogeneity for UCB subtypes defined by 
COX2 positivity. The variant allele of rs187084 reduced the risk of COX2-negative UCB 
(OR=0.63; Pheterogeneity= 1.47E-06), while the variant of rs352139 increased risk of COX2-
negative tumors (OR=1.44) but decreased risk of COX2-positive tumors (OR=0.81) ( Phet.= 
1.67E-06). The observed heterogeneity in risk remained robust after correction for multiple 
testing. Interestingly, patients harboring the variant allele in TLR9-rs187084 and manifesting 
COX2-negative tumors were less likely to exhibit cancer progression (HR=0.39, 95%CI 0.15-
0.94, p=0.036) and were more responsive to BCG immunotherapy (HR=0.16, 95%CI 0.03-0.81, 
p=0.027) than wild-type patients or patients with COX2-positive tumors. We report for the first 
time that UCB subphenotypes defined by COX2 expression present differential risk according to 
genetic variation in the innate immune response gene TLR9. Moreover, the variant allele of 
TLR9-rs187084 exhibits potential as a predictive marker of good prognosis in patients 
manifesting COX-negative tumors treated with BCG treatment response in patients manifesting 
COX2-negative tumors.
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5.2 INTRODUCTION 
The majority of patients with urothelial carcinoma of the bladder (UCB) (70-80%) present with 
non-muscle invasive disease (NMIBC) confined to the bladder mucosa (pTa, pT1), with a 
smaller proportion (20-30%) observing tumors that invade into or beyond the surrounding 
muscle layer (MIBC; pT2-pT4). Tumors are further subcategorized according to their degree of 
differentiation: G1, G2, G3 or low/high grade (Eble et al., 2004; Mostofi et al., 1999). Following 
resection, about 70% of patients with NMIBC observe tumor recurrence, while a further 15% 
with high-grade NMIBC will experience tumor progression into the muscle layer (Wu, 
2005).Tumor progression is particularly frequent (50%) among patients with high-grade NMIBC 
(TaG3 and T1G2/3) These high-risk patients are commonly treated with Mycobacterium bovis 
Bacillus Calmette Guerin (BCG) instillation therapy and 50-60% respond positively. Although 
the exact therapeutic mechanism of BCG instillation remains unclear, a functional host innate 
immune system is necessary to induce a localized Th1-polarized inflammatory response leading 
to tumor ablation (Luo et al., 2011). 
 Well established UCB risk factors include a dozen genetic susceptibility loci (Rothman 
et al., 2010) and environmental factors like smoking (Samanic et al., 2006), which can interact to 
further modulate disease risk as observed in smokers harbouring the NAT2 slow acetylator 
phenotype (Garcia-Closas et al., 2005; Garcia-Closas et al., 2013). Conditions that induce 
chronic inflammation of the bladder mucosa, such as Schistosoma haematobium infestation or 
extended catheter use in spinal cord injury patients also contribute to increased bladder cancer 
risk, albeit of the squamous cell type (SCC) (Michaud, 2007). Furthermore, recurrent cystitis has 
been associated with UCB, though results from the published studies are inconclusive (Chang 
and Parsonnet, 2010). Conversely, prolonged use of cyclooxygenase targeting non-steroidal anti-
inflammatory drugs (NSAIDs) has been associated with a reduction in UCB risk (Daugherty et 
al., 2011). This evidence, together with findings that common sequence variants in inflammation 
regulating genes (e.g. PTGS2/COX2) modulate UCB risk (Yang et al., 2008), further implicate 
inflammation in the etiology of this complex disease.  
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Cyclooxygenase-2 (COX2) is a prostaglandin endoperoxide synthase induced by 
proinflammatory cytokines, growth factors and tumor promoters, among other factors (Harris, 
2007). Together with the prostanoid products of arachidonic acid metabolism, COX2 signaling 
mediates the inflammatory response under physiological conditions, but its aberrant 
overexpression has been implicated in tumor promotion through the induction of angiogenesis, 
stimulation of cellular proliferation and inhibition of apoptosis (Greenhough et al., 2009). 
Animal models overexpressing COX2 in basal epithelial cells manifest increased transitional cell 
hyperplasia and carcinoma (Klein et al., 2005) while in humans, COX2 levels are elevated in 
bladder tissue from patients with cystitis and in UCB (Shirahama, 2000; Wheeler et al., 2002). 
Given the association between COX2, inflammation and bladder cancer, we wanted to 
determine whether genetic variation in genes involved in inflammatory processes could 
differentially predispose individuals to discrete subgroups of UCB characterized by the presence 
of COX2 expression. This information was subsequently evaluated for its prognostic utility in 
UCB patients from 18 hospitals in Spain, with emphasis placed on response to BCG 
immunotherapy. 
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5.3. MATERIALS AND METHODS 
5.3.1 Population 
 
All patients were of white ethnicity and recruited between 1998 and 2001 from 18 hospitals in 
five regions of Spain as part of the Spanish Bladder Cancer (SBC) / EPIdemiology of Cancer of 
the UROthelium (EPICURO) study, a hospital-based case-control study described previously 
(Garcia-Closas et al., 2005). A set of 608 newly diagnosed UCB cases with available tumor 
tissue and genotype information were included in the current analysis. All tumor samples were 
reviewed by a panel of expert pathologists to confirm diagnosis and were collected prior to the 
administration of any intravesical or systemic therapy. The T stage and grade (G) of each tumor 
was assessed according to the criteria of the TNM classification and the ISUP-WHO (Epstein et 
al., 1998), using the three grade redefinition provided by the WHO (Eble et al., 2004; Mostofi et 
al., 1999). Subsequently, cases were immunohistochemically categorized based on COX2 
positivity (negative, n=334; positive, n=274). Nine-hundred eighty-eight inpatients with 
complete genotype information and diagnoses unrelated to the exposures of interest were 
included as controls and matched to cases on age, gender and hospital region. Informed written 
consent was obtained from study participants in accordance with the Ethics Committees of each 
participating hospital. 
5.3.2 Immunohistochemistry and evaluation of COX2 expression  
 
COX2 immunostaining of patient tumors and subsequent evaluation of epithelial protein 
expression has been described previously (Czachorowski et al., 2012). Briefly, paraffin-
embedded primary bladder tumors were used to construct tissue microarrays (TMA) containing 
tumor cores of 0.6-mm in diameter represented in duplicate. Tissue sections were incubated with 
anti-COX2 rabbit monoclonal antibody (ThermoFisher Scientific, Fremont, CA, USA; #RM-
9121-R7; pre-diluted, ready-to-use) at room temperature. Epithelial COX2 expression was 
quantified using the Ariol SL-50 (version 3.1.2) high-throughput slide imaging scanner. The 
threshold of positive COX2 expression (>0.340 au) was determined by applying receiver 
operating characteristics (ROC) analysis (Metz, 1978) by comparing the machine-derived 
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expression score to a pathologist‟s (MMM) binary assignment of COX2 expression of a 
randomly chosen TMA representing approximately 10% of all tissue cores used. Cases were 
immunohistochemically categorized based on COX2 positivity as described previously 
(negative, n=334; positive, n=274) (Czachorowski et al., 2012)  
5.3.3 Polymorphism selection, genotyping and quality control 
 
SNP selection, genotyping and quality control for all SNPs (with the exception of TLR9-
rs352139 and TLR9-rs352140) used in this study were done as previously described by Lopez et 
al (unpublished). Briefly, three genotyping platforms (two GoldenGate Illumina and one 
TaqMan) were used to analyze tagSNPs in genes related to the inflammatory response and 
having an association with cancer were selected. The SYSNPs application (Lorente-Galdos et 
al., 2012) (using databases dbSNP b25, hg17 and HapMap Release #21) was used to tag SNPs 
applying Haploview‟s Tagger algorithm (v. 3.32) with parameters set to default. SNPs were 
genotyped following manufacturer‟s instructions (http://www.illumina.com/). 
Good agreement (98.2%-99.8%) was observed for SNPs genotyped in all three platforms 
with any missing genotype data in one platform complemented by SNP data from the remaining 
platforms. Patients with >95% of successfully genotyped SNPs in each platform were included 
in the analyses. However, SNPs with >5% missing genotypes, and those with a MAF of <5% 
and no association with UCB after Fisher‟s exact test, were excluded from the analyses. The 
final number of cases and controls included in the analysis was 1,047 and 988, respectively. 
Missing genotypes were imputed with the k-NN method using the package SCRIME in R. To 
minimize colinearity between variables, pairwise linkage disequilibrium between SNPs was 
estimated based on r
2
 values using the package GENETICS in R; only one of each pair of SNPs 
was retained for further analyses when r
2
 >0.8. Following quality control, the final dataset 
yielded a total of 911 SNPs from 214 genes. 
TLR9-rs352139 and TLR9-rs352140, available from a previous genotyping effort using 
the Illumina Infinium 1M SNP platform (Rothman et al., 2010), were selected for inclusion in 
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the study post-hoc. Thirteen cases and 23 controls had missing genotype information for these 
two SNPs when compared to the main set of inflammatory SNPs used in this study.  
5.3.4 Statistical analysis 
 
Demographic characteristics of controls, and UCB cases defined by the COX2-positivity of their 
tumors, were compared using the analysis of variance for continuous variables and the Chi-
square test for categorical variables. Additionally, Fisher‟s exact test was used to make 
comparisons between the two UCB subphenotypes. 
Odds ratios (OR) and 95% confidence intervals (CI) were estimated for each of the two 
molecular UCB subphenotypes using polytomous logistic regression models for each genetic 
variant and considering codominant and additive modes of inheritance. In each model, the tumor 
groups were compared to the control group adjusting for the potential confounders: age, gender, 
region and smoking status (never, occasional, former and current smoker) (Samanic et al., 2006). 
The global association between variants and risk of any tumor type was assessed using the 
likelihood ratio test (LRT) comparing models with and without all variant coefficients for the 
two modes of inheritance examined. The association between variants and risk of distinct 
subphenotypes was tested with a 2-df LRT in the codominant model and a Wald t-test for each 
subphenotype in the additive inheritance models. Moreover, heterogeneity of genotype conferred 
risk was examined in the UCB subphenotypes using the LRT to compare a model in which the 
variant coefficients were constrained to be equal in both subphenotypes to an unconstrained 
model for both modes of inheritance. 
Recurrence-free and progression-free survival curves were generated using the Kaplan-
Meier method, with statistical significance assessed using the log-rank test. Time to each 
endpoint was calculated from date of primary treatment to the date of event or date of last 
follow-up. Individuals who did not present any event until the end of the study, those lost to 
follow-up, or those who died from other causes were censored either at the time of last medical 
visit or at death. Time to recurrence and progression were defined by applying the “mid-time” 
between the date of the previous disease-free visit and that when a new event was diagnosed. 
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Univariable and multivariable Cox-proportional hazards analysis was used to calculate hazard 
ratios (HR) and 95% CIs. Schoenfeld residual analysis did not suggest any departure from the 
proportional hazards assumption in multivariable models.   
All statistical analyses were done using STATA (version 10.1 SE, StataCorp, College 
Station, TX, USA). Statistical tests were two-sided and p-values less than 0.05 were considered 
significant. Bonferroni correction for multiple testing was applied in exploratory risk analyses of 
the inflammatory gene SNPs. 
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5.4 RESULTS 
5.4.1 Distribution of patient characteristics 
 
The majority of patients were men (88.7%) and either former (38.6%) or current smokers 
(44.0%). No difference was observed in the distribution of demographic characteristics between 
patients with negatively or positively COX2 expressing tumors (Table 5.1). However, nearly half 
(40%) of all COX2 expressing tumors were muscle-invasive as compared to 19% of COX2 
negative tumors; a difference that was statistically significant (p < 0.0001). 
 Controls were similar to both subgroups of cases with respect to gender, but were 
slightly younger (mean age: 64.4 yrs in controls; 66.7 yrs in COX2 negative cases; and 65.7 yrs 
in COX2-positive cases). The distribution of cases with respect to controls differed by region (p 
= 0.004). As expected, fewer controls (27.1%) than cases were current smokers. 
5.4.2 Heterogeneity in genetic susceptibility according to tumor COX2 expression 
 
Overall, 46 SNPs in 37 inflammatory genes were associated with UCB risk in at least one of the 
modes of inheritance considered, and significantly contributed to heterogeneity in genetic 
susceptibility to the two UCB subgroups examined (Supplementary Table 5.1A-D). None of 
these 46 SNPs were found to be associated with UCB risk in a logistic regression analysis that 
pooled cancer subtypes; likely resulting from an attenuation of the risk estimates (data not 
shown). Two SNPs in TLR9 (rs187084 and rs352162) maintained these associations in all of the 
inheritance models examined (Table 5.2) with the strongest evidence of heterogeneity being 
observed when the additive mode of inheritance was examined (rs187084, p=1.47e-06; 
rs352162, p=4.50e-04). In the case of TLR9-rs187084, this association remained robust after 
Bonferroni correction for multiple testing (p-value for heterogeneity that was < 6.86e-06). TLR9-
rs187084 was associated with a 37% reduction in the risk of COX2-negative UCB for every 
copy of the variant allele (C) (OR=0.63, 95%CI=0.52-0.77, p-value =4.65E-06), but had no 
association with risk of COX2-positive UCB (OR=1.13, 95%CI=0.93-1.38, p-value =0.218
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Table 5.1 Patient and tumor characteristics 
 
  Bladder Cancer Subphenotypes     Group Comparisons 
Factors 
      
All Groups Case Groups 
(N=1588) Low COX2 (n=331) High COX2 (n=273) Controls (n=984) P value P value 
         T stageb 
      
- <0,0001 
Ta, T1 (NMIBC) 267 (80,7) 163 (59,7) - 
  T2-T4 (MIBC) 63 (19,0) 110 (40,3) - 
  Age, mean(SD) 66,7 (9,1) 65,7 (10,6) 64,4 (10,0) 0,0011 0,2 
Gender 
      
1,0 0,8 
Men 293 (88,5) 243 (89,0) 869 (88,3) 
  Women 38 (11,5) 30 (11,0) 115 (11,7) 
  Region 
      
0,004 0,1 
Barcelona 58 (17,5) 28 (10,3) 196 (19,9) 
  Valles 62 (18,7) 49 (18,0) 157 (16,0) 
  Elche 26 (7,9) 17 (6,2) 79 (8,0) 
  Tenerife 62 (18,7) 60 (22,0) 145 (14,7) 
  Asturias 123 (37,2) 119 (43,6) 407 (41,4) 
  Smoking statusc 
      
<0,0001 0,7 
Never 44 (13,3) 39 (14,3) 277 (28,2) 
  Occasional 10 (3,0) 12 (4,4) 79 (8,0) 
  Former 133 (40,2) 100 (36,6) 361 (36,7) 
  Current 144 (43,5) 122 (44,7) 267 (27,1)     
a Chi-square test of independence for categorical variables and one-way analysis of variance for age b 
One case could not be assigned any T stage because the paraffin block could not be retrieved c 
Specification of smoking status variable: never, those who smoked <100 cigarettes in their lifetime; 
occasional, those who smoked <1 cigarette per day for 6 mo; former, those who smoked at least 1 
cigarette per day for 6 mo but did not smoke within 1 yr previous to the interview date; current, those 
who smoked at least 1 cigarette per day within 1 yr of the interview date. 
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Table 5.2 Association of common SNPs in TLR9 with UCB characterized by differential expression of COX2 in EPICURO study patients 
 
    N = 1588   1: COX2-negative UCB   2: COX2-negative UCB   LRT p-val 
rs number   Controls COX2 (-ve) COX2 (+ve)   OR L95 U95 p-val   OR L95 U95 p-val   Globala Hetero.b 
rs187084 
 
984 331 273 
 
0,63 0,52 0,77 4,65E-06c 
 
1,13 0,93 1,38 0,218 
 
6,47E-07 1,47E-06 
rs352139d 
 
965 325 266 
 
1,44 1,19 1,74 1,72E-04 
 
0,81 0,66 0,99 0,039 
 
4,50E-06 1,67E-06 
rs352140d 
 
965 325 266 
 
1,46 1,21 1,76 9,50E-05 
 
0,81 0,66 0,99 0,042 
 
2,42E-06 1,02E-06 
rs352143 
 
984 331 273 
 
0,99 0,79 1,23 9,23E-01 
 
1,27 1,01 1,59 0,038 
 
9,52E-02 6,71E-02 
rs352162 
 
984 331 273 
 
1,33 1,10 1,60 2,73E-03 
 
0,88 0,72 1,07 0,197 
 
9,82E-04 4,45E-04 
rs4082828  984 331 273  1,15 0,87 1,52 3,16E-01   1,16 0,86 1,55 0,332   4,74E-01 9,79E-01 
LRT = likelihood ratio test; OR = odds ratio; rs = reference number for SNPs; SNP = single nucleotide polymorphism 
 a The ‘‘Global’’ LRT tests for a genetic association with any bladder cancer subphenotype. 
     b The ‘‘Hetero’’ LRT tests for heterogeneity in risk estimates between both subphenotypes. 
     c Remained significant after Bonferroni correction for multiple testing (p < 6,86E-06; 911 SNPs * 4 MOIs * 2 UCB subphenotypes) 
d Included in analysis post hoc (see text); missing genotype information for 19 controls, and 6 COX2-negative and 7 COX2-positive cases 
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(Table 5.2). This association was further examined in strata of several factors/conditions 
correlated with inflammation to determine whether they could modify the observed association, 
namely: bladder infection, NSAID/aspirin/paracetamol use, BMI and asthma. The association 
between TLR9-rs187084 and UCB risk remained inversed in nearly all strata examined, and no 
significant interactions were observed with any of these factors/conditions (Supplementary Table 
5.2). Two other SNPs in TLR9 (TLR9-rs352143 and TLR9-rs4082828) were also present in our 
original set of candidate SNPs, but did not associate with the tumor subtypes examined (Table 
5.2). 
It has been reported that the TLR9 gene variants, rs187084 (-1486T>C) and rs352139 
(+1174A>G), concomitantly act to down regulate TLR9 mRNA expression in vitro as evidenced 
by reporter gene assay (Omar et al., 2012; Tao et al., 2007). The potential mechanistic utility of 
rs352139 led us to subsequently include this SNP in our study, together with another in high 
linkage disequilibrium (TLR9-rs352140; r
2
=0.94 in SBC population). The genotype information 
for both of these SNPs (rs352139 and rs352140) was obtained from a previous genotyping effort 
using the Illumina Infinium 1M platform. Interestingly, both TLR9-rs352139 and TLR9-
rs352140 were significantly associated with an increased risk of COX2-negative UCB, while an 
inverse association was observed with COX2-postive UCB (additive MOI, 
pLRTheterogeneity=1.67E-06 for rs352139; pLRTheterogeneity=1.02E-06 for rs352140) (Table 5.2). 
We proceeded by constructing a categorical variable with sublevels representing patients 
homozygous for the putative low TLR9 mRNA expressing combined genotype (i.e. CC/GG in 
rs187084/rs352139; homozygous at both loci for variant alleles), patients homozygous for the 
putative high TLR9 mRNA expressing combined genotype (i.e. TT/AA; homozygous at both 
loci for common alleles) and a reference category representing patients with combined 
genotypes that did not fall into the two previous categories (Table 5.3a). Patients harboring the 
CC/GG combined genotype were similarly protected against COX2-negative UCB as observed 
previously (OR=0.64, 95%CI=0.42-0.98), however those with the TT/AA combined genotype 
were at an increased risk of the same tumor subtype (OR=1.51, 95%CI=1.11-2.06). Interestingly, 
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Table 5.3a Association of combined genotypes for TLR9-rs187084 and TLR9-rs352139 with UCB characterized by differential expression of COX2
1 
 
Combined genotype   N = 1556a   1:COX2 (-ve) UCB   2:COX2 (+ve) UCB   LRT p-val 
(rs187084/rs352139)   Controls COX2 (-ve) COX2 (+ve)   OR L95 U95 pLRT   OR L95 U95 pLRT   Globalb Hetero.c 
others* 
 
621 200 171 
 
1 REF. 
   
1 REF. 
     low (CC/GG) 
 
149 31 48 
 
0,64 0,42 0,98 7,68E-04 
 
1,14 0,78 1,67 0,528 
 
6,69E-04 3,51E-04 
high (TT/AA)  195 94 47   1,51 1,11 2,06     0,87 0,60 1,27         
1 see footnotes below Table 3b for superscript explanations 
             *patients with genotypes that were neither (CC/GG; homozygous for variant alleles) nor (TT/AA; homozygous for common alleles) for (rs187084/rs352139) 
 
 
Table 5.3b Association of frequent haplotypes of common SNPs in TLR9 with UCB characterized by differential expression of COX2 (additive MOI) 
 
    Haplotype freq.   1:COX2 (-ve) UCB   2:COX2 (+ve) UCB   LRT p-val 
Haplotype* Haplotype % Controls COX2 (-ve) COX2 (+ve) 
 
OR 95% CI pval. 
 
OR 95% CI pval. 
 
Global Hetero. 
WWMWMM 46,0 512 169 133 
 
1,35 1,12 1,63 0,002 
 
0,81 0,66 1,00 0,046 
 
9,93E-05 2,68E-05 
MWWWWW 27,6 397 103 111 
 
0,64 0,52 0,80 6,41E-05 
 
0,97 0,79 1,20 0,780 
 
1,58E-04 2,05E-03 
WMWMWW 10,7 176 73 56 
 
1,09 0,81 1,46 0,570 
 
1,06 0,77 1,45 0,737 
 
8,38E-01 8,69E-01 
MMWWWW 7,0 123 32 49 
 
0,68 0,45 1,01 0,055 
 
1,31 0,92 1,85 0,132 
 
1,52E-02 4,03E-03 
WMWWWW 3,1 49 22 19   1,19 0,71 1,98 0,509   1,35 0,80 2,28 0,254   5,05E-01 6,71E-01 
* W=common allele, M=variant allele; SNP order: rs187084; rs352139; rs352140; rs352143; rs352162; rs4082828 
      LRT = likelihood ratio test; OR = odds ratio; rs = reference number for SNPs; SNP = single nucleotide polymorphism 
     a rs352139 had genotype data missing for 19 controls; 6 COX2 negative tumors; 7 COX2 positive tumors 
      b The ‘‘Global’’ LRT tests for a genetic association with any bladder cancer subphenotype. 
         c The ‘‘Hetero’’ LRT tests for heterogeneity in risk estimates between both subphenotypes. 
        d Remained significant after Bonferroni correction for multiple testing (p < 6,85E-06) 
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while no significant association between these combined genotypes was observed in patients 
with COX2-positive tumors (pLRTCOX2+=0.528), the effect estimates of cancer risk for both 
combined genotypes were inverse to those observed in COX2-negative tumors 
(pLRTheterogeneity=3.51e-04). These associations between the concomitant effect of 
rs187084/rs352139 and UCB risk were reiterated when in a haplotype analysis that included the 
five most frequent haplotypes of the six TLR9 SNPs identified in this study (Table 5.3b). 
TLRs share overlapping downstream signaling cascades and a certain degree of cross-
regulation has been reported between TLR9 and other TLRs in various pathologies (Liu et al., 
2012; Nickerson et al., 2010; Simmons et al., 2010). To evaluate the potential influence of other 
TLRs on the UCB risk association observed with TLR9-rs187084, the interaction between this 
SNP and 28 other SNPs in five TLR genes identified in our study (TLRs 1, 2, 4, 6, 7) was 
examined (Supplementary Table 5.3). Of the 28 SNPs evaluated, one SNP, TLR7-rs179008, 
demonstrated a significant interaction with TLR9-rs187084 that remained robust after multiple 
testing correction (pGlobalinteraction = 4.64e-04) and increased the risk of COX2-negative UCB 
(OR=1.63, 95%CI=1.27-2.09, p-value =1.22e-04). However, no association was observed with 
COX2 positive UCB, and the observed effect estimate (OR) was not significantly heterogeneous 
between the two UCB subgroups examined (pHetinteraction = 0.100). 
5.4.3 TLR9-rs187084 (-1486T>C) and patient prognosis 
 
Kaplan-Meier analysis was used to evaluate whether the TLR9-rs187084 variant allele (C) could 
affect patient prognosis in tumors characterized by COX2 expression. Wild-type homozygous 
patients (TT) were compared to patients harboring at least one variant allele (TC/CC) for tumor 
recurrence and progression in patients with NMIBC, and tumor progression and patient survival 
in patients with MIBC (Figure 5.1). While no significant prognostic differences were observed 
for the two genetic backgrounds in patients with COX2-positive tumors (log rank p>0.05), 
patients with COX2-negative NMIBC and harboring at least one variant allele (TC/CC) in TLR9-
rs187084 were significantly less likely to observe tumor progression than wild-type homozygous 
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Figure 5.1 (previous page) Association of the variant allele -1486T>C in TLR9 (rs187084) with 
patient prognosis in the EPICURO study. Patients homozygous for the wild type allele (TT) were 
compared to individuals harbouring at least one variant allele (TC/CC) for the events indicated along the 
x-axis of each Kaplan-Meier plot. Patients with: NMIBC (A-D); MIBC (E-H); COX2-negative tumors 
(A, C, E, G); COX2-positive tumors (B, D, F, H). 
 
A) 
 
B) 
 
C) 
 
D) 
 
Figure 5.2 The effect of BCG immunotherapy on the association between the variant allele -
1486T>C in TLR9 (rs187084) and patient prognosis in COX2-negative NMIBCs. Patients 
homozygous for the wild type allele (TT) were compared to individuals harbouring at least one variant 
allele (TC/CC) for the events indicated along the x-axis of each Kaplan-Meier plot. Patients: not treated 
with BCG immunotherapy (A, C); treated with BCG immunotherapy (B, D). 
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patients (log rank p=0.01). Importantly, the reduction in tumor progression was maintained in 
multivariate analysis when adjusting for patient age, hospital region, number of tumor 
recurrences, tumor T-stage and grade, tumor multiplicity and treatment received (HR=0.39, 
95%CI=0.16-0.94, p-value =0.036) (Table 5.4). 
5.4.4 TLR9-rs187084 and response to BCG immunotherapy 
 
 We evaluated whether the reduction in tumor progression observed in the patients of this 
study could be associated with past treatment by BCG instillation therapy. Patients homozygous 
for the wild type alleles in TLR9-rs187084 who did not receive BCG instillation observed no 
significant differences in risk of recurrence or progression compared to patients harbouring at 
least one variant allele (TC/CC) (Figure 5.2). However, patients harbouring a variant allele and 
treated with BCG immunotherapy observed a reduction in the risk of progression compared to 
wild type homozygous patients (log rank p=0.025). In the multivariate analysis this equated to an 
84% reduction in tumor progression of BCG treated carriers of the variant allele in TLR9-
rs187084 as compared to BCG treated homozygous wild type patients (HR=0.16, 95%CI=0.03-
0.82, p-value =0.027) (Table 5.4).  
These analyses were repeated for the putative “low” and “high” TLR9 expressing 
genotype combinations evaluated earlier in the risk assessment, however no significant 
associations with prognosis (logrank p>0.05) were identified (data not shown). 
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Table 5.4 Prognosis in patients with differential COX2 expression in NMIBC or MIBC based on their genotype at postion -1486 in TLR9
a 
 
  Low COX2 UCB   High COX2 UCB 
Event Patients Events HR L95 U95 p-valb 
 
Patients Events HR L95 U95 p-valb 
NMIBCc 
             Recurrence 
             All 196 64 0,70 0,41 1,17 0,175 
 
122 53 1,24 0,65 2,34 0,514 
BCG treated 68 20 0,65 0,26 1,67 0,375 
 
30 12 2,46 0,59 10,35 0,218 
Non-BCG treated 128 44 0,79 0,41 1,50 0,463 
 
92 41 1,73 0,79 3,78 0,170 
Progression 
             All 258 27 0,39 0,16 0,94 0,036 
 
153 6 4,13 0,32 53,44 0,278 
BCG treated 93 11 0,16 0,03 0,82 0,027 
 
38 3 - - - - 
Non-BCG treated 165 16 0,64 0,21 1,90 0,417 
 
115 3 - - - - 
MIBC 
             Progression 52 29 0,88 0,34 2,24 0,786 
 
102 55 0,86 0,48 1,52 0,599 
Survival 51 22 1,01 0,29 3,49 0,989   101 46 1,27 0,67 2,42 0,466 
BCG = Bacillus Calmette Guerin intravesical instillation therapy; HR = hazard ratio; N/MIBC = Non-/Muscle invasive bladder cancer 
a Time to event specified was compared between patients homozygous for the wildtype allele (i.e. TT) and  those with at least one variant allele (i.e. TC or 
CC) 
b Multivariate Cox proportional hazards analysis. Prognostic models adjusted as follows: NMIBC Recurrence adjusted by region, gender, tumour stage and 
grade, # tumours, size of tumours (≤3 cm, >3 cm), and treatment (transurethral resection *TUR+, TUR+BCG, TUR+chemotherapy *chemo], TUR+BCG+chemo, 
other); NMIBC Progression adjusted by region, # recurrences, age, tumour stage and grade, # tumours, and treatment; MIBC Progression adjusted by region, 
tumour stage, treatment (cystectomy [cys], cys+chemo, chemo only, radiotherapy +/- chemo, superficial treatment, other) and presence of nodes; MIBC 
Survival adjusted by region, tumour stage, treatment, presence of nodes, and metastases. 
C In patients with NMIBC, analysis was also stratified by BCG treatment 
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5.5 DISCUSSION 
 
In the current study, tagged SNPs in inflammatory genes identified through the literature as 
relevant to cancer were investigated for heterogeneity in their genetic predisposition to 
subgroups of UCB characterized by the presence of epithelial COX2 expression. The variant 
alleles of two SNPs in the gene encoding the innate immune receptor TLR9 (rs187084, 
rs352139) were observed to contribute to heterogeneity in bladder cancer risk, with the former 
also showing potential as a predictive marker of BCG treatment response in patients with COX2-
negative UCB. 
TLR9 is a member of the Toll-like receptor family of integral membrane proteins and is 
highly expressed in immune cells, particularly plasmocytoid dendritic cells (pDCs), and to a 
lesser extent in healthy and tumor urothelium (Ayari et al., 2011; Jarrossay et al., 2001). TLR9 
receptors become activated and dimerize upon binding to unmethylated CpG-DNA found most 
prominently in bacteria and viruses. Receptor dimerization induces pDC secretion of T-helper-1 
(Th1) polarizing cytokines such as type 1 interferons (IFN-I) and, to a lesser extent, TNF-α 
(Hemmi et al., 2000). Subsequent pDC maturation and antigen cross-presentation primes CD4
+
 
and CD8
+
 T-cells thereby targeting the invading pathogen. The same immune response has 
shown efficacy in mediating tumor rejection leading to the development of artificial TLR9 
agonists for use in cancer therapy (Krieg, 2007). 
 rs187084 is characterized by a T>C transition at position -1486 within the promoter 
region of TLR9 and has been associated with increased susceptibility to several pathologies with 
an underlying inflammatory component (Etem et al., 2011; Kastelijn et al., 2010; Lazarus et al., 
2003; Liao et al., 2010). Moreover, woman harboring the variant allele are reported as more 
susceptible to cervical cancer (Roszak et al., 2012) but less likely to develop endometrial cancer 
(Ashton et al., 2010) (when also carriers of the variant in TLR9-rs5743836), while patients with 
prostate cancer harboring the variant allele observe a better prognosis than homozygous wild-
type individuals (Stark et al., 2009). When investigating the functional capacity of rs187084, 
Chen et al reported an allele-dose dependent increase of the pro-inflammatory cytokine TNF-α 
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in PBMCs isolated from trauma patients and stimulated with bacterial DNA ex vivo; suggesting 
that rs187084 may contribute to increasing pro-inflammatory cytokine production (Chen et al., 
2011). However, Sam-Agudu et al did not observe any rs187084 allele dependent differences in 
TNF-α or IFN-γ levels in serum drawn from pediatric cerebral malaria patients (Sam-Agudu et 
al., 2010).  
 rs352139 is characterized by an A>G transition at position +1174 within intron 1 of 
TLR9. Despite its intronic location, the variant allele of rs352139 has been reported to decrease 
serum IFN-γ in children with cerebral malaria in an allele-dependent manner, and is associated 
with susceptibility to several other infectious diseases (Chen et al., 2011; Sam-Agudu et al., 
2010; Villani et al., 2010). In contrast to the reduction in COX2-negative tumor risk observed in 
patients harboring rs187084, the variant allele in rs352139 was associated with an increased risk 
of COX2-negative UCB and a decreased risk of COX2-positive UCB; with significant 
heterogeneity between both risk estimates. Using 557 patients of Han Chinese ancestry, Chen et 
al reported that rs352139 and rs187084 fall within the same haplotype block and are in high 
linkage disequilibrium (D’=1.00; r2=1.00). In contrast, the two SNPs were not linked (D’=0.98; 
r
2
=0.54) in our study population which consists of Caucasian patients; a difference probably 
arising from the ethnic heterogeneity of the two populations. The inversion of UCB risk 
estimates by these two SNPs for COX2-postive/negative tumors may suggest that each SNP 
influences the immune response in a distinct molecular manner that should be the focus of future 
studies.  
Using gene reporter assays two independent studies indicated that while having no effect 
on TLR9 expression individually, the variant alleles of rs187084 and rs352139 actually decrease 
TLR9 expression when the two SNPs are considered jointly (Omar et al., 2012; Tao et al., 2007). 
By using the combined patient genotypes from rs187084 and rs352139 as a proxy for TLR9 
expression, we investigated whether the UCB risk associations observed herein could be 
influenced by relative TLR9 expression. Combined genotypes presumed to decrease TLR9 gene 
expression (i.e. CC/GG in rs187084/rs352139) significantly reduced the risk of COX2-negative 
UCB, while combined genotypes presumed to increase TLR9 gene expression (TT/AA) 
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increased risk of the same tumor subtype. No significant associations were observed between 
these genotype combinations and risk of COX2-positive tumors. By activating the TLR9 
signaling pathway, CpG DNA has been shown to up-regulate COX2 expression through post-
transcriptional mRNA stabilization while also inducing the production of PGE2 in immune cells 
(Yeo et al., 2003). In this regard, patients harboring the low-TLR9 expressing genetic signature 
may produce less COX2 upon TLR9 activation and subsequently generate less PGE2 to hinder an 
anti-tumor Th1 immune response - resulting in the reduced UCB risk observed herein. 
Conversely, high-TLR9 expressing patients may generate increased levels of PGE2 and 
experience immune polarization towards a tolerogenic Th2 response - increasing their risk of 
UCB.  
In a previous study using the same patient population, we did not observe tumor COX2 
levels to influence patient prognosis independently of established UCB prognostic factors 
(Czachorowski et al., 2012). Similarly, none of the SNPs in TLR9 identified in the current study 
were found associated with UCB prognosis in a genome wide analysis using patients from the 
SBC study (Malats et al, unpublished). Thus it would appear that the reduction in risk of 
progression observed in BCG treated patients in this study depends on both a low COX2 tumor 
microenvironment and, presumably, changes in the innate immune response conferred by the 
variant allele in TLR9-rs187084. A localized Th1cytokine profile, as induced by TLR9 activation 
by CpG-DNA, is associated with successful BCG therapy while a Th2 profile marks failure of 
the immunotherapy in patients (Luo et al., 2011). Interestingly, BCG administration has the 
tendency to induce COX2 expression in dendritic cells and up-regulate PGE2 production. In a 
tumor microenvironment where COX2 levels are already high, additional production of COX2 
by BCG administration can lead to elevated IL-10 cytokine levels and polarize the immune 
response in a Th2 direction (Dovedi et al., 2008). Elevated PGE2 levels in COX2-positive UCB 
may explain why a positive response to BCG treatment was only observed in COX2-negative 
tumors in which a Th1 immune profile would have been prominent. In fact, a recent randomized 
controlled trial reported a marginally significant reduction of metachronous recurrences in UCB 
patients given celecoxib as an adjuvant to BCG immunotherapy (Sabichi et al., 2011).  
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No associations with UCB risk were observed when the combined genotypes for TLR9-
rs187084 and TLR9-rs352139 were assessed in the prognostic analyses; suggesting that inherent 
differences in TLR9 mRNA levels were not responsible for the reduction in UCB progression 
observed previously. BCG administration activates not only TLR9 via CpG-DNA but also 
initiates a complex cytokine response through the activation of other TLRs, particularly TLR2/4 
on various immune cells, which may have contributed to the immune response independently of 
how much TLR9 was being expressed (Godaly and Young, 2005; Tsuji et al., 2000). 
The study benefitted from a large sample size that included uniformly characterized 
incident tumors spanning a broad spectrum of pathological stages and grades uniformly 
classified by a panel of expert pathologists. Moreover, genotype information was of high quality 
showing good agreement among all the genotyping platforms used and meeting the quality 
control guidelines put forth by Anderson et al (Anderson et al., 2010). We also opted to collect 
COX2 expression data using an automated scoring system providing a reproducible assessment 
of expression that correlates well with sample scoring by a pathologist (Czachorowski et al., 
2012). Importantly, heterogeneity in genetic susceptibility to UCB remained robust after 
correction for multiple testing for SNPs in TLR9, suggesting the observed associations could be 
real. Despite these attributes, an automated scoring system may incorporate some 
immunostained stromal material and thereby increase Type I error within the study. Moreover, 
despite the large size of the study it was not designed with sufficient power to evaluate 
heterogeneity by tumor subphenotypes necessitating replication in independent datasets. 
To our knowledge this is the first study to evaluate heterogeneity of genetic 
susceptibility to bladder tumors defined by levels of epithelial COX2 expression. The study 
implicated a SNP in TLR9 (rs187084) with reduced risk of COX2-negative bladder cancer that 
also shows potential as a predictive biomarker of BCG treatment response in patients with 
tumors characterized by low levels of COX2 expression. Moreover, the study emphasizes the 
utility of sub-grouping bladder cancers by their inherent molecular characteristics as a means of 
elucidating predictive markers of therapeutic value.  
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5.6 SUPPLEMENTARY TABLES 5.1 - 5.3 
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Supplementary Table 5.1 Association of SNPs in inflammatory genes of EPICURO study patients with UCBs characterized by differential expression of COX2 
 by MOI 
                A) CODOMINANT    N = 1588   COX2-neg.    COX2-pos.  LRT p-val  
gene_SNP MAF Genotype Control COX2-neg. COX2-pos. OR1 Lower_CI1 Upper_CI1 pLRT1 OR2 Lower_CI2 Upper_CI2 pLRT2 pLRT_Global pLRT_Het 
anpep_rs4932250 0,08 wt 817 276 208 1 REF. 9,47E-01 1 REF. 3,77E-03 2,20E-02 1,36E-02 
  
hetero 167 55 64 1,01 0,72 1,43 
 
1,50 1,07 2,11 
   
  
variant 0 0 1 0,02 na na 
 
na na na 
   bcl10_rs2647396 0,32 wt 452 153 164 1 REF. 9,30E-01 1 REF. 1,21E-04 7,04E-04 2,00E-03 
  
hetero 445 148 90 0,97 0,74 1,27 
 
0,54 0,40 0,72 
   
  
variant 87 30 19 1,06 0,66 1,69 
 
0,60 0,35 1,03 
   bcl10_rs962409 0,44 wt 309 95 61 1 REF. 5,14E-01 1 REF. 3,09E-03 1,39E-02 4,97E-02 
  
hetero 480 171 141 1,19 0,88 1,60 
 
1,55 1,10 2,18 
   
  
variant 195 65 71 1,08 0,74 1,58 
 
1,94 1,30 2,89 
   blnk_rs2861304 0,08 wt 824 277 226 1 REF. 9,69E-03 1 REF. 2,74E-01 4,36E-03 2,58E-03 
  
hetero 155 46 47 0,86 0,60 1,25 
 
1,08 0,75 1,57 
   
  
variant 5 8 0 5,67 1,72 18,68 
 
0,00 na na 
   blnk_rs7099132 0,07 wt 849 286 234 1 REF. 2,44E-02 1 REF. 5,38E-01 3,16E-02 2,57E-02 
  
hetero 132 40 39 0,93 0,63 1,38 
 
1,08 0,73 1,61 
   
  
variant 3 5 0 8,37 1,72 40,76 
 
0,00 na na 
   cd80_rs9282638 0,15 wt 716 241 175 1 REF. 7,87E-01 1 REF. 1,80E-02 4,35E-02 2,40E-02 
  
hetero 239 84 85 1,01 0,75 1,37 
 
1,39 1,02 1,89 
   
  
variant 29 6 13 0,73 0,29 1,84 
 
2,24 1,10 4,56 
   il17a_rs1974226 0,17 wt 674 236 197 1 REF. 7,79E-01 1 REF. 2,23E-03 1,18E-02 7,92E-03 
  
hetero 283 87 76 0,90 0,67 1,21 
 
0,95 0,70 1,29 
   
  
variant 27 8 0 0,91 0,39 2,12 
 
0,00 na na 
   il7_rs11777205 0,08 wt 834 269 237 1 REF. 1,98E-02 1 REF. 5,45E-01 4,14E-02 2,84E-02 
  
hetero 140 62 34 1,28 0,91 1,81 
 
0,81 0,54 1,23 
   
  
variant 10 0 2 0,00 na na 
 
0,67 0,14 3,19 
   irak2_rs263412 0,09 wt 819 256 226 1 REF. 1,34E-02 1 REF. 2,92E-01 1,13E-02 1,16E-02 
  
hetero 160 68 47 1,37 0,99 1,91 
 
1,08 0,75 1,57 
   
  
variant 5 7 0 4,31 1,29 14,47 
 
0,00 na na 
   jak1_rs10889513 0,12 wt 769 270 211 1 REF. 1,75E-01 1 REF. 4,50E-02 2,12E-02 4,77E-03 
  
hetero 202 55 62 0,74 0,53 1,05 
 
1,09 0,78 1,53 
   
  
variant 13 6 0 1,38 0,49 3,88 
 
0,00 na na 
   map2k4_rs12603036 0,10 wt 805 265 239 1 REF. 8,87E-01 1 REF. 3,66E-03 1,51E-02 8,41E-03 
  
hetero 167 62 34 1,07 0,76 1,49 
 
0,65 0,43 0,98 
   
  
variant 12 4 0 0,84 0,26 2,77 
 
0,00 na na 
   map3k7_rs150126 0,25 wt 556 223 157 1 REF. 1,19E-03 1 REF. 6,21E-01 4,53E-03 1,46E-02 
Supplementary Table 5.1 (cont’d) 
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A) CODOMINANT       N = 1588     COX2-neg.       COX2-pos.   LRT p-val   
gene_SNP MAF Genotype Control COX2-neg. COX2-pos. OR1 Lower_CI1 Upper_CI1 pLRT1 OR2 Lower_CI2 Upper_CI2 pLRT2 pLRT_Global pLRT_Het 
  
hetero 360 95 94 0,64 0,48 0,84 
 
0,91 0,68 1,22 
   
  
variant 68 13 22 0,49 0,26 0,92 
 
1,17 0,69 2,00 
   nfkb1_rs4648127 0,05 wt 882 306 234 1 REF. 1,04E-02 1 REF. 5,99E-02 7,51E-03 3,11E-02 
  
hetero 99 21 35 0,57 0,35 0,95 
 
1,22 0,80 1,87 
   
  
variant 3 4 4 4,97 0,98 25,20 
 
6,23 1,27 30,64 
   nos2a_rs2297518 0,19 wt 643 202 193 1 REF. 4,91E-02 1 REF. 1,71E-01 3,36E-02 3,87E-02 
  
hetero 299 121 72 1,27 0,97 1,67 
 
0,81 0,59 1,10 
   
  
variant 42 8 8 0,56 0,25 1,23 
 
0,57 0,26 1,26 
   ticam1_rs4807653 0,14 wt 729 236 221 1 REF. 3,39E-01 1 REF. 1,26E-02 1,86E-02 1,60E-02 
  
hetero 237 84 44 1,10 0,81 1,48 
 
0,61 0,42 0,87 
   
  
variant 18 11 8 1,76 0,81 3,86 
 
1,45 0,61 3,43 
   tlr7_rs179007 0,27 wt 695 236 211 1 REF. 9,64E-01 1 REF. 1,82E-03 1,13E-02 1,45E-02 
  
hetero 54 17 4 0,91 0,46 1,82 
 
0,19 0,06 0,56 
   
  
variant 235 78 58 1,01 0,74 1,37 
 
0,86 0,61 1,20 
   tlr9_rs187084 0,40 wt 360 168 89 1 REF. 1,77E-05 1 REF. 4,49E-01 8,45E-06 8,65E-06 
  
hetero 467 132 134 0,61 0,46 0,80 
 
1,17 0,86 1,60 
   
  
variant 157 31 50 0,42 0,27 0,65 
 
1,27 0,84 1,90 
   tlr9_rs352162 0,47 wt 262 70 87 1 REF. 8,04E-03 1 REF. 3,06E-01 5,13E-03 2,53E-03 
  
hetero 508 163 131 1,20 0,87 1,67 
 
0,79 0,57 1,09 
   
  
variant 214 98 55 1,76 1,21 2,54 
 
0,79 0,53 1,17 
   tnfrsf7_rs2286598 0,42 wt 331 87 106 1 REF. 2,43E-02 1 REF. 3,37E-01 1,32E-02 2,98E-03 
  
hetero 468 187 120 1,51 1,12 2,04 
 
0,80 0,59 1,08 
   
  
variant 185 57 47 1,22 0,83 1,81 
 
0,83 0,56 1,24 
   ulbp3_rs2010259 0,47 wt 332 104 81 1 REF. 8,40E-01 1 REF. 5,74E-03 1,57E-02 9,03E-03 
  
hetero 384 124 133 1,01 0,74 1,38 
 
1,44 1,04 1,98 
     variant 268 103 59 1,10 0,79 1,52  0,84 0,57 1,23    
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Supplementary Table 5.1 (cont’d) 
B) ADDITIVE   N = 1588 COX2-neg. COX2-pos. LRT p-val 
gene_SNP MAF Control COX2-neg. COX2-pos. OR1 Lower_CI1 Upper_CI1 pTREND1 OR2 Lower_CI2 Upper_CI2 pTREND2 pLRT_Global pLRT_Het 
akr1c3_rs6601899 0,14 984 331 273 1,33 1,03 1,70 2,73E-02 0,90 0,67 1,21 4,82E-01 3,73E-02 2,05E-02 
anpep_rs4932250 0,08 984 331 273 1,01 0,71 1,42 9,70E-01 1,56 1,12 2,17 9,25E-03 2,92E-02 3,26E-02 
bcl10_rs2647396 0,32 984 331 273 1,00 0,82 1,23 9,70E-01 0,65 0,52 0,82 2,26E-04 4,54E-04 1,06E-03 
bcl10_rs962409 0,44 984 331 273 1,05 0,88 1,27 5,70E-01 1,40 1,15 1,70 8,83E-04 3,57E-03 1,59E-02 
card4_rs11536450 0,14 984 331 273 1,11 0,86 1,44 4,16E-01 0,72 0,53 0,99 4,33E-02 4,30E-02 1,51E-02 
casp8_rs2349070 0,28 984 331 273 0,81 0,66 1,00 4,50E-02 1,14 0,92 1,41 2,17E-01 2,40E-02 7,70E-03 
casp8_rs10931934 0,40 984 331 273 0,82 0,68 0,97 2,46E-02 1,09 0,91 1,32 3,39E-01 2,06E-02 8,64E-03 
casp9_rs4646075 0,23 984 331 273 0,77 0,61 0,96 2,03E-02 1,02 0,82 1,29 8,39E-01 4,27E-02 3,82E-02 
cd80_rs9282638 0,15 984 331 273 0,97 0,75 1,25 7,85E-01 1,44 1,12 1,84 4,20E-03 1,03E-02 9,21E-03 
icam1_rs3093032 0,13 984 331 273 0,69 0,52 0,93 1,60E-02 1,05 0,79 1,39 7,49E-01 2,86E-02 2,33E-02 
ikbkb_rs17875671 0,08 984 331 273 0,80 0,56 1,15 2,24E-01 1,41 1,01 1,96 4,19E-02 2,43E-02 7,18E-03 
il21r_rs8060368 0,38 984 331 273 0,82 0,68 0,99 4,10E-02 1,11 0,91 1,35 3,17E-01 3,22E-02 1,22E-02 
irak2_rs263412 0,09 984 331 273 1,51 1,12 2,03 6,26E-03 1,02 0,72 1,45 9,19E-01 2,08E-02 4,25E-02 
map2k4_rs12603036 0,10 984 331 273 1,03 0,77 1,39 8,31E-01 0,58 0,40 0,86 6,29E-03 9,57E-03 7,25E-03 
map3k7_rs13208824 0,11 984 331 273 1,13 0,86 1,50 3,72E-01 0,65 0,46 0,93 1,73E-02 1,34E-02 4,62E-03 
map3k7_rs150126 0,25 984 331 273 0,67 0,53 0,84 4,27E-04 1,00 0,80 1,25 9,85E-01 8,81E-04 3,33E-03 
ncf2_rs2296164 0,47 984 331 273 1,11 0,92 1,33 2,77E-01 0,81 0,67 0,99 4,22E-02 2,97E-02 9,09E-03 
scarb1_rs4765621 0,42 984 331 273 0,92 0,76 1,11 3,65E-01 0,72 0,59 0,89 1,88E-03 7,18E-03 4,82E-02 
tlr9_rs187084 0,40 984 331 273 0,63 0,52 0,77 4,65E-06 1,13 0,93 1,38 2,18E-01 6,47E-07 1,47E-06 
tlr9_rs352162 0,47 984 331 273 1,33 1,10 1,60 2,73E-03 0,88 0,72 1,07 1,97E-01 9,82E-04 4,45E-04 
ulbp3_rs12202737 0,26 984 331 273 0,91 0,73 1,14 4,12E-01 1,27 1,02 1,58 3,48E-02 3,88E-02 1,46E-02 
 
C) DOMINANT     N = 1588 COX2-neg. COX2-pos. LRT p-val 
gene_SNP MAF Genotype Control COX2-neg. COX2-pos. OR1 Lower_CI1 Upper_CI1 pval1 pLRT1 OR2 Lower_CI2 Upper_CI2 pval2 pLRT2 pLRT_Global pLRT_Het 
akr1c3_rs6601899 0,14 wt 731 227 211 1 REF. 1 REF. 
  
  
het.+hom. 253 104 62 1,36 1,02 1,80 3,42E-02 3,55E-02 0,88 0,64 1,23 4,61E-01 4,58E-01 4,32E-02 2,15E-02 
anpep_rs4932250 0,08 wt 817 276 208 1 REF. 1 REF. 
  
  
het.+hom. 167 55 65 1,01 0,71 1,43 9,59E-01 9,59E-01 1,53 1,09 2,14 1,30E-02 1,45E-02 4,05E-02 4,29E-02 
arhgdib_rs2075267 0,41 wt 354 124 80 1 REF. 1 REF. 
  
  
het.+hom. 630 207 193 0,98 0,75 1,28 8,84E-01 8,84E-01 1,45 1,08 1,96 1,47E-02 1,34E-02 3,28E-02 2,48E-02 
bcl10_rs2647396 0,32 wt 452 153 164 1 REF. 1 REF. 
  
  
het.+hom. 532 178 109 0,98 0,76 1,27 8,97E-01 8,97E-01 0,55 0,41 0,73 2,75E-05 2,32E-05 7,35E-05 4,26E-04 
casp8_rs2349070 0,28 wt 514 198 133 1 REF. 1 REF. 
  
  
het.+hom. 470 133 140 0,74 0,57 0,96 2,25E-02 2,20E-02 1,17 0,89 1,55 2,53E-01 2,53E-01 1,34E-02 4,90E-03 
casp8_rs10931934 0,40 wt 386 153 99 1 REF. 1 REF. 
  
  
het.+hom. 598 178 174 0,75 0,58 0,97 3,11E-02 3,14E-02 1,14 0,86 1,52 3,56E-01 3,54E-01 2,85E-02 1,20E-02 
casp9_rs4646075 0,23 wt 583 218 156 1 REF. 1 REF. 
  
  
het.+hom. 401 113 117 0,73 0,55 0,95 1,97E-02 1,88E-02 1,08 0,81 1,43 6,05E-01 6,05E-01 3,07E-02 1,98E-02 
cd80_rs9282638 0,15 wt 716 241 175 1 REF. 1 REF. 
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Supplementary Table 5.1 (cont’d) 
C) DOMINANT     N = 1588 COX2-neg. COX2-pos. LRT p-val 
gene_SNP MAF Genotype Control COX2-neg. COX2-pos. OR1 Lower_CI1 Upper_CI1 pval1 pLRT1 OR2 Lower_CI2 Upper_CI2 pval2 pLRT2 pLRT_Global pLRT_Het 
  
het.+hom. 268 90 98 0,99 0,74 1,32 9,36E-01 9,36E-01 1,47 1,09 1,97 1,04E-02 1,11E-02 2,84E-02 2,59E-02 
gata3_rs10752126 0,41 wt 345 107 116 1 REF. 1 REF. 
  
  
het.+hom. 639 224 157 1,13 0,86 1,49 3,72E-01 3,70E-01 0,74 0,56 0,98 3,77E-02 3,85E-02 3,68E-02 1,29E-02 
icam1_rs3093032 0,13 wt 737 268 200 1 REF. 1 REF. 
  
  
het.+hom. 247 63 73 0,68 0,49 0,94 1,79E-02 1,58E-02 1,07 0,78 1,46 6,71E-01 6,72E-01 2,97E-02 2,12E-02 
irak2_rs263408 0,10 wt 807 250 225 1 REF. 1 REF. 
  
  
het.+hom. 177 81 48 1,47 1,08 2,00 1,56E-02 1,69E-02 0,97 0,67 1,39 8,61E-01 8,61E-01 3,91E-02 4,11E-02 
jak3_rs2286662 0,39 wt 374 101 108 1 REF. 1 REF. 
  
  
het.+hom. 610 230 165 1,38 1,05 1,82 2,19E-02 2,07E-02 0,94 0,71 1,25 6,66E-01 6,66E-01 3,76E-02 2,57E-02 
lepr_rs1137100 0,23 wt 579 173 167 1 REF. 1 REF. 
  
  
het.+hom. 405 158 106 1,36 1,05 1,76 2,17E-02 2,17E-02 0,91 0,69 1,21 5,24E-01 5,23E-01 3,03E-02 1,74E-02 
map2k4_rs12603036 0,10 wt 805 265 239 1 REF. 1 REF. 
  
  
het.+hom. 179 66 34 1,05 0,76 1,46 7,53E-01 7,53E-01 0,60 0,40 0,90 1,37E-02 1,06E-02 2,20E-02 1,32E-02 
map3k7_rs13208824 0,11 wt 774 250 232 1 REF. 1 REF. 
  
  
het.+hom. 210 81 41 1,14 0,84 1,55 3,96E-01 3,99E-01 0,63 0,44 0,92 1,70E-02 1,39E-02 1,43E-02 5,08E-03 
map3k7_rs150126 0,25 wt 556 223 157 1 REF. 1 REF. 
  
  
het.+hom. 428 108 116 0,61 0,47 0,81 4,16E-04 3,50E-04 0,95 0,72 1,25 7,14E-01 7,14E-01 1,38E-03 1,05E-02 
socs6_rs713129 0,14 wt 731 243 181 1 REF. 1 REF. 
  
  
het.+hom. 253 88 92 1,04 0,77 1,39 7,98E-01 7,98E-01 1,50 1,11 2,03 7,71E-03 8,35E-03 2,72E-02 4,10E-02 
ticam1_rs4807653 0,14 wt 729 236 221 1 REF. 1 REF. 
  
  
het.+hom. 255 95 52 1,15 0,86 1,53 3,41E-01 3,43E-01 0,67 0,48 0,94 2,13E-02 1,85E-02 1,64E-02 5,43E-03 
tlr9_rs187084 0,40 wt 360 168 89 1 REF. 1 REF. 
  
  
het.+hom. 624 163 184 0,56 0,43 0,73 1,29E-05 1,28E-05 1,20 0,89 1,60 2,32E-01 2,30E-01 3,26E-06 6,80E-06 
tlr9_rs352162 0,47 wt 262 70 87 1 REF. 1 REF. 
  
  
het.+hom. 722 261 186 1,37 1,00 1,86 4,75E-02 4,45E-02 0,79 0,58 1,07 1,22E-01 1,24E-01 1,27E-02 3,37E-03 
tnfrsf7_rs2267966 0,30 wt 473 148 154 1 REF. 1 REF. 
  
  
het.+hom. 511 183 119 1,17 0,91 1,52 2,25E-01 2,25E-01 0,75 0,57 0,99 4,02E-02 3,97E-02 2,20E-02 6,28E-03 
tnfrsf7_rs2286598 0,42 wt 331 87 106 1 REF. 1 REF. 
      het.+hom. 653 244 167 1,43 1,07 1,90 1,49E-02 1,36E-02 0,81 0,61 1,07 1,41E-01 1,43E-01 4,09E-03 1,21E-03 
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Supplementary Table 5.1 (cont’d) 
D) RECESSIVE     N = 1588 COX2-neg. COX2-pos. LRT p-val 
gene_SNP MAF Genotype Control COX2-neg. COX2-pos. OR1 Lower_CI1 Upper_CI1 pval1 pLRT1 OR2 Lower_CI2 Upper_CI2 pval2 pLRT2 pLRT_Global pLRT_Het 
aicda_rs2580874 0,38 wt+het. 844 284 216 1 REF. 1 REF. 
  
  
hom. 140 47 57 0,98 0,68 1,42 9,21E-01 9,21E-01 1,55 1,09 2,20 1,55E-02 1,75E-02 4,30E-02 3,64E-02 
blnk_rs2861304 0,08 wt+het. 979 323 273 1 REF. 1 REF. 
  
  
hom. 5 8 0 5,80 1,76 19,09 3,84E-03 3,26E-03 0,00 na na 1,00E+00 1,21E-01 8,60E-04 9,46E-04 
blnk_rs7099132 0,07 wt+het. 981 326 273 1 REF. 1 REF. 
  
  
hom. 3 5 0 8,45 1,74 41,09 8,18E-03 6,86E-03 0,00 na na 1,00E+00 2,97E-01 6,03E-03 8,35E-03 
casp8_rs11674814 0,38 wt+het. 845 266 238 1 REF. 1 REF. 
  
  
hom. 139 65 35 1,46 1,04 2,05 2,81E-02 3,02E-02 0,88 0,59 1,33 5,58E-01 5,54E-01 4,39E-02 2,65E-02 
il21r_rs2189521 0,46 wt+het. 784 272 199 1 REF. 1 REF. 
  
  
hom. 200 59 74 0,80 0,57 1,12 1,93E-01 1,88E-01 1,42 1,03 1,96 3,11E-02 3,32E-02 1,42E-02 3,94E-03 
il2ra_rs12722588 0,19 wt+het. 940 324 258 1 REF. 1 REF. 
  
  
hom. 44 7 15 0,39 0,17 0,89 2,57E-02 1,44E-02 1,14 0,61 2,13 6,86E-01 6,89E-01 2,69E-02 1,72E-02 
irak2_rs263412 0,09 wt+het. 979 324 273 1 REF. 1 REF. 
  
  
hom. 5 7 0 4,05 1,21 13,57 2,32E-02 2,28E-02 0,00 na na 1,00E+00 1,31E-01 8,42E-03 5,64E-03 
ly96_rs11786591 0,28 wt+het. 906 310 239 1 REF. 1 REF. 
  
  
hom. 78 21 34 0,80 0,48 1,33 3,91E-01 3,84E-01 1,66 1,07 2,58 2,47E-02 2,84E-02 2,77E-02 1,10E-02 
oscar_rs11669029 0,43 wt+het. 799 269 202 1 REF. 1 REF. 
  
  
hom. 185 62 71 1,00 0,72 1,38 9,78E-01 9,78E-01 1,49 1,07 2,06 1,67E-02 1,82E-02 4,76E-02 4,30E-02 
tlr9_rs187084 0,40 wt+het. 827 300 223 1 REF. 1 REF. 
  
  
hom. 157 31 50 0,54 0,35 0,82 3,71E-03 2,37E-03 1,16 0,81 1,66 4,31E-01 4,34E-01 2,56E-03 1,63E-03 
tlr9_rs352162 0,47 wt+het. 770 233 218 1 REF. 1 REF. 
  
  
hom. 214 98 55 1,55 1,16 2,08 3,45E-03 3,79E-03 0,91 0,65 1,29 6,09E-01 6,07E-01 5,94E-03 6,33E-03 
tmem189_rs6125888 0,12 wt+het. 972 320 270 1 REF. 1 REF. 
  
  
hom. 12 11 3 2,78 1,16 6,67 2,23E-02 2,47E-02 0,83 0,23 3,06 7,80E-01 7,76E-01 4,67E-02 4,58E-02 
ulbp3_rs2010259 0,47 wt+het. 716 228 214 1 REF. 1 REF. 
      hom. 268 103 59 1,09 0,82 1,44 5,57E-01 5,58E-01 0,68 0,49 0,95 2,23E-02 1,98E-02 2,96E-02 1,30E-02 
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Supplementary Table 5.2 Association of TLR9 (-1486T>C) and bladder cancer risk based on level of COX2 expression and stratified by patient characteristics 
      Cases   Low COX2 Cases   High COX2 Cases   LRT 
ADDITIVE MOI N Controls Low COX2 High COX2 
 
OR Lower_CI Upper_CI pTREND 
 
OR Lower_CI Upper_CI pTREND 
 
Global
a
 Hetero
b
 Interaction
c
 
Overall 
                  
 
1588 984 331 273 
 
0,63 0,52 0,77 4,65E-06 
 
1,13 0,93 1,38 2,18E-01 
 
6,47E-07 1,47E-06 
 Gender 
                  Men 1405 869 293 243 
 
0,65 0,53 0,80 5,26E-05 
 
1,10 0,89 1,36 3,78E-01 
 
2,35E-05 4,53E-05 
 Women 183 115 38 30 
 
0,53 0,27 1,04 6,56E-02 
 
1,28 0,72 2,29 4,03E-01 
 
7,31E-02 2,79E-02 
 Age 
                  <=60 439 299 69 71 
 
0,57 0,37 0,89 1,27E-02 
 
0,87 0,59 1,29 4,93E-01 
 
3,84E-02 1,17E-01 
 >60 & <=70 617 386 134 97 
 
0,60 0,44 0,83 2,24E-03 
 
1,28 0,91 1,80 1,50E-01 
 
4,50E-04 2,15E-04 
 >70 532 299 128 105 
 
0,66 0,48 0,90 9,09E-03 
 
1,20 0,87 1,66 2,66E-01 
 
4,10E-03 1,74E-03 
 Smoking 
                  Non-smoker 360 277 44 39 
 
0,61 0,36 1,01 5,68E-02 
 
1,13 0,69 1,85 6,31E-01 
 
1,09E-01 6,42E-02 
 Occasional 101 79 10 12 
 
0,86 0,30 2,44 7,80E-01 
 
1,23 0,49 3,11 6,61E-01 
 
8,47E-01 5,76E-01 
 Former 594 361 133 100 
 
0,66 0,49 0,91 9,65E-03 
 
1,16 0,84 1,59 3,62E-01 
 
8,25E-03 4,43E-03 
 Current 533 267 144 122 
 
0,56 0,41 0,78 4,42E-04 
 
1,03 0,76 1,42 8,31E-01 
 
5,31E-04 1,14E-03 
 Region 
                  Barcelona 282 196 58 28 
 
0,81 0,51 1,29 3,74E-01 
 
1,44 0,80 2,62 2,27E-01 
 
2,42E-01 9,24E-02 
 Valles 268 157 62 49 
 
0,31 0,18 0,54 3,32E-05 
 
0,90 0,54 1,49 6,71E-01 
 
3,15E-05 7,53E-04 
 Elche 122 79 26 17 
 
0,53 0,25 1,11 9,33E-02 
 
2,17 0,95 4,94 6,56E-02 
 
1,29E-02 3,25E-03 
 Tenerife 267 145 62 60 
 
1,05 0,68 1,63 8,27E-01 
 
1,51 0,97 2,34 6,84E-02 
 
1,73E-01 1,62E-01 
 Asturias 649 407 123 119 
 
0,57 0,42 0,79 7,07E-04 
 
0,91 0,67 1,22 5,10E-01 
 
2,27E-03 1,82E-02 
 Bladder infection 
                 
0,307 
No 1267 777 270 220 
 
0,64 0,51 0,80 6,16E-05 
 
1,04 0,83 1,30 7,34E-01 
 
7,54E-05 3,31E-04 
 Yes 299 202 52 45 
 
0,60 0,36 1,01 5,23E-02 
 
1,54 0,96 2,46 7,44E-02 
 
1,19E-02 2,93E-03 
 Enlarged prostate 
                 
0,523 
No 911 564 189 158 
 
0,68 0,52 0,87 2,59E-03 
 
0,89 0,68 1,15 3,71E-01 
 
9,29E-03 8,76E-02 
 Yes 195 139 28 28 
 
0,69 0,35 1,34 2,71E-01 
 
1,23 0,67 2,25 4,99E-01 
 
3,52E-01 1,54E-01 
 NSAIDs 
                 
0,395 
Never 1134 701 236 197 
 
0,65 0,52 0,82 2,58E-04 
 
0,98 0,78 1,24 8,68E-01 
 
6,88E-04 4,21E-03 
 Ever 78 61 11 6 
 
0,35 0,05 2,40 2,88E-01 
 
2,60 0,21 32,64 4,60E-01 
 
1,80E-01 5,43E-01 
 Aspirin 
                 
0,287 
Never 564 349 111 104 
 
0,53 0,37 0,74 2,78E-04 
 
0,99 0,72 1,37 9,55E-01 
 
5,25E-04 2,07E-03 
 Ever 648 413 136 99 
 
0,74 0,55 1,00 4,88E-02 
 
0,97 0,70 1,34 8,52E-01 
 
1,30E-01 1,66E-01 
 Paracetamol 
                 
0,041
d
 
Never 864 529 177 158 
 
0,60 0,46 0,78 1,54E-04 
 
0,85 0,66 1,11 2,31E-01 
 
5,48E-04 3,00E-02 
 Ever 348 233 70 45 
 
0,79 0,51 1,22 2,80E-01 
 
1,70 1,03 2,79 3,73E-02 
 
3,30E-02 9,80E-03 
 BMI 
                 
0,296 
<25 656 398 138 120 
 
0,54 0,39 0,74 1,72E-04 
 
0,90 0,66 1,24 5,30E-01 
 
4,91E-04 7,00E-03 
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Supplementary Table 5.2 (cont’d) 
      Cases   Low COX2 Cases   High COX2 Cases   LRT 
ADDITIVE MOI N Controls Low COX2 High COX2 
 
OR Lower_CI Upper_CI pTREND 
 
OR Lower_CI Upper_CI pTREND 
 
Global
a
 Hetero
b
 Interaction
c
 
>=25 & <30 456 293 97 66 
 
0,86 0,61 1,23 4,19E-01 
 
1,39 0,95 2,05 9,32E-02 
 
1,10E-01 3,93E-02 
 >=30 88 60 14 14 
 
0,79 0,32 1,96 6,09E-01 
 
0,91 0,34 2,42 8,44E-01 
 
8,72E-01 8,22E-01 
 Asthma 
                 
0,970 
Yes 105 73 17 15 
 
0,59 0,24 1,42 2,38E-01 
 
1,20 0,48 3,00 6,97E-01 
 
4,04E-01 2,27E-01 
 No 1170 736 235 199 
 
0,67 0,53 0,84 5,11E-04 
 
1,00 0,79 1,26 9,95E-01 
 
1,22E-03 4,39E-03 
 Cruciferous veg. (quart.) 
                
0,545 
Q1 328 180 90 58 
 
0,72 0,49 1,07 1,09E-01 
 
1,23 0,79 1,90 3,62E-01 
 
7,81E-02 3,02E-02 
 Q2 346 215 67 64 
 
0,47 0,30 0,75 1,40E-03 
 
0,88 0,57 1,37 5,79E-01 
 
3,74E-03 2,38E-02 
 Q3 364 237 67 60 
 
0,90 0,60 1,36 6,23E-01 
 
1,14 0,76 1,72 5,28E-01 
 
6,55E-01 3,59E-01 
 Q4 107 63 18 26  0,93 0,38 2,29 8,81E-01  1,08 0,49 2,37 8,51E-01  9,57E-01 7,70E-01  
BMI = body mass index; LRT = likelihood ratio test; OR = odds ratio; rs = reference number for SNPs; SNP = single nucleotide polymorphism 
  
a
 The ‘‘Global’’ LRT tests for a genetic association with any bladder cancer subphenotype. 
         
b
 The ‘‘Hetero’’ LRT tests for heterogeneity in risk estimates between both subphenotypes. 
         
c
 The "Interaction" LRT tests for modification of UCB risk in strata of the factors examined 
         
d
 Did not remain significant after Bonferroni correctin for multiple testing (p=0,328) 
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Supplementary Table 5.3  Interaction between TLR9 rs187084 and other SNPs in TLR genes in tumors subphenotyped by level of COX2 expression 
            Main Effects TLR9 rs187084   Main Effects SNPs in other TLR genes 
Additive MOI N = 1588 
 
low COX2 tumors 
 
high COX2 tumors 
 
low COX2 tumors 
 
high COX2 tumors 
Gene : rs no. Total Controls low COX2 high COX2 
 
OR L95 U95 pTREND 
 
OR L95 U95 pTREND 
 
OR L95 U95 pTREND 
 
OR L95 U95 pTREND 
tlr1 : rs4833095 1588 984 331 273 
 
0,70 0,53 0,94 1,597E-02 
 
1,22 0,92 1,63 0,172 
 
1,15 0,88 1,51 0,309 
 
1,18 0,86 1,62 0,310 
tlr1 : rs5743594 1588 984 331 273 
 
0,62 0,49 0,78 3,160E-05 
 
1,17 0,94 1,47 0,156 
 
0,93 0,65 1,32 0,687 
 
0,97 0,64 1,48 0,902 
tlr1 : rs5743611 1588 984 331 273 
 
0,60 0,49 0,74 2,200E-06 
 
1,12 0,91 1,39 0,281 
 
0,59 0,30 1,17 0,130 
 
1,24 0,64 2,40 0,528 
tlr2 : rs4696480 1588 984 331 273 
 
0,60 0,44 0,83 1,878E-03 
 
1,31 0,96 1,78 0,087 
 
1,00 0,77 1,29 0,981 
 
1,13 0,83 1,53 0,450 
tlr2 : rs11938228 1588 984 331 273 
 
0,62 0,47 0,82 6,558E-04 
 
1,15 0,88 1,51 0,293 
 
0,98 0,75 1,27 0,865 
 
0,92 0,67 1,26 0,608 
tlr2 : rs3804099 1588 984 331 273 
 
0,62 0,45 0,85 2,678E-03 
 
1,17 0,84 1,62 0,349 
 
1,02 0,78 1,33 0,885 
 
1,27 0,93 1,74 0,128 
tlr2 : rs3804100 1588 984 331 273 
 
0,65 0,52 0,80 5,360E-05 
 
1,08 0,88 1,34 0,454 
 
1,09 0,68 1,74 0,714 
 
0,79 0,44 1,43 0,432 
tlr2 : rs7656411 1588 984 331 273 
 
0,60 0,45 0,80 4,185E-04 
 
1,08 0,81 1,43 0,608 
 
0,98 0,74 1,29 0,878 
 
1,01 0,73 1,40 0,929 
tlr4 : rs4986790 1588 984 331 273 
 
0,61 0,50 0,76 4,860E-06 
 
1,11 0,90 1,37 0,348 
 
0,97 0,54 1,76 0,925 
 
1,25 0,65 2,40 0,500 
tlr4 : rs11536889 1588 984 331 273 
 
0,61 0,49 0,77 3,380E-05 
 
1,20 0,95 1,51 0,122 
 
0,71 0,49 1,04 0,082 
 
0,97 0,63 1,49 0,885 
tlr4 : rs11536897 1588 984 331 273 
 
0,67 0,54 0,82 1,384E-04 
 
1,11 0,90 1,37 0,339 
 
1,29 0,78 2,12 0,319 
 
1,13 0,62 2,05 0,693 
tlr4 : rs11536898 1588 984 331 273 
 
0,64 0,51 0,80 8,120E-05 
 
1,13 0,90 1,41 0,299 
 
1,03 0,69 1,52 0,901 
 
1,07 0,67 1,69 0,784 
tlr4 : rs1554973 1588 984 331 273 
 
0,65 0,51 0,84 9,603E-04 
 
1,09 0,84 1,40 0,525 
 
1,07 0,80 1,43 0,652 
 
0,97 0,68 1,38 0,863 
tlr4 : rs1927906 1588 984 331 273 
 
0,65 0,52 0,80 7,370E-05 
 
1,10 0,88 1,37 0,396 
 
1,22 0,79 1,90 0,368 
 
1,03 0,61 1,76 0,902 
tlr4 : rs2737191 1588 984 331 273 
 
0,60 0,46 0,78 1,468E-04 
 
1,18 0,90 1,54 0,229 
 
1,07 0,81 1,42 0,618 
 
1,27 0,92 1,76 0,149 
tlr4 : rs5030717 1588 984 331 273 
 
0,61 0,49 0,76 9,110E-06 
 
1,10 0,89 1,36 0,376 
 
0,80 0,53 1,22 0,308 
 
0,59 0,34 1,02 0,059 
tlr6 : rs3775073 1588 984 331 273 
 
0,59 0,45 0,78 2,323E-04 
 
1,28 0,98 1,67 0,073 
 
0,91 0,69 1,19 0,471 
 
0,95 0,69 1,30 0,732 
tlr6 : rs5743810 1588 984 331 273 
 
0,63 0,47 0,84 1,622E-03 
 
0,94 0,70 1,26 0,676 
 
0,95 0,73 1,25 0,723 
 
0,80 0,58 1,10 0,171 
tlr7 : rs1634319 1588 984 331 273 
 
0,64 0,52 0,79 2,470E-05 
 
1,12 0,91 1,38 0,285 
 
0,95 0,70 1,29 0,746 
 
0,78 0,52 1,17 0,233 
tlr7 : rs1634320 1588 984 331 273 
 
0,64 0,52 0,79 2,890E-05 
 
1,13 0,91 1,39 0,267 
 
1,07 0,77 1,49 0,683 
 
1,07 0,73 1,57 0,730 
tlr7 : rs1634322 1588 984 331 273 
 
0,66 0,53 0,83 3,072E-04 
 
1,17 0,93 1,47 0,171 
 
1,04 0,83 1,30 0,719 
 
1,05 0,80 1,36 0,744 
tlr7 : rs179007 1588 984 331 273 
 
0,61 0,49 0,78 4,230E-05 
 
1,10 0,88 1,38 0,408 
 
0,97 0,78 1,20 0,772 
 
0,84 0,64 1,11 0,218 
tlr7 : rs179008 1588 984 331 273 
 
0,51 0,41 0,64 1,050E-08 
 
1,02 0,82 1,28 0,842 
 
0,72 0,56 0,92 0,009 
 
0,92 0,70 1,22 0,561 
tlr7 : rs179010 1588 984 331 273 
 
0,72 0,57 0,91 6,406E-03 
 
1,21 0,95 1,54 0,116 
 
1,17 0,95 1,43 0,139 
 
1,22 0,96 1,54 0,107 
tlr7 : rs179012 1588 984 331 273 
 
0,51 0,40 0,65 5,930E-08 
 
1,00 0,79 1,27 0,974 
 
0,81 0,65 1,00 0,052 
 
0,90 0,70 1,15 0,394 
tlr7 : rs179014 1588 984 331 273 
 
0,70 0,56 0,87 1,405E-03 
 
1,18 0,94 1,49 0,143 
 
1,08 0,86 1,35 0,521 
 
1,18 0,91 1,53 0,203 
tlr7 : rs5741880 1588 984 331 273 
 
0,67 0,54 0,83 2,314E-04 
 
1,22 0,98 1,51 0,077 
 
1,02 0,79 1,32 0,882 
 
1,11 0,83 1,49 0,490 
tlr7 : rs864058 1588 984 331 273 
 
0,64 0,51 0,79 2,990E-05 
 
1,16 0,94 1,43 0,178 
 
1,03 0,78 1,35 0,849 
 
0,94 0,67 1,33 0,747 
tlr9 : rs352139* 1556 965 325 266 
 
0,75 0,54 1,04 8,079E-02 
 
1,04 0,76 1,44 0,794 
 
1,17 0,88 1,57 0,280 
 
0,84 0,61 1,17 0,301 
tlr9 : rs352140* 1556 965 325 266 
 
0,75 0,53 1,04 8,737E-02 
 
1,06 0,77 1,47 0,705 
 
1,20 0,90 1,61 0,223 
 
0,86 0,62 1,20 0,369 
tlr9 : rs352143 1588 984 331 273 
 
0,58 0,46 0,75 2,290E-05 
 
1,04 0,81 1,35 0,742 
 
0,86 0,63 1,17 0,341 
 
1,10 0,78 1,56 0,591 
tlr9 : rs352162 1588 984 331 273 
 
0,69 0,50 0,95 2,117E-02 
 
1,04 0,76 1,44 0,794 
 
1,05 0,80 1,39 0,721 
 
0,90 0,65 1,23 0,499 
tlr9 : rs4082828 1588 984 331 273  0,60 0,49 0,75 6,590E-06  1,10 0,88 1,37 0,410  0,87 0,62 1,23 0,438  1,00 0,66 1,50 0,989 
LRT = likelihood ratio test; OR = odds ratio; rs = reference number for SNPs; SNP = single nucleotide polymorphism 
          * From Illumin Infinium 1M genotyping platform (selected a posteriori) 
                
a
 The ‘‘Global’’ LRT tests for a genetic association with any bladder cancer subphenotype. 
             
b
 The ‘‘Hetero’’ LRT tests for heterogeneity in risk estimates between both subphenotypes. 
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Supplementary Table 5.3 (cont’d) 
            Interaction: TLR9 rs187084 and SNPs in other TLR genes       
Additive MOI N = 1588 
 
low COX2 tumors 
 
high COX2 tumors 
 
LRT 
Gene : rs no. Total Controls low COX2 high COX2 
 
OR L95 U95 pTREND 
 
OR L95 U95 pTREND 
 
Global
a
 Hetero.
b
 
tlr1 : rs4833095 1588 984 331 273 
 
0,86 0,65 1,15 0,308 
 
0,90 0,68 1,20 0,464 
 
0,528 0,806 
tlr1 : rs5743594 1588 984 331 273 
 
1,06 0,73 1,54 0,744 
 
0,87 0,59 1,28 0,471 
 
0,674 0,393 
tlr1 : rs5743611 1588 984 331 273 
 
1,56 0,85 2,88 0,153 
 
1,03 0,58 1,84 0,910 
 
0,352 0,259 
tlr2 : rs4696480 1588 984 331 273 
 
1,05 0,79 1,39 0,732 
 
0,84 0,64 1,11 0,226 
 
0,379 0,201 
tlr2 : rs11938228 1588 984 331 273 
 
1,03 0,77 1,36 0,858 
 
0,97 0,73 1,28 0,809 
 
0,942 0,731 
tlr2 : rs3804099 1588 984 331 273 
 
1,03 0,78 1,36 0,847 
 
0,97 0,73 1,28 0,808 
 
0,938 0,721 
tlr2 : rs3804100 1588 984 331 273 
 
0,85 0,50 1,45 0,547 
 
1,33 0,78 2,26 0,297 
 
0,381 0,173 
tlr2 : rs7656411 1588 984 331 273 
 
1,08 0,80 1,46 0,621 
 
1,08 0,80 1,46 0,628 
 
0,827 0,996 
tlr4 : rs4986790 1588 984 331 273 
 
1,28 0,69 2,37 0,433 
 
1,21 0,67 2,20 0,527 
 
0,676 0,881 
tlr4 : rs11536889 1588 984 331 273 
 
1,11 0,75 1,64 0,612 
 
0,83 0,56 1,23 0,353 
 
0,491 0,247 
tlr4 : rs11536897 1588 984 331 273 
 
0,62 0,34 1,15 0,128 
 
1,14 0,67 1,96 0,625 
 
0,195 0,087 
tlr4 : rs11536898 1588 984 331 273 
 
0,95 0,62 1,45 0,795 
 
1,02 0,67 1,54 0,941 
 
0,956 0,782 
tlr4 : rs1554973 1588 984 331 273 
 
0,93 0,67 1,29 0,676 
 
1,09 0,78 1,50 0,623 
 
0,754 0,453 
tlr4 : rs1927906 1588 984 331 273 
 
0,89 0,54 1,45 0,636 
 
1,16 0,72 1,89 0,536 
 
0,659 0,363 
tlr4 : rs2737191 1588 984 331 273 
 
1,10 0,82 1,49 0,521 
 
0,94 0,70 1,27 0,709 
 
0,695 0,402 
tlr4 : rs5030717 1588 984 331 273 
 
1,18 0,75 1,88 0,473 
 
1,16 0,70 1,94 0,557 
 
0,707 0,957 
tlr6 : rs3775073 1588 984 331 273 
 
1,10 0,82 1,47 0,511 
 
0,82 0,61 1,12 0,211 
 
0,276 0,117 
tlr6 : rs5743810 1588 984 331 273 
 
1,00 0,74 1,34 0,989 
 
1,29 0,96 1,74 0,091 
 
0,216 0,164 
tlr7 : rs1634319 1588 984 331 273 
 
0,94 0,67 1,32 0,707 
 
1,06 0,74 1,52 0,765 
 
0,862 0,589 
tlr7 : rs1634320 1588 984 331 273 
 
0,89 0,62 1,28 0,540 
 
1,02 0,73 1,43 0,898 
 
0,790 0,533 
tlr7 : rs1634322 1588 984 331 273 
 
0,91 0,71 1,15 0,424 
 
0,93 0,73 1,18 0,555 
 
0,668 0,862 
tlr7 : rs179007 1588 984 331 273 
 
1,05 0,84 1,32 0,668 
 
1,06 0,84 1,35 0,629 
 
0,846 0,951 
tlr7 : rs179008 1588 984 331 273 
 
1,63 1,27 2,09 1,221E-04 
 
1,27 0,99 1,63 0,061 
 
4,642E-04 0,100 
tlr7 : rs179010 1588 984 331 273 
 
0,79 0,63 0,99 0,040 
 
0,89 0,72 1,11 0,304 
 
0,100 0,365 
tlr7 : rs179012 1588 984 331 273 
 
1,42 1,14 1,77 0,002 
 
1,23 0,98 1,53 0,075 
 
0,005 0,282 
tlr7 : rs179014 1588 984 331 273 
 
0,74 0,56 0,97 0,030 
 
0,91 0,72 1,16 0,443 
 
0,082 0,191 
tlr7 : rs5741880 1588 984 331 273 
 
0,84 0,63 1,12 0,230 
 
0,80 0,61 1,06 0,126 
 
0,209 0,806 
tlr7 : rs864058 1588 984 331 273 
 
0,97 0,72 1,31 0,857 
 
0,91 0,66 1,26 0,572 
 
0,851 0,740 
tlr9 : rs352139* 1556 965 325 266 
 
0,87 0,63 1,19 0,368 
 
0,92 0,67 1,26 0,599 
 
0,637 0,768 
tlr9 : rs352140* 1556 965 325 266 
 
0,92 0,68 1,25 0,587 
 
0,91 0,67 1,25 0,567 
 
0,781 0,973 
tlr9 : rs352143 1588 984 331 273 
 
1,18 0,85 1,65 0,325 
 
1,20 0,88 1,66 0,254 
 
0,408 0,929 
tlr9 : rs352162 1588 984 331 273 
 
0,86 0,63 1,16 0,318 
 
1,04 0,77 1,41 0,791 
 
0,527 0,300 
tlr9 : rs4082828 1588 984 331 273  1,29 0,76 2,22 0,348  1,56 0,93 2,61 0,092  0,215 0,560 
LRT = likelihood ratio test; OR = odds ratio; rs = reference number for SNPs; SNP = single nucleotide polymorphism 
   * From Illumin Infinium 1M genotyping platform (selected a posteriori) 
         
a
 The ‘‘Global’’ LRT tests for a genetic association with any bladder cancer subphenotype. 
      
b
 The ‘‘Hetero’’ LRT tests for heterogeneity in risk estimates between both subphenotypes. 
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CHAPTER 6. SUMMARY AND GENERAL DISCUSSION 
 
 
6.1. Introduction 
 
UCB is a complex disease with both environmental and genetic factors contributing to its etiology. 
Similarly, induction and resolution of the inflammatory response is dependent on the interplay of an 
assortment of immunoregulatory factors in the host and, in the case of infection, in the pathogen as 
well. Consequently, studies investigating the complex relationship between bladder carcinogenesis and 
chronic inflammation should undertake a multi-faceted approach in which environmental, molecular 
and genetic factors are all considered. It was within the aim of this thesis to further clarify and broaden 
the current body of knowledge linking chronic inflammation and UCB by evaluating environmental, 
molecular and genetic factors associated, to various degrees, with both of these conditions.  
The experiments described in chapters 3 and 4 of this thesis have attempted to reevaluate long-
standing questions regarding the association between UCB risk and UTIs, and the prognostic utility of 
COX2 tumor expression in the disease, respectively. While numerous studies have tackled these issues 
to various extents, the larger patient sample size together with more detailed medical and 
epidemiologic data afforded by the Spanish Bladder Cancer/EPICURO Study enabled for a more in-
depth and precise evaluation than has been reported in the literature to date. In contrast, the studies 
undertaken in chapter 5 analyzed an as of yet unexamined relationship between germline genetic 
variation in inflammatory genes and susceptibility to UCB subgroups delimited by their level of 
COX2 expression; with particular emphasis placed on how this information could improve patient 
responsiveness to BCG immunotherapy. The following section briefly summarizes these studies, their 
main findings and how they compared to the original hypotheses outlined in chapter 2. 
6.2. Summary of presented work 
 
 In chapter 3 a case-control analysis was used to evaluate the widely studied yet inconclusive 
notion that inflammation resulting from uropathogensis contributes to elevating UCB risk. Self-
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reported patient information regarding the frequency of lifetime bladder infections was collected along 
with information regarding patient use of UTI medications and the urinary tract analgesic 
phenazopyridine. Nearly a 50% reduction in UCB risk was observed in patients who reported using 
medication to treat episodes of UTI compared to uninfected individuals (OR=0.51; 95% CI=0.37-
0.70); while non-medicating patients exhibited a non-significant increase in UCB risk (OR=1.3; 95% 
CI=0.61-2.79). Interestingly, the reduced UCB risk was most prominent in patients who reported using 
phenazopyridine (OR= 0.35; 95% CI=0.20-0.62). A reduction in UCB risk in patients who medicated 
to treat episodes of UTI is consistent with the experimentally-based hypothesis that some commonly 
administered UTI medications have antitumorigenic properties (Kamat and Lamm, 2004), as is the 
increased risk seen in non-medicating patients. That phenazopyridine, an azo-based compound, would 
protect against UCB risk falls in contrast to our hypothesis based on the uro-carcinogenic properties of 
this class of molecules (Gonzales et al., 1988). 
 In chapter 4 the largest and most comprehensive evaluation to date of the independent 
prognostic utility of COX2 tumor expression in UCB was undertaken. Moreover, an attempt was made 
to homogenize and compare the array of data already available on the topic through a systematic 
review of the literature and a meta-analysis. Using follow-up information collected over a period of 
nearly ten years for almost 800 UCB patients with available tumor tissue, COX2 expression was 
evaluated for its association with recurrence and progression of NMIBC, and progression and survival 
of patients with MIBC. COX2 expression was not a significant independent prognostic marker of any 
of the endpoints considered; a finding that was corroborated by the results from the meta-analysis. 
This finding contrasts the original hypothesis that COX2 expression is a biomarker of poor prognosis 
in UCB given its overexpression in an array premalignant lesions and tumors (Subbaramaiah and 
Dannenberg, 2003) and correlation with tumor invasiveness and high tumor grade in UCB. 
 In chapter 5, the association between genetic aberrations in inflammatory genes and the risk of 
UCB subtypes defined by their level of COX2 expression was evaluated. Two SNPs, rs184087 and 
rs352139, found within the promoter and first intron, respectively, of the gene encoding the innate 
immune response receptor TLR9, exhibited heterogeneity in genetic susceptibility for the two cancer 
subtypes (rs184087, Phet= 1.47E-06; rs312139, Phet= 1.67E-06) . Patients harboring the variant allele of 
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rs187084 were at a reduced risk of COX2-negative UCB (OR=0.63, 95% CI 0.52-0.77); the reverse 
was true of patients harboring variants of rs352139 who observed an increased risk of COX2-negative 
UCB (OR=1.44, 95% CI 1.19-1.74) and a decreased risk of COX2-positive UCB (OR=0.81, 95% CI 
0.66-0.99). A history of bladder infections was not observed to influence these associations. The 
variant allele of rs187084 also conferred a reduced rate of tumor progression in patients with COX2-
negative tumors, but only in those treated with BCG instillation therapy (HR=0.39, 95% CI=0.16-
0.94), suggesting it may be an independent predictive marker of BCG response for these patients. 
While, a priori we expected to identify some variants in inflammatory genes that conferred differential 
susceptibility to tumor subtypes defined by COX2 expression given the role of COX2 and PGE2 in 
inflammation, cancer and immunity (Greenhough et al., 2009), it was unexpected that one gene 
(TLR9) would factor so prominently in both the UCB risk and prognostic assessments. 
6.3 Clinical and public health implications of presented work 
6.3.1 Antibiotics and UCB prophylaxis 
 
Mounting experimental evidence indicates that commonly administered antibiotics used to 
treat UTIs also confer cytotoxicity against UCB cells by means that, although not completely 
understood, reduce cellular proliferation and block apoptosis (Kamat and Lamm, 2004). The analyses 
described in chapter 3 of this thesis are the first to corroborate this experimental evidence in a large 
study. Together with data from experimental studies, these results provide a strong basis for the 
introduction of certain antibiotics in the prophylactic arsenal against UCB (Gurtowska et al., 2010). 
Antibiotic prophylaxis is already used (discretionary) at the start of various urologic surgical 
interventions including TUR to minimize post-operative infectious complications (Bootsma et al., 
2008). However, prolonged antibiotic regimens can be associated with various side-effects that range 
from minor gastrointestinal discomfort to serious cardiotoxicity (De Sarro and De Sarro, 2001), and 
the potential of developing microbial resistance to certain pathogens is also a very real concern. 
Consequently, these risks must be weighed against the benefits of a potential reduction in UCB risk. 
Therefore, antibiotic prophylaxis may be best suited for high-risk patients such as smokers with the 
NAT2-slow acetylator phenotype who have a high potential of developing UCB and would benefit 
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most from an antibiotic regimen as a means of primary prevention despite the risks associated with 
prolonged usage. Moreover, patients already diagnosed with low-grade NMIBC could also benefit 
from such a drug regimen as a means of reducing their risk of tumor progression. 
The finding that phenazopyridine use was associated with a further reduction in UCB risk 
went contrary to our original hypothesis given the uro-carcinogenic nature of azo-dyes. Long term 
local exposure (40 or 52 weeks) of phenazopyridine in mouse bladders has been reported to induce 
tumors in a small proportion of mice (Allen et al., 1957). While long-term exposure to 
phenazopyridine in humans may similarly be tumorigenic, phenazopyridine use in UTI treatment is 
generally short-term and not recommended for periods of more than two days (Zelenitsky and Zhanel, 
1996). To date, no association between phenazopyridine use and neoplasia has been reported despite 
side-effects that may include myo- and nephrotoxicity (Lin, 2008). As the nature of the potential 
protective mechanism proposed for this association in chapter 3 is highly speculative and the 
association could arise from uncontrolled confounding, extreme caution is advised along with 
replication and corroboration of this finding in experimental and large observational studies before any 
prophylactic measures are considered. 
6.3.2 TLR9, COX2 and UCB risk and therapy 
 
 The highest levels of COX2 protein expression in UCB are generally noted in MIBCs which 
are characterized by poor overall prognosis. Therefore, the availability of biomarkers identifying 
individuals based on their susceptibility to COX2-positive UCB would provide a means to take early 
preventive measures for this high-risk group. This could entail changes in lifestyle to reduce potential 
exposure to UCB risk factors (e.g. ceasing smoking or leaving a high-risk occupation) and/or initiation 
of a long-term chemotherapeutic regimen, such as low-dose aspirin or NSAIDs, to reduce UCB risk 
and keep COX2 activity in check (Baris et al., 2013). In chapter 5 of this thesis, TLR9 was observed to 
harbor several SNPs (TLR-rs197084, -rs352139, -rs352140) shown to predict heterogeneity in genetic 
susceptibility to COX2-positive or -negative UCB. Variants of TLR9-rs352139 (in linkage 
disequilibrium with TLR9-rs352140) conferred increased susceptibility for COX2-negative tumors and 
reduced the risk of COX2-positive tumors. Thus, WT homozygous patients could be considered for 
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prolonged NSAID therapy, while those harboring the variant alleles may consider not initiating such a 
regimen given the cardiovascular complications associated with prolonged NSAID use (Marnett, 
2009). 
 BCG instillation is the most effective adjuvant therapy for high-grade NMIBC, but 30-50% of 
patients do not respond to treatment and 15% suffer from tumor progression to MIBC (Zuiverloon et 
al., 2012). No reliable biomarkers are currently available that can predict patient response to BCG 
instillation but a urinary cytokine profile favoring a Th1 immune response (e.g. IL2, IL12, IFN-g, 
TNF-B) is generally associated with successful therapy. TLR9-rs187084 has the potential to fill to this 
void in BCG predictive markers when considered together with COX2 expression levels in NMIBCs; 
both factors predict positive BCG response characterized by decreased tumor progression 
independently of conventional clinicopathological parameters. Although it is unclear how TLR9-
rs187084 may affect TLR9 activity, reduced tumor progression following BCG instillation was only 
observed for COX2-negative tumors suggestive of an immunoregulatory role for tumor COX2, or 
more likely PGE2 (Greenhough et al., 2009). This observation brings with it the clinically relevant 
implication that tumor COX2 levels may confer a tolerogenic effect that influences the BCG induced 
cytotoxic response. Therefore, patients with COX2-positive tumors may derive benefit from taking 
NSAIDs before BCG instillation and into the maintenance period. While a recent randomized, double-
blind, placebo-controlled clinical trial did not observe a significant difference in recurrence rates when 
examining BCG response in patients given long-term COXIBs or a placebo, it would be interesting to 
examine recurrence rates when taking TLR9-rs187084 genotype status into consideration in the same 
trial (Sabichi et al., 2011).   
6.4 Considerations 
6.4.1 UTIs and chronic inflammation of the bladder 
 
There is strong evidence implicating a role for chronic inflammation in bladder cancer 
(Michaud, 2007). From an observational study point of view, distinguishing chronic from acute 
inflammation or from other tumor initiating/promoting factors is not an elementary undertaking. 
Squamous cell carcinoma of the bladder arises in spinal cord injury patients outfitted with indwelling 
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catheters and more prevalently in cases of S. haematobium infestation. In both of these instances 
prolonged and continuous irritation of the bladder urothelium, resulting from physical contact with the 
catheter or S. haematobium eggs, is sufficient to induce a chronic inflammatory state (Michaud, 2007). 
While a slight increase in UCB risk was observed in patients who did not use UTI medication (chapter 
3), the results were not significant; potentially due to the small sample size in this stratum. Another 
explanation may be that the inflammation produced by common bladder pathogens like E. coli, even 
after multiple recurrences, is not prolonged nor continuous enough (i.e. acute inflammation) to 
precipitate tumorigenesis as observed during S. haematobium infestation or indwelling catheter use 
(i.e. chronic inflammation). This is iterated by the observation that bladder cancer risk factors that 
produce prolonged and continuous urothelial irritation, such as S. haematobium infestation, indwelling 
catheter use and certain urogenital pathologies (e.g. calculi and BPH), also have a tendency to increase 
the risk of concurrent chronic bacterial infections in the bladder which in turn contribute to 
tumorigenesis (Michaud, 2007). Thus, the determining factor in the association between UTI and UCB 
risk may be the length of time uropathogens are continuously exposed to the urothelium, and whether 
or not they were treated with UTI medication. 
Alternatively, chronic irritation of the bladder in humans may only lead to SCC, and not UCB. 
In an analysis of patients with UCB, SCC and adenocarcinomas of the bladder, Kantor et al reported 
that individuals with a high frequency of urinary tract infections had a significantly elevated risk of 
SCC (relative risk=5.7) (Kantor et al., 1988). Given that no SCC patients were included in the 
analyses presented in this thesis, it would lend an explanation as to why the study in chapter 3 did not 
observe any meaningful association between UCB risk and infection in individuals who did not use 
UTI medication.  
6.4.2 Linking chronic inflammation, COX2 expression and bladder cancer 
 
Under normal physiological conditions the prostaglandin products of COX2 expression are involved in 
mediating the inflammatory response induced by both endogenous and exogenous stimuli such as 
proinflammatory cytokines, pathogens and growth factors. However, aberrant overexpression of 
COX2 can maintain persistent inflammation in both premalignant and malignant lesions and promote 
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tumorigenesis by blocking apoptosis and accelerating cell proliferation and angiogenesis (Kundu and 
Surh, 2008). While COX2 appears to play an instrumental role in bladder carcinogenesis, not all facets 
of how it functions to link chronic inflammation and tumor development, particularly in UCB, are 
clear.  
 In histological variants of bladder cancer with a well established chronic inflammatory 
etiology such as squamous cell carcinoma, tumor COX2 expression is substantially elevated in 
comparison to UCB (Shirahama and Sakakura, 2001). Moreover, factors that elicit an inflammatory 
response in the bladder, such as cyclophosphamide induced cystitis, also increase urothelial COX2 
expression; but similar levels of expression are obtained regardless of whether the exposure induces 
acute or chronic cystitis (Klinger et al., 2007). These findings suggest that COX2 expression in UCB 
may not be solely related to the presence of chronic inflammation in the bladder. This was shown to be 
the case in Barrett‟s esophagus, a premalignant condition of the esophageal cells in which COX2 
levels are increased, but independently of the degree of inflammation (Abdalla et al., 2005).  
Alternatively, aside from inflammatory stimuli, COX2 expression in UCB may be dependent 
on tumor-specific factors. When considering tumor lymphocyte infiltration as a marker of 
inflammation, Cai et al did not observe a significant difference (p>0.05) in the degree of inflammation 
between NMIBC and MIBC (Cai et al., 2006). However, as reported in chapter 4 of this thesis, COX2 
protein expression is significantly elevated in MIBC compared to NMIBC. In contrast to NMIBC, 
MIBC are characterized by a high degree of genomic instability and genetic aberrations in tumor 
suppressor genes like TP53 (Netto, 2012). Genomic instability could affect the molecular players 
involved in COX2 signalling pathways, resulting in COX2 upregulation observed in MIBC. In fact 
mutations in TP53 have been reported to result in a protein product incapable of binding to the TATA 
motif of COX2 mRNA resulting in stabilization and increased expression of COX2 (Subbaramaiah et 
al., 1999). Thus, in a pathological state like UCB, factors intrinsic to the tumor microenvironment may 
have a supporting or even prominent role in shaping the influence of COX2 in contrast to tumor with a 
more prominent inflammatory etiology such as SCC
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6.5 Strengths and limitations of the study 
 
 The patient data used in most of the analyses detailed in this thesis was collected as part of the 
SBC/EPICURO study, a hospital-based case-control study. This study benefitted from a large patient 
sample size and extensive and thoroughly collected patient information that was further strengthened 
by very high response rates of 84% in cases and 88% in controls. The clinical data collected from 
patients was of high quality and all tumor samples were uniformly classified by expert pathologists to 
reduce the possibility of tumor misclassification. Good agreement was observed between all platforms 
used to genotype patient DNA ensuring the accuracy of the genetic data. While COX2 expression was 
assessed using quantitative image analysis software instead of a pathologist, this approach was highly 
correlated with a pathologist‟s assessment on a small set of tissue cores and, as a result of its 
automated nature, is very reproducible. 
 A case-control approach is ideal for studying associations in rare multifactorial diseases like 
cancer and allows for the inclusion of a large number of cases in a relatively small patient sample 
(relative to cohort studies), while providing the opportunity to study a variety of different exposures 
(important for multifactorial diseases like UCB). Although a convenient means of selecting cases and 
controls, hospital-based studies have the limitation that not all factors assessed can be generalized to 
the whole population; with one study in Spain indicating that hospital controls have elevated alcohol 
consumption in comparison to the general population (Ruano-Ravina et al., 2008) – a factor not 
evaluated in this thesis. Moreover, as information is collected retrospectively by patient interview, 
case-control studies (like other observational studies) are susceptible to bias. 
 Recall bias occurs when cases, as a result of their disease status, consistently over or under 
report exposure in comparison to controls. This type of bias can lead to differential misclassification in 
which the true effect estimate for an association is amplified away from unity. Recall bias may have 
influenced the urinary tract exposures evaluated in chapter 3; however its effect was probably 
marginal given that an inverse association was observed between cystitis and UCB risk. As the history 
of urinary tract conditions was self-reported, a greater concern is the misclassification of symptoms of 
cystitis with the early manifestation of UCB; especially given the overlap of symptoms between both 
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pathologies. To reduce the effects of this type of misclassification, time of last infection relative to 
tumor diagnosis was taken into account with patients who reported presenting with symptoms of 
cystitis within a year of diagnosis excluded from the analyses (chapter 3). 
 Confounding can occur when a factor related to the disease of interest and associated with 
another exposure, distorts the magnitude of the association between that exposure and the disease. 
Although the possibility of uncontrolled confounding is always an issue in observational studies, 
potential confounders were included in multivariable models or examined by stratification.  
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CONCLUSIONS 
 
1.) These results do not support an association between bladder infections or other urinary tract 
conditions and increased UCB risk. 
 
a. Use of UTI medication to treat episodes of infection is associated with a reduced risk of 
UCB that correlates with the frequency of infection. 
 
b. Use of the azo-based urinary tract analgesic phenazopyridine is associated with reduced 
UCB risk; a reduction in risk that is not associated with the frequency of treatment with 
this drug. 
 
2.) Tumor COX2 expression is associated with UCB T-stage and G-grade in low- and high-risk 
NMIBC/MIBC tumors. 
 
3.) Tumor COX2 expression is not independently associated with tumor recurrence and progression 
in NMIBC patients, nor with progression and disease-free survival in MIBC patients. 
 
4.) Germline variants in the innate immune response gene, TLR9, confer heterogeneity in 
susceptibility to UCB subgroups defined by levels of COX2 expression in tumors. 
 
a. TLR9-rs187084, located in the 5‟ promoter region, is associated with a reduced risk of 
COX2-negative UCB. 
 
b. TLR9-rs352139, located within the first intron, is associated with an increased risk of 
COX2-negative UCB and a reduced risk of COX2-positive UCB. 
 
5.) The variant allele of TLR9-rs187084 is an independent predictor of improved progression-free 
survival time in patients with COX2-negative NMIBC who undergo BCG immunotherapy. 
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CONCLUSIONES 
 
1.) Los resultados de esta tesis no apoyan la asociación entre las infecciones del tracto urinario 
(ITU), u otras enfermedades del tracto urinario, y un aumento de riesgo de CUV. 
 
a. El uso de medicamentos para tratar la ITU se asocia con un riesgo reducido de CUV que 
se correlaciona con la frecuencia de las infecciones. 
 
b. El uso de fenazopiridina, un analgésico del tracto urinario, se asocia con una reducción 
de riesgo de CUV; esta asociación no se correlaciona con la frecuencia del tratamiento. 
 
2.) La expresión tumoral de COX2 se asocia con los valores histológicos de T-estadio y G-grado en 
tumores no músculo invasivos de bajo riesgo, y en tumores no músculo invasivo de alto 
riesgo/tumores invasivos. 
 
3.) La expresión tumoral de COX2 no se asoció independientemente con la recurrencia y progresión 
en en tumores no músculo invasivos ni con progresión y la supervivencia de los pacientes con 
tumores invasivos. 
 
4.) Variantes en el gen que codifica el receptor de la inmunidad innata, TLR9, confirieron 
heterogeneidad en la susceptibilidad a CUV. 
 
a. TLR9-rs187084, localizado en la región promotora, se asoció con un riesgo reducido de 
los tumores negativos para COX2. 
 
b. TLR9-rs352139, ubicado en el primer intrón, se asoció con un riesgo aumentado de los 
tumores negativos para COX2 pero con un riesgo reducido de los tumores positivos para 
COX2. 
 
5.) El alelo variante de TLR9-rs187084 confirió, de manera independiente, una tasa reducida de 
progresión tumoral en pacientes con tumores negativos para COX2 en los pacientes tratados con 
inmunoterapia de BCG. 
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Abstract
Aberrant overexpression of cyclooxygenase-2 (COX2) is observed in urothelial carcinoma of the bladder (UCB). Studies
evaluating COX2 as a prognostic marker in UCB report contradictory results. We determined the prognostic potential of
COX2 expression in UCB and quantitatively summarize the results with those of the literature through a meta-analysis.
Newly diagnosed UCB patients recruited between 1998–2001 in 18 Spanish hospitals were prospectively included in the
study and followed-up (median, 70.7 months). Diagnostic slides were reviewed and uniformly classified by expert
pathologists. Clinical data was retrieved from hospital charts. Tissue microarrays containing non-muscle invasive (n = 557)
and muscle invasive (n = 216) tumours were analyzed by immunohistochemistry using quantitative image analysis.
Expression was evaluated in Cox regression models to assess the risk of recurrence, progression and disease-specific
mortality. Meta-hazard ratios were estimated using our results and those from 11 additional evaluable studies. COX2
expression was observed in 38% (211/557) of non-muscle invasive and 63% (137/216) of muscle invasive tumors. Expression
was associated with advanced pathological stage and grade (p,0.0001). In the univariable analyses, COX2 expression - as a
categorical variable - was not associated with any of the outcomes analyzed. As a continuous variable, a weak association
with recurrence in non-muscle invasive tumors was observed (p-value = 0.048). In the multivariable analyses, COX2
expression did not independently predict any of the considered outcomes. The meta-analysis confirmed these results. We
did not find evidence that COX2 expression is an independent prognostic marker of recurrence, progression or survival in
patients with UCB.
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Introduction
Urothelial carcinoma of the bladder (UCB) is the most common
bladder cancer type in developed nations [1]. UCB predominantly
manifests (70–80% of patients) as a non-muscle invasive tumor
(NMIBC: pTa-pT1) characterized by an overall good prognosis
following transurethral resection in patients with low-grade tumors
(pTaG1/2), and intravesical chemotherapy and/or Bacillus
Calmette Guerin (BCG) instillation in patients with high-grade
tumors (pTaG3 or pT1G2/3) [2]. Approximately 70% of NMIBC
patients suffer a recurrence following treatment and a further 15%
progress, developing new tumors exhibiting muscle invasion
(MIBC: pT2-pT4); the risk of progression being higher among
patients with high-grade tumors [2]. Due to a high rate of
recurrence and the need for close follow-up over a patient’s
lifetime, UCB remains one of the most expensive tumors to treat
on a per patient basis [3]. A lower proportion (20–30%) of UCB
patients are diagnosed with muscle invasive tumors (MIBC; pT2-
pT4) characterized by poor prognosis: 50% of these patients die
from their cancer [2]. Genomic profiling and gene expression
analyses indicate a strong correlation between these pathologic
classifications and the underlying molecular architecture of UCB
[4].
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Growing evidence indicates that chronic inflammation may
increase the risk of UCB [5]. Studies investigating the prolonged
use of cyclooxygenase-2 (COX2) inhibiting non-steroidal anti-
inflammatory drugs (NSAIDs) have reported a decrease in UCB
risk [6,7]. COX2 is a prostaglandin endoperoxide synthetase that
catalyzes the production of prostanoids upon induction by
proinflammatory cytokines, growth factors, tumor promoters and
other external stimuli [8]. COX2 activation mediates cellular
processes also implicated in carcinogenesis such as angiogenesis,
cell survival/proliferation and apoptosis [9]. Moreover, studies
have shown that bladder tissue from patients with cystitis or UCB
exhibits elevated COX2 levels in contrast to benign bladder tissue
[10,11].
While numerous groups have investigated the prognostic
potential of COX2 expression in UCB [12–31], there is no clear
consensus on its utility. The objective of this study was to assess
whether COX2 protein expression in UCB cells is associated with
prognosis using a large and standardized cohort of newly
diagnosed bladder cancer patients. A meta-analysis was also done
to summarize these results together with those from other studies
published on the topic.
Materials and Methods
Study Population
A total of 773 newly diagnosed UCB cases aged 22–80 years
(mean 6 SD = 66610 yrs) with a median follow-up of 70.7
months (range 0.7–117.7 months) and available tumor tissue were
used in the current analysis. All cases were recruited between 1998
and 2001 from 18 hospitals in five regions of Spain as part of the
Spanish Bladder Cancer (SBC)/EPIdemiology of Cancer of the
UROthelium (EPICURO) study, a hospital-based case-control
study described previously [32]. A pathologist review panel
uniformly classified the T stage and grade (G) of each tumor
biopsy according to the criteria of the TNM classification and the
WHO-ISUP [33], using the three grade redefinition provided by
the WHO [34,35]. All bladder tumor samples used in the study
were collected prior to the administration of any intravesical or
systemic therapy. Clinical information related to diagnostic
procedures, tumor characteristics and treatment was collected
from medical records, and a computerized questionnaire was used
for the collection of sociodemographic data. NMIBCs were
removed by transurethral resection and patients received intra-
vesical chemo- or immunotherapy (i.e. BCG) as appropriate. The
majority of patients presenting with MIBCs were treated by
radical cystectomy; in cases where surgery was not possible,
radiotherapy or systemic chemotherapy were administered.
Follow-up information was collected annually from hospital
records and through direct telephone interviews by trained
monitors using structured questionnaires. Among NMIBCs,
recurrence was defined as the appearance of a new NMIBC
following a previous negative follow-up cystoscopy, and progres-
sion, as the development of a MIBC. In patients initially
presenting with MIBCs, any tumor reappearance after treatment
was considered progression, regardless of whether the tumor
relapse was local or distal. Tumour-specific survival was assessed
only for patients with MIBCs. Informed written consent was
obtained from study participants in accordance with the Ethics
Committees of each participating hospital.
Immunohistochemistry
Tissue blocks of formalin-fixed, paraffin-embedded primary
bladder tumors were used to construct tissue microarrays (TMA)
containing tumor cores of 0.6-mm in diameter represented in
duplicate and selected from the most representative regions of the
tumor on which T and G were based. After deparaffinisation and
heat-induced antigen retrieval, all slides were stained simulta-
neously at the Histology and Immunohistochemistry Core Unit of
the CNIO using the PT LINK system as per manufacturer’s
instructions (Dako Inc., Glostrup, Denmark). Briefly, tissue
sections were incubated with anti-COX2 rabbit monoclonal
antibody (ThermoFisher Scientific, Fremont, CA, USA; #RM-
9121-R7; pre-diluted, ready-to-use) at room temperature, followed
by visualization using the EnVision Flex Visualization system
(Dako Inc., Glostrup, Denmark) and exposure to diaminobenze-
dine. Tissues were then counterstained with haematoxylin,
dehydrated and mounted. A section of colon tissue was used as
a positive control.
Evaluation of COX2 Immunostaining
COX2 expression was quantified using the Ariol SL-50 (version
3.1.2, Applied Imaging Corp., San Jose, CA, USA) high-
throughput slide imaging scanner. All cores were imaged and
processed using a light microscope and the accompanying TMA
Multistain Imaging software. The program was trained by a
pathologist (SM) to maximize the inclusion of positively stained
tumor epithelium while minimizing stromal material, as described
previously [36]. COX2 expression score was calculated as the
product of the mean intensity of staining (by defining the
background and saturation limits of the antibody and imaging
sensor, respectively) and the proportion of cellular antibody-
positive area divided by total cellular area. Values from replicate
cores were averaged to provide a final expression score for each
patient. Furthermore, one randomly selected TMA (representing
10% of all cores) was analyzed by direct visual microscopic
inspection by an independent pathologist (MMM) to enable
comparison with the automated scoring approach. The patholo-
gist-derived score was calculated as the product of COX2 staining
intensity (1 = weak, 2 = intermediate, 3 = strong) and a quartile of
the percentage of epithelial tumor cells stained (0–4; with 0
representing 0% staining), providing a final categorical score in the
range of 0–12. There was a high and significant correlation
between the machine and pathologist derived scores (Spearman
rho = 0.85; 95%CI = 0.79–0.90; p-value,0.00001). COX2 ex-
pression was analyzed as both a continuous variable and
categorical variables partitioned at the median and extreme
tertiles. Additionally, expression was examined as a categorical
variable dichotomized at a threshold (0.340 arbitrary units [au])
above which COX2 expression was considered to be positive. This
expression threshold was derived by comparing the pathologist’s
(MMM) binary assignment of positive expression (i.e. score of 0 vs.
score $1, as described above) to the machine-derived continuous
score using receiver operating characteristic (ROC) curve analysis
(area under the curve = 0.95; 86% sensitivity and 92% specificity)
[37].
Meta-analysis
The meta-analysis included COX2 expression results from our
own series (using the ROC-derived categorical expression variable)
and relevant studies published before 1 January 2012 identified by
searching PubMed and ISI Web of Knowledge. The search string
used was: (cox2 OR cox-2 OR cyclooxygenase-2 OR "cycloox-
ygenase 2" OR ptgs2) AND (prognos* OR survival OR mortality
OR recurrence OR relapse OR progression) AND ("bladder
cancer"). Studies were considered eligible if: (i) they reported the
effect measure (as HRs, survival curves or log-rank p-values) of
COX2 protein expression on recurrence, progression or disease-
specific survival; (ii) COX2 was assessed in primary tumors
COX2 Expression and Bladder Cancer Prognosis
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exhibiting homogeneity in tumor histology ($75% UCB), and
subphenotype ($75% NMIBC or MIBC); (iii) they were written in
English or Spanish (Table S1). Reviews, abstracts, non-clinical
studies, and duplicate publications were excluded. HRs and
95%CIs were directly extracted from the publications whenever
available. For those reporting only the log-rank p-value or the
Kaplan–Meier survival curves, the HRs and 95%CIs were
independently calculated by two of the co-authors (MJC, AFSA)
using the spreadsheet prepared by Sydes and Tierney with any
discrepancies resolved by discussion [38]. In a few indicated cases,
authors were directly contacted for clarification or provision of
data not shown in the published manuscripts (Table S1). The level
of heterogeneity among studies was calculated by means of the I2
statistic [39], and publication bias was assessed by analyzing funnel
plots and Egger’s asymmetry test [40].
Statistical Analysis
Associations between demographic and clinico-pathological
parameters and COX2 expression were assessed using Fisher’s
exact test. In NMIBCs, expression was also assessed distinctly in
low-grade/risk (pTaG1/G2) and high-grade/risk (pTa/pT2G3)
tumors, based on our previous evidence suggesting differential
prognostic, genetic and molecular profiles between these sub-
groups [41,42]. Recurrence-free, progression-free, and overall
disease-specific survival curves were generated using the Kaplan-
Meier method, with statistical significance assessed using the log-
rank test. Time to each endpoint was calculated from date of
primary treatment to the date of event, date of last follow-up, or
date of patient’s death. Individuals who did not present any event
until the end of the study, those lost to follow-up, or those who
died from other causes were censored either at the time of last
medical visit or at death. Time to recurrence and progression were
defined by applying the ‘‘mid-time’’ between the date of the
previous disease-free visit and that when a new event was
diagnosed. Survival time was measured as the time from initial
treatment to death resulting from cancer. Univariable and
multivariable Cox-proportional hazards analysis was used to
calculate hazard ratios (HR) and 95% confidence intervals (CI).
Schoenfeld residual analysis did not suggest any departure from
the proportional hazards assumption in multivariable models.
All statistical analyses were done using STATA (version 10.1
SE, StataCorp, College Station, TX, USA). Statistical tests were
two-sided and p-values less than 0.05 were considered significant.
The REMARK [43] guidelines for prognostic studies as well as the
PRISMA [44] guidelines for systematic reviews and meta-analyses
were adhered to in the preparation of the manuscript.
Results
Patients and COX2 Expression in Bladder Cancer TMAs
COX2 expression was assessed in 557 patients with NMIBCs
and 216 individuals with MIBCs. Median COX2 expression was
0.121 au (range 0–42.590; interquartile range 1.382) in NMIBCs,
and 0.760 au (0–30.806; 3.600) in MIBCs (p-value = 4610212).
Representative COX2 immunostaining patterns in UCBs are
shown in Figure S1. Of patients with NMIBCs, 41% (230/557)
were treated only by transurethral resection, with the remainder
(56%) receiving endovesical BCG immunotherapy and/or che-
motherapy following transurethral resection, or other treatment
(3%; Table 1). Nearly half (46%) of patients with MIBCs were
treated by cystectomy, with the remainder receiving systemic
chemotherapy, radiotherapy, superficial or other treatment, or
some combination thereof (Table 2).
Table 1. Distribution of characteristics of patients with
NMIBCs by COX2 expression.
COX2 expression*
Patient characteristics Total, N
negative,
n
positive,
n P value{
557 346 211
Area 0,506
Barcelona 98 68 30
Valles 105 66 39
Elche 51 32 19
Tenerife 122 71 51
Asturias 181 109 72
Age (yrs.) 0,385
#60 140 81 59
.60 and #70 210 130 80
.70 207 135 72
Gender 0,891
Men 494 306 188
Women 63 40 23
Tumor Invasion ,0,0001
Ta 477 277 200
T1 80 69 11
Grade ,0,0001
GI 200 131 69
GII 219 95 124
GIII 138 120 18
Low/High Grade ,0,0001
Low (TaG1/TaG2) 408 221 187
High (TaG3/T1G2/T1G3) 149 125 24
Number of tumors 0,106
1 348 209 139
.1 178 120 58
missing 31 17 14
Tumour Size 0,564
#3 cm 294 188 106
.3 cm 111 67 44
missing 152 91 61
Number of Recurrences 0,409
none 366 232 134
at least 1 191 114 77
Treatment{ 0,393
TUR 230 133 97
TUR+BCG 158 105 53
TUR+Chem. 132 83 49
TUR+BCG+Chem. 19 14 5
Other 18 11 7
*COX2 expression score dichotomised at the threshold of positivitiy (0,340 au).
{Fisher’s exact test comparing distribution of COX-2 negative versus positive
patients; missing values excluded from analysis where applicable.
{TUR: transurethral resection; BCG: Bacillus Calmette-Guerin instillation; Chem.:
chemotherapy via endovesical instillation.
doi:10.1371/journal.pone.0045025.t001
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Table 2. Distribution of characteristics of patients with MIBCs by COX2 expression.
COX2 expression*
Patient Characteristics Total, N negative, N positive, N P value{
216 79 137
Area 0,207
Barcelona 39 16 23
Valles 36 9 27
Elche 15 9 6
Tenerife 39 14 25
Asturias 87 31 56
Gender 0,816
Men 194 72 122
Women 22 7 15
Age (yrs.) 0,426
#60 45 14 31
.60 and #70 84 35 49
.70 87 30 57
Tumor invasion 0,896
T2 114 42 72
T3 55 21 34
T4 47 16 31
Grade 0,326
GII 19 9 10
GIII 197 70 127
Metastases 0,296
M0 168 57 111
M1 29 13 16
Mx 19 9 10
Lymphatic invasion 0,862
N0 141 50 91
N1, N3 49 16 33
Nx 26 13 13
Number of tumors 0,008
1 146 63 83
.1 54 12 42
missing 16 4 12
Tumour size 0,572
#3 cm 53 19 34
.3 cm 66 28 38
missing 97 32 65
Treatment{ 0,417
Cystectomy 67 19 48
Cystectomy+Chem. 32 15 17
Chem. only 23 9 14
RT +/2 Chem. 19 7 12
Superficial Treatment 13 3 10
Others 61 25 36
missing 1 1 0
*COX2 expression score dichotomised at the threshold of positivity (0,340 au).
{Fisher’s exact test comparing distribution of patients with negative or positive COX-2 expression; missing, Nx and Mx values excluded from analysis where applicable.
{Chem.: Systemic chemotherapy; RT: Radiation therapy.
doi:10.1371/journal.pone.0045025.t002
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COX2 Expression and Clinicopathological Features
Two-hundred eleven (38%) NMIBCs and 137 (58%) MIBCs
expressed COX2 (Tables 1 and 2, respectively), with positive
expression defined as a score equal to or greater than the ROC-
derived threshold of 0.340 au. Patient and tumor characteristics in
the analyzed sample did not differ significantly from the initial
SBC/EPICURO study population with the exception of geo-
graphic region and tumor size in NMIBC patients (data not
shown). The distribution of COX2 positivity was assessed
according to established bladder cancer prognosticators including
tumor invasion and grade, tumor multiplicity, tumor size and
treatment, among others. Demographic factors like age, gender
and region were not associated with COX2 expression, nor was
the type of primary treatment received by patients (Tables 1 and
2). In NMIBCs, COX2 expression was significantly associated
only with T and G; being more prominent in low-grade/risk
pTaG1/2 tumors than in high-grade/risk pTa/pT1G3 tumors (p-
value,0.0001; Table 1). Further assessment of COX2 distribution
in relevant molecular subtypes of UCB [4], revealed a greater
proportion of pTaG2 than pTaG1 tumors positively expressing
COX2 in low-grade NMIBCs (p,0.0001, subtype 1; Figure S2).
COX2 expression did not differ among high-grade/risk NMIBCs
(p = 0.075), but a greater proportion of MIBCs positively expressed
COX2 than did all high-grade/risk NMIBCs combined
(p,0.0001, subtype 2; Figure S2). Only tumor multiplicity was
associated with positive COX2 expression in MIBC patients (p-
value = 0.008; Table 2).
COX2 Expression and Prognosis in Bladder Cancer
Patients
We analyzed the association of COX2 expression with tumor
recurrence and progression in patients with NMIBCs and with
progression and disease-specific survival in patients with MIBCs
(Table 3; Figure 1). When considered as a continuous variable in
the univariable analysis, COX2 expression was marginally
associated with an increased risk of recurrence in NMIBCs
(HR = 1.02, 95%CI = 1.00–1.04, p-value = 0.048; Table 3). How-
ever, this association disappeared upon multivariable analysis
when adjusting for region, gender, tumor stage and grade,
multiplicity, tumor size, and treatment. Moreover, COX2
expression was not significantly associated with recurrence in
NMIBCs when considered as a categorical variable, neither in the
univariable nor multivariable analyses (Figure 1A; Figure S3AC;
Table 3). Lastly, no significant association between COX2
expression and progression or survival was observed in patients
with NMIBCs or MIBCs, regardless of whether expression was
considered as a continuous or categorical variable in non-adjusted
or adjusted analyses (Figure 1B–D; Figure S3B, 3D–H; Table 3).
Meta-analysis of COX2 Expression and Bladder Cancer
Prognosis
Twenty publications on COX2 expression and bladder cancer
prognosis were identified through the literature review (Table S1)
[12–31]. Three of them lacked prognostic data, two overlapped
with other larger studies and four included patient cohorts that did
not meet the eligibility criteria outlined earlier, leaving 11
evaluable publications [12–14,19,21–25,28,29] plus the current
study for the meta-analysis (Figure S4). Studies were classified by
the tumor subtype(s) they reported on (i.e. NMIBC or MIBC), and
whether adjustment for covariates was considered for each
prognostic endpoint examined (i.e. univariable or multivariable;
Figures 2 and 3). Of the four meta-analyses conducted with
univariable data, only the metaHR of the association between
COX2 expression and recurrence in NMIBCs showed marginal
significance (metaHR = 1.35, 95%CI = 1.00–1.83; Figure 2). This
result was not affected by study heterogeneity (I2 p-value = 0.13)
but exhibited significant publication bias, as evidenced by Egger’s
test (p-value = 0.019). The remaining meta-analyses considering
univariable data suggested increased, albeit non-significant, risks of
tumor progression in patients with NMIBCs (metaHR = 2.07,
95%CI = 0.76–5.64) and MIBCs (metaHR = 1.45, 95%CI = 0.77–
2.74), and death in patients with MIBCs (metaHR = 1.13,
95%CI = 0.8–1.59; Figure 2). Notably, the summary effect for
progression in NMIBCs and that observed for survival in MIBCs
were both significantly affected by study heterogeneity (I2 p-values:
0.006 and 0.004, respectively), with the former also significantly
influenced by publication bias (Egger’s test p-value = 0.001).
Due to a paucity of published prognostic studies performing
multivariable analysis on patients with NMIBCs, we could only
address the multivariable meta-association with progression and
survival in patients with MIBCs (Figure 3). A small, non-significant
increased summary risk of progression (metaHR = 1.12,
95%CI = 0.53–2.35; Figure 3) was observed in COX2 expressing
MIBCs that was unaffected by study heterogeneity (I2 p-
value = 0.139). Similarly, a null summary effect was observed for
survival (metaHR = 0.97, 95%CI = 0.69–1.36; Figure 3). This
effect was influenced neither by study heterogeneity (I2 p-
value = 0.114) nor by publication bias (Egger’s test p-val-
ue = 0.108.
Discussion
Despite many published studies, contradictory findings prevail
on COX2 expression as an independent prognostic marker in
patients with UCB. The current study suggests that COX2
expression is not an independent marker associated with
recurrence, progression or survival in patients with UCB.
Using the largest cohort of patients with NMIBCs evaluated for
COX2 expression to date, we observed that 38% of these tumors
expressed the protein. Other groups have reported frequencies
ranging from 53–88%; however, these studies used different
COX2 antibodies and expression evaluation techniques and had
smaller sample sizes [16,28,29,45,46]. In accordance with
reported results [11,18,45] we observed significantly higher
COX2 expression in MIBCs (58%) than in NMIBCs. This
frequency is similar to that observed in other large, histologically
homogeneous studies [21,28], while groups using heterogeneous
cohorts of squamous and transitional cell carcinomas report
frequencies different from our own [12,29]. Collectively, these
findings reiterate the importance of homogeneity, or stratification,
in tumor marker studies.
The association between COX2 and clinico-pathological
characteristics remains a contentious issue in the literature. The
majority of studies report an association between COX2
overexpression and advanced tumor invasion and grade, but use
heterogeneous populations of NMIBCs and MIBCs in their
assessments [21,25,26,28,47]. Given the known disparity in
COX2 expression between NMIBCs and MIBCs, an association
of this type would be expected in a mixed tumor population. After
pooling NMIBCs and MIBCs in our study we also observe a
strong significant association between COX2 overexpression and
advanced tumor invasion (p.0.0001) and grade (p.0.0001).
Notably, several groups report no association between COX2
expression and T and G [14,29,45]; especially those working
strictly with homogeneous cohorts of MIBCs [12,23]. Similarly, in
our study, COX2 expression did not differ significantly among
pT2, pT3 and pT4 tumors (p = 0.896). Interestingly, we observed
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lower COX2 positivity in pT1 and high-grade/risk NMIBCs, than
in pTa and low-grade/risk NMIBCs tumors. This result may seem
counterintuitive if grade progression is considered a linear trait
and COX2 expression is deemed to increase linearly with T and
G. However, there is strong evidence indicating that UCB exists as
two molecularly distinct subtypes, with high-grade/risk NMIBCs
having a molecular signature more similar to MIBCs than to low-
grade/risk NMIBCs [4,42]. In this respect, we observed that
COX2 positivity increased significantly with increasing T and G
within each molecular tumor subtype (Figure S2). Shirahama et al.
[26] reported a COX2 distribution similar to ours, observing 8%
positivity in pT1 tumors and 50% in MIBCs when using whole
section staining and a 5% expression threshold. Collectively, these
results reiterate the disparity in COX2 expression between
NMIBCs and MIBCs first reported by Komhoff et al. [47], and
highlight the importance of considering expression within the
proper molecular context.
To minimize the effects resulting from selecting an arbitrary
expression threshold, we investigated COX2 protein expression
as a continuous variable and three categorical variables. Only
when considered as a continuous variable in the univariable
analysis was COX2 expression found to be associated with a
slight increase in the risk of recurrence. The meta-analysis,
consisting of five other univariable studies, reiterated this
association and showed a 35% increased risk of recurrence in
patients with COX2 expressing NMIBCs. However, both effect
estimates exhibit only marginal significance, suggesting that the
observed associations may be due to chance. Moreover, the
association observed in the univariable analysis did not hold after
adjustment for conventional prognostic factors of recurrence in
the multivariable analysis. Lastly, the summary effect observed in
the meta-analysis may have been skewed by two small studies
which selected only high risk NMIBCs (T1G3 [19] and Cis [24]).
When a sensitivity analysis was performed removing these two
studies from the meta-analysis, the association between recur-
rence and COX2 expression was no longer maintained
(metaHR = 1.14, 95%CI = 0.94–1.38). The observed disparity
between effect estimates of progression in the present study and
the meta-analysis could also be attributed to the inclusion of
these two studies. Upon their exclusion, the summary HR
showed no association with progression (metaHR = 0.98,
95%CI = 0.47–2.03). These results do not support a role for
COX2 expression in NMIBCs as an independent prognostic
marker of recurrence or progression.
Several groups have investigated the ability of COX2 expression
to predict outcome in patients with MIBCs. Despite wide inter-
Table 3. Analysis of COX2 expression in NMIBCs and MIBCs; univariable and multivariable analyses.
Univariate COX-regression Multivariate COX-regression{
Score Categorization* Patients, n Events, n HR (95% CI) P value{ Patients, n Failures, n HR (95% CI) P value{
Non-muscle invasive tumors
Recurrence 1
Continuous 556 191 1,02 1,00–1,04 0,048 401 141 1,02 1,00–1,04 0,140
Negative vs. Positive 556 191 1,08 0,81–1,44 0,612 401 141 1,11 0,78–1,59 0,555
Median 556 191 1,08 0,82–1,44 0,583 401 141 1,17 0,82–1,67 0,390
Extreme tertiles 370 127 1,06 0,89–1,27 0,483 268 94 1,08 0,86–1,37 0,510
Progression
Continuous 557 48 0,92 0,84–1,01 0,094 526 43 0,96 0,87–1,05 0,350
Negative vs. Positive 557 48 0,72 0,39–1,33 0,302 526 43 1,38 0,61–3,11 0,434
Median 557 48 0,67 0,38–1,20 0,181 526 43 1,11 0,53–2,33 0,780
Extreme tertiles 371 33 0,71 0,49–1,01 0,059 351 29 0,92 0,54–1,56 0,750
Muscle invasive tumors
Progression
Continuous 216 131 0,99 0,96–1,03 0,617 189 110 0,99 0,96–1,03 0,750
Negative vs. Positive 216 131 0,94 0,66–1,34 0,734 189 110 0,85 0,56–1,29 0,448
Median 216 131 0,97 0,69–1,37 0,869 189 110 0,89 0,60–1,32 0,560
Extreme tertiles 144 85 0,92 0,75–1,14 0,464 128 75 0,90 0,70–1,15 0,410
Disease specific survival
Continuous 216 110 1,00 0,97–1,04 0,908 187 89 1,01 0,97–1,05 0,730
Negative vs. Positive 216 110 0,91 0,61–1,34 0,627 187 89 0,77 0,48–1,23 0,267
Median 216 110 0,94 0,64–1,36 0,726 187 89 0,78 0,50–1,23 0,290
Extreme tertiles 144 68 0,90 0,71–1,15 0,407 126 57 0,78 0,58–1,04 0,090
*Expression cut-points used for categorical variables: "Neg. vs. Pos." - NMIBC/MIBC: 0.340; "Median" - NMIBC: 0.121, MIBC: 0.760; "Extreme tertiles" - NMIBC: (,0.0239,
.0.586), MIBC: (,0.270, .2.149).
{Multivariate models adjusted for established bladder cancer prognostic factors as follows: NMIBC Recurrence adjusted by region, gender, tumour stage and grade, #
tumours, size of tumours, and treatment; NMIBC Progression adjusted by region, # recurrences, age, tumour stage and grade, # tumours, and treatment; MIBC
Progression adjusted by region, tumour stage, treatment, and presence of nodes; MIBC Survival adjusted by region, tumour stage, treatment, presence of nodes, and
metastases.
{Cox proportional hazards analysis.
1One patient excluded due to incomplete follow-up record.
doi:10.1371/journal.pone.0045025.t003
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study variation in methodology, antibodies used, sample size, and
adjustment parameters in the case of multivariable analyses, the
majority of these studies did not identify any significant association
between COX2 expression and progression or survival, consistent
with our findings [13,14,23,28,29]. Shariat and Margulis and their
colleagues observed a negative association between high COX2
expression and tumor progression and mortality [21,25]. Howev-
er, both studies relied on heterogeneous sample populations which
included a small proportion of patients with NMIBCs; potentially
accounting for the observed associations given the disparity in
COX2 expression between superficial and advanced bladder
tumors [45]. In another study, Wulfing et al. reported that high
COX2 expression was an independent predictor of poor overall
survival in a subgroup of 62 patients with MIBC treated with
cisplatin-based chemotherapy [29]. We did not identify any
meaningful interaction between COX2 expression and treatment
(data not shown), and were unable to replicate their findings in a
smaller subset of 39 patients treated with cisplatin (HR = 1.47,
95%CI = 0.48–4.51, p-value = 0.497). Aziz et al. reported a 36%
survival advantage associated with increased COX2 levels in a
cohort of 266 patients with MIBCs (221 with UCB) that was
independent of lymph node status and neo/adjuvant chemother-
apy [12]. While we also observed improved survival among
patients with COX2 overexpressing MIBCs, this association did
not reach significance, consistent with other univariable [23,28]
and multivariable [26] analyses.
Our study had a large sample size, included only incident cases
and relied on extensive and accurately acquired follow-up
information spanning ten years. Additionally, we used automated
scoring of immunostained TMAs, a strategy providing a repro-
ducible assessment of expression that correlated highly with the
independent evaluation of a subset of samples by an independent
pathologist. COX2 staining was done in one laboratory to avoid
heterogeneity in immunohistochemical staining and scoring, and
evaluated as a continuous variable in the prognostic analyses to
avoid potential bias related to selection of an expression threshold.
Moreover, the sample population provides an accurate represen-
tation of bladder cancer in the general population as no inclusion
criteria were applied in the recruitment process which included a
good mix of referral centers and county hospitals. Lastly, the
recommendations of the REMARK and PRISMA studies were
followed in all of the reported analyses.
Despite these considerations and attempts to accurately quantify
COX2 expression only in epithelial cells, the pathologist-trained
automated imaging system may have incorporated some immu-
nostained stromal material found on the tissue core, thereby
increasing type I error. To reduce potential error we averaged the
expression scores from duplicate cores and also explored a method
investigated by Henriksen et al. [48] in which the higher score was
used (data not shown). Both methods produced similar material
associations between COX2 expression and clinico-pathological
parameters or HRs. Moreover, adjusted analyses for progression
Figure 1. Kaplan-Meier survival curves corresponding to failures in superficial (A, B) and invasive (C, D) tumors for specified
prognostic endpoints. Dashed curves: patients with tumors positive for COX2 protein staining; solid curves: patients with tumors negative for
COX2 protein staining. Significance values from two-sided logrank test.
doi:10.1371/journal.pone.0045025.g001
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in NMIBCs should be interpreted cautiously given the low number
of events in relation to covariates. Also, different patient
management practices across recruitment hospitals could increase
sample heterogeneity, necessitating the inclusion of both recruit-
ment area and treatment regimen in our multivariable analyses.
The results presented herein focus on COX2 expression levels
measured in tumor epithelial cells – only one aspect of the complex
interplay between the tumor and the host immune/inflammatory
response [49]. The prognostic potential of COX2 (if any) may only
be revealed when considered together with other tumoral markers.
When investigating several potential prognostic parameters in
UCB, Hilmy et al. concluded that systemic factors of the
inflammatory response such as levels of C-reactive protein were
superior to tumor-based factors such as grade, COX2 expression
or T-lymphocytic infiltration [18]. Moreover, in models of cervical
cancer, Ferrandina et al. observed that while COX2 expression
was mutually exclusive in the tumor and stromal inflammatory
cells, high expression in both cell types could be used as an
independent marker of poor survival [50]. Future studies
investigating the prognostic value of COX2 expression in UCB
should take into consideration the multi-factorial and multi-
dimensional context of the inflammatory response during carci-
nogenesis.
The current study is the largest to investigate COX2 expression
as an independent marker of outcome in a prospective cohort of
UCB patients. These findings, supported by a meta-analysis that
included our own data and that from other relevant studies, do not
Figure 2. Forest plots from selected univariable studies indicating the risk of reaching the indicated prognostic endpoints in non-
muscle invasive (NMIBC; two upper panels), and muscle invasive (MIBC; two lower panels) UCBs in the presence of urothelial COX2
expression.
doi:10.1371/journal.pone.0045025.g002
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support COX2 tumor cell expression being an independent
prognosticator of UCB.
Supporting Information
Figure S1 Immunohistochemical staining of COX2 in
primary UCBs on TMAs. Expression was scored as a product
of the percentage of epithelial area stained and the staining
intensity using automated imaging analysis. A score of ,0.340 au
was considered negative for COX2 expression, while a score of
$0.340 was considered positive. Representative sections of a
pTaG1 UCB lacking COX2 expression (A and D) and a pT2G3
UCB expressing COX2 (B and E) are shown. Normal colon tissue
was used as a positive control (C and F). Upper panels show
sections under 100x magnification (A-C); lower panels show
sections under 200x magnification (D–F).
(PDF)
Figure S2 Distribution of positive COX2 expression in
urothelial carcionomas of the bladder classified by their
molecular and pathological stage-grade subtypes. Posi-
tive COX2 expression assessed as described in Figure S1.
Statistical significance assessed using Fisher’s exact test with a
0.05 significance level. pT1G2 tumors excluded due to low sample
size in the current study (n = 11), and a reported tendency to
overlap both molecular subtypes.
(PDF)
Figure S3 Kaplan-Meier survival curves corresponding
to failures in superficial (A, B, C, D) and invasive (E, F,
G, H) tumors for specified prognostic endpoints and
quantiles of COX2 expression. Dashed curves: patients with
tumors expressing COX2 at lower specified quantiles; solid curves:
patients with tumors expressing COX2 at upper specified
quantiles. Significance values from two-sided logrank test.
(PDF)
Figure S4 Flow diagram of study selection and inclusion
in meta-analysis.
(PDF)
Figure 3. Forest plots from selected multivariable studies indicating the risk of reaching the indicated prognostic endpoints in non-
muscle invasive (NMIBC; two upper panels), and muscle invasive (MIBC; two lower panels) UCBs in the presence of urothelial COX2
expression.
doi:10.1371/journal.pone.0045025.g003
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Table S1 Main characteristics of eligible studies used in
meta-analysis.
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